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1 Introduction 
1.1 Pesticides 
After the fipronil scandal became known to the public in 2017, in which the insecti-
cide fipronil, which is used as a contact poison against ticks and mites, has been de-
tected in chicken eggs and egg products, it could be assumed that the use of pesti-
cides and the presence of residues in food is a relatively topical issue 1. However, the 
history of pesticides goes back to the 19th century, where inorganic substances such 
as copper sulfate or lime sulfur were first used for pest control 2. During the Second 
World War and the following years, synthetic organic substances were developed, 
which represented a breakthrough in pest control, and the introduction of insecti-
cides greatly reduced diseases such as malaria and typhus 3. Dichlorodiphenyltri-
chloroethane (DDT), first synthesized in 1874, was associated with insecticidal ac-
tivity by Paul Hermann Müller in 1939, for which he was later awarded the Nobel 
Prize in physiology or medicine regarding the discovery of DDT’s high efficiency as 
a contact poison against several arthropods 2,4. Since then, new substances have 
been continuously developed, and a great variety of different pesticides have been 
introduced. The definition of a pesticide could be described as follows: The ideal 
function of a pesticide is that it is lethal to the target but not harmful to non-target 
species 5. They are, for example, used for the protection of plants. This protection 
leads to higher crop yields and also better quality in cabbage 5. Although many old 
pesticides with higher toxic potential were withdrawn, the global pesticide market 
is still growing 2. Figure 1 shows the world's pesticide consumption in tonnes (t) 
from 1990 to 2016 6. The graph shows a steady increase in pesticide consumption 
from approximately 2.3 million tonnes up to 4.1 million tonnes in the last three dec-
ades.  
Introduction 
2 
 
Figure 1. Pesticide consumption of the world from 1990 to 2016. The graph shows the pesticide consumption 
of the whole world in the specified period. A steady increase in pesticide use can be observed (from approxi-
mately 2.3 million t up to 4.1 million t). Data were obtained from the database FAOSTAT provided by the food 
and agriculture organization of the United Nations 6. 
 
According to data from the Food and Agriculture Organization of the United Nations 
(FAOSTAT), rice (paddy) is one of the most produced crops in the world. In the last 
three decades, the production increased globally from 519 million tonnes in 1990 
up to 756 million tonnes in 2016, shown in Figure 2.6 
 
 
Figure 2. Rice, paddy production from 1990 to 2016. The production increased globally from 519 million t to 
756 million t. Data was obtained from FAOSTAT 6. 
 
As the world population is expected to rise to about 9.8 billion people by 2050 and 
even up to 11.2 billion people by 2100, it is necessary to provide sufficient and safe 
food 7. It is, therefore, hardly surprising that the number of pesticides used increases 
with the amount of food that needs to be provided. In 2016, the amount of pesticides 
used accounted for 2.6 kg ha-1 (260 mg m-2) 6. Although the definition of an ideal 
pesticide states that it should be lethal to the target and harmless to non-targets, for 
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most substances, this is not the case. Due to the high use, residues of these can get 
into the human body. Typical ways, how a pesticide can enter the body are via the 
skin, eyes, by oral uptake, or by inhalation 8. Therefore, the exposure to certain pes-
ticides can be associated with various diseases like cancer 9, asthma 10, leukemia 11, 
and others 12-14. 
Furthermore, not all formerly or presently used pesticidal active compounds and 
additives, such as organochlorine pesticides 15 (OCPs) or polychlorinated biphen-
yls 16 (PCBs), are biodegradable, which makes them to so-called persistent organic 
pollutants 17 (POPs). These POPs are more stable to degradation, thus persisting in 
the environment for a long time, and bioaccumulation can occur after new applica-
tion of the substance, which means that the initial concentration can even be ex-
ceeded many times over 8. Therefore, the use of POPs like hexachlorobenzene (HCB) 
or endrin is nowadays forbidden. Since the use of pesticides has not only positive 
effects, such as increased crop yields but also adverse effects, such as health impair-
ment, the production and use of new pesticides must be strictly controlled. The reg-
ulatory framework for the authorization of new pesticides is described in 1.1.2 (The 
Regulatory Framework for Market Release of New Single Pesticides). So far, how-
ever, only the influence of individual pesticides has been considered. In many cases, 
pesticides are already offered as mixtures, which means that different pesticides, as 
well as co-formulants and excipients, are used in these formulations, or farmers use 
several pesticides simultaneously in their fields to increase the spectrum of action. 
Since only the effect of the individual substance is examined when new substances 
are authorized, data on possible mixture effects are lacking, and the question arises 
as to whether the consumption of pesticides as residues and the additional mixing 
of these substances may lead to adverse health effects. 
 
1.1.1 Pesticide Types 
Pesticides are either chemical or biological substances that are used for the control 
of pests, mites, rodents, weeds, nematodes, and many more 18. Depending on the 
vermin, pesticides can be classified as fungicides, herbicides, insecticides, nemati-
cides, or rodenticides 2,19. Besides that, the World Health Organization (WHO) rec-
ommended a classification system according to the toxicity of pesticides. Table 1 
shows the classification of pesticides based on the WHO 20.  
Introduction 
4 
Table 1. Classification of pesticides according to the WHO. The classification was based on the 50% lethal dose 
(LD50) of rat in mg kg-1, and the table was prepared based on the WHO.20 
Class 
Toxic effect based on the LD50 in rat  
in mg kg-1 body weight 
Ia Extremely hazardous 
Ib Highly hazardous 
II Moderately hazardous 
III Slightly hazardous 
U Unlikely to present acute hazard 
 
Fungicides are used to eradicate fungi and prevent their growth. The Bordeaux mix-
ture, which consisted of inorganic compounds such as copper sulfate, was one of the 
first fungicides 2. Nowadays, mainly organic fungicides are used. Pathogens that can 
become resistant to a specific fungicide are problematic. Therefore, it is essential 
that not only substances with a specific mode of action are used, but that they are 
applied alternately with other substances that follow a different route of effect. Be-
cause of that, it is also recommended to use mixtures thereof, which comprise dif-
ferent modes of action. Most of the substances that were investigated in this work 
come from the fungicide group, as they are already frequently applied as mixtures.2 
These are azoxystrobin, boscalid, captan, carbendazim, cyproconazole, cyprodinil, 
difenoconazole, dimethomorph, epoxiconazole, fenhexamid, fludioxonil, flusilazole, 
fluxapyroxad, imazalil, iprodione, maneb, metalaxyl, myclobutanil, prochloraz, pro-
piconazole, pyraclostrobin, tebuconazole, and thiram. 
Within pesticides, herbicides are the most widely used substances in pest control. 
These chemical substances destroy weeds selectively in order to increase crop yield. 
The use of herbicides can increase crop yield by up to 10%. Among this group, there 
are many different chemical classes such as phenolic herbicides, phenoxy acids, di-
nitroanilines, carbamates, or amide herbicides.2,18 
Insecticides are used in different fields like agriculture, medicine, or at home against 
insects. Also, eggs or larvae of insects are thereby addressed. They can be differen-
tiated to inorganic and organic substances, whereby the organic insecticides can be 
further divided into organochlorines (OCs) and organophosphates (OPs). Both 
groups act as neurotoxins. Another group of insecticides is the neonicotinoids. These 
substances are used in particular where insects started to show resistance against 
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other types of insecticides. They are also distinguished by their high effectiveness, 
even at low doses, and rapid onset of action.2,18 
Insecticides that were used in this study are chlorpyrifos, ethoprophos, fipronil, thi-
acloprid, and thiamethoxam. 
Nematicides are used to kill nematodes. Many nematicides are too toxic to be used 
as sprays. These substances can be used as granules and are introduced directly into 
the soil, e.g., to protect potatoes. Substances, which can be used as nematicides and 
were investigated in this work are ethoprophos and iprodione.2 
Other pesticides that were used in this study were acaricides, which are used against 
ticks and mites, like fenpyroximate, or plant growth regulators like chlormequat. 
 
1.1.2 The Regulatory Framework for Market Release of New Single Pesticides 
The approval procedure for a new active substance is based on the European Union 
(EU) Regulation 1107/2009/EC 21. This achieves a homogenous and high level of 
safety for humans, animals, the environment, and groundwater in all member 
states 21,22. The approval of a new active substance involves several steps. Firstly, an 
application for approval of this substance must be submitted by the manufacturer 
to a member state. This responsible member state is called rapporteur member state 
(RMS). The content of the application for authorization can be found in EU Regula-
tion 1107/2009/EC and includes, among other things, the summary and the com-
plete dossier of the active substance. Secondly, an initial risk assessment of the RMS 
takes place, and a draft assessment report (DAR) is prepared. The RMS can modify 
the application and add amendments. Thirdly, the Pesticides Unit of the European 
Food Safety Authority (EFSA) carries out a peer review of the RMS's dossier. A con-
clusion report is then written and published by EFSA. In the next step, the Standing 
Committee on Plants, Animals, Food and Feed (SCoPAFF) decides whether the new 
active substance will be approved or not. Upon approval, this is adopted by the Com-
mission, and the regulation is published in the EU official journal (list of approved 
active substances). These steps must be taken to obtain authorization of a new ac-
tive substance at the EU level. Once the EU approval has been granted, the individual 
member states decide separately on the approval of plant protection products 
(PPPs) at the national level. In Germany, for example, this is coordinated by the Fed-
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eral Office of Consumer Protection and Food Safety (BVL) and carried out in coop-
eration with the Julius Kühn Institute (JKI), the Federal Environment Agency (UBA) 
and the German Federal Institute for Risk Assessment (BfR).22,23 
While EU Regulation 1107/2009/EC sets the framework for the authorization of a 
new active substance, Regulation 283/2013/EU 24 (active substances) and Regula-
tion 284/2013/EU 25 (plant protection products) set the necessary tests required 
for authorization. In addition to physical and chemical properties, toxicity and me-
tabolism studies must also be carried out. These last-mentioned studies include 
many animal experiments. They comprise acute toxicity tests, short-term toxicity, 
long-term toxicity, and carcinogenicity, as well as many others. Regulation 
1107/2009/EC describes that pesticide residues must not have harmful effects on 
humans or animals and that it is necessary to address potential cumulative and syn-
ergistic effects. These cumulative effects can be divided into additive, antagonistic, 
and synergistic effects. The following scheme (Figure 3) illustrates how these effects 
might look like.  
 
 
Figure 3. Schematic illustration of cumulative effects. Illustrated are cumulative effects of a binary mixture 
consisting of Substance A and Substance B as an example. In the first case (left), the substances are additive. The 
effects of the individual substances are added. The second case (mid) represents a synergism, whereby the effect 
in the mixture is stronger than the additive effect. In the third case (right), an antagonism is shown where the 
effects of the individual substances cancel each other out, and the resulting effect in the mixture is weaker than 
the additive effect. 
 
An additive effect of substances A and B (left side) is schematically shown, where 
the effect of the binary mixture represents the sum of A and B. For a synergistic ef-
fect (mid), the effect in the mixture is even stronger than that of the additive. An 
antagonism (right) is defined as the effect in the mixture of substance A and B being 
weaker than the additive effect. 
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Due to the ever-increasing number of new active substances and the associated in-
crease in potential mixtures, the number of animal experiments would increase dra-
matically if the examination of combinatorial effects in animals would become part 
of the authorization procedure. This fact calls for an alternative. With the develop-
ment of suitable in vitro methods, this problem of the risk assessment of potential 
combinatorial effects can be addressed, and the number of animal experiments can 
be reduced to a minimum. 
 
1.2 Metabolism of Pesticides & Regulation of Metabolic Enzymes 
1.2.1 Xenobiotic Metabolism 
The introduction to pesticides showed that an enormous amount thereof is used 
worldwide (1.1). However, pesticides are not the only substances to which organ-
isms are exposed. Organisms can also be exposed to a great variety of different for-
eign substances, also termed xenobiotics, such as chemicals 26,27 or active pharma-
ceutical substances 28. Due to this multitude of different influencing factors, which 
can also constantly change, organisms have developed defense mechanisms against 
these xenobiotics. In the so-called xenobiotic metabolism, which consists of several 
phases, endogenous or exogenous substances are processed and prepared for ex-
cretion from the body.29 
In order to be metabolized intracellularly, the substances must first enter the cell. 
The uptake of these substances is mainly accomplished by transport proteins be-
longing to the solute carrier (SLC) transporter family 30,31. In phase I, the often lipo-
philic xenobiotics are then converted by drug-metabolizing enzymes (DMEs). Acti-
vation is achieved by introducing a functional group to the substance by oxidation, 
reduction, or hydrolysis 29. The majority of DMEs in Phase I are covered by the cyto-
chrome P450 family (CYPs). This superfamily consists of many subfamilies, with 
mainly CYP1, CYP2, and CYP3 being responsible for the conversion of xenobiotics 32. 
After the activation step, the substances are made even more water-soluble by con-
jugation reactions in phase II. This additionally improves the renal and biliary ex-
cretion. Phase II enzymes are transferases, like glutathione S-transferases (GSTs), 
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UDP-glucuronosyltransferases (UGTs), N-acetyltransferases (NATs), or sulfotrans-
ferases (SULTs).33 
In phase III, metabolized, as well as unmetabolized substances, are excreted by mul-
tidrug resistance proteins (MRPs), which belong to the ATP-binding cassette (ABC) 
transporter family 31,32. 
In addition to these enzymes and transporters that play a role in the various phases 
of the xenobiotic metabolism, there are also receptors involved that are responsible 
for regulating these proteins. The mechanisms on which signal transduction is 
mainly based on include nuclear receptors 34, such as the pregnane X recep-
tor (PXR), the constitutive androstane receptor (CAR), the aryl hydrocarbon recep-
tor 35 (AhR), as well as other important transcription factors 32. The transcription 
regulation of genes related to xenobiotic metabolism takes place as soon as the nu-
clear receptors are activated. Activation is obtained through the binding of a ligand, 
for example, a pesticide. There are several ways to regulate transcription. For exam-
ple, after activation, the receptors can translocate from the cytosol into the nucleus. 
Here, they can bind to specific response elements of the target genes and thus either 
activate or inhibit transcription. This binding leads to the induction or repression of 
protein synthesis.36,37 PXR and CAR are mainly responsible for the transcriptional 
regulation of CYP3A and CYP2B isoforms, whereas CYP1A isoforms are primarily 
regulated by AhR 38. 
 
1.2.2 Preliminary Study for the Determination of Toxicologically Relevant 
Markers at mRNA Level 
The metabolism of xenobiotics mainly takes place in the liver, the most important 
organ for detoxification. As already mentioned, many different enzymes are in-
volved in these metabolic pathways. Foreign substances such as pesticides can alter 
the protein profile of these enzymes, which then could indicate liver toxicity. A pre-
selection of these potential markers was identified in a first study conducted by the 
group of Dr. Philip Marx-Stoelting, in which potential combinatorial effects of azole 
fungicides were investigated using “omics” technologies (Table 13). They state that 
for the identification of common mode of actions (MOAs) or adverse outcome path-
ways (AOPs), not only mechanistic analyses but also the analysis of mixture toxici-
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ties using relevant biomarkers are required to determine the assumed dose addi-
tions or concentration additions. The tested substances can then later be classified 
into cumulative assessment groups (CAGs). They also showed that species differ-
ences (between human and rat) were observed based on individual genes. In the 
case of pathway-level evaluation, the following five pathways were identified, which 
were affected across species by treatment with cyproconazole, epoxiconazole, and 
the mixture thereof: Chemical carcinogenesis, xenobiotic metabolism, drug metab-
olism, retinol metabolism, and steroid metabolism.39 
This implies the need to perform analyses in a human model, such as HepaRG cells, 
when the analysis is performed at the individual gene level and not at the pathway 
level (differences could also occur on pathway level, but it was shown that the eval-
uation on pathway level led to higher accordances), since the analysis in an animal 
model may not reflect the situation in humans.  
 
1.3 Proteomics 
The era of "omics" began with genome analysis, known as genomics, and considera-
ble progress has been made with these technologies 40. In 1995 the term proteome 
was coined by Marc Wilkins, who defined it as the total protein equivalent of a ge-
nome 41. Since then, the analyses of the proteome or transcriptome, which are gen-
erally referred to as proteomics or transcriptomics, came to the fore. 
Genes are only the carriers of information, so expression analysis gives only indirect 
information on proteins and their functions. In the course of understanding how a 
biological system works, it is necessary to investigate proteins or protein functions 
directly.40 
Comparing the genome with the proteome, one major difference is that the genome 
is a static source of information, which typically remains the same, while the prote-
ome is of dynamic origin. That means that the proteome can not only vary quantita-
tively (changes in protein levels) but also qualitatively (presence of different pro-
teins) depending on internal as well as external stimuli. This leads to the fact that 
different proteome data of the same genome can be obtained, depending on the time 
at which it is measured.40,42  
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In order to determine the function of a biological system, it is therefore essential to 
have a closer look at its proteome. One key aspect would be post-transcriptional 
protein regulation. Besides that, the protein synthesis, as well as the protein turno-
ver rates, can be different for particular transcripts.40  
A proteomic analysis typically involves several steps which consist of separation of 
complex sample mixtures, the identification of individual proteins as well as the 
quantification thereof 40,43,44. Within the last two decades, the use of chromato-
graphic methods such as high-performance liquid chromatography (HPLC) in com-
bination with mass spectrometric (MS) detection methods has been the key technol-
ogy of proteome analysis 44-46. Regarding MS-based proteomics, it can be further 
subdivided into top-down or bottom-up approaches, which will be further explained 
in the following section. 
 
1.3.1 Mass Spectrometry-Based Protein-Profiling Strategy 
In general, there are two different MS-based protein-profiling strategies. These tech-
niques are called top-down and bottom-up approach. Figure 4 (adapted from  
Gregorich et al. 47) depicts both strategies. On the left side, the top-down, on the right 
side, the bottom-up approach is shown. The main difference between the two strat-
egies is that the top-down approach aims to measure intact proteins, while the bot-
tom-up approach measures peptides as surrogates for the proteins of interest. In the 
first step, proteins need to be extracted out of cells or tissues. A variety of different 
extraction methods already exist 48, but it is crucial to choose an appropriate proto-
col regarding the MS analysis. Exemplarily, if buffers contain sodium, the formation 
of sodium adducts during the ionization process takes place, which changes the 
masses of analytes of interest 49. 
After the extraction of proteins, the workflow of the bottom-up approach comprises 
a proteolysis step. Proteolysis is either obtained by in-gel digestion or in-solution 
digestion (trypsin, endoprotease LysC, or endoprotease AspN are commonly used 
for MS-based proteomics approaches 41,47). After proteolysis, peptides are sepa-
rated, and MS profiling is done. In bottom-up approaches, separation is generally 
obtained with online liquid chromatography (LC). Compared to top-down, this ap-
proach offers a more robust way for protein identification 47. Also, the production of 
internal standards is more convenient. On the other hand, it has to be taken into 
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account that an intensive and comprehensive database search has to be performed 
in advance to achieve reliable identification and quantification. Peptides as surro-
gates for the protein of interest should be unique and should not contain sequence 
variants or modifications within their sequence.  
 
 
Figure 4. Top-down vs. Bottom-up approach. In the top-down approach (left), the protein is extracted from the 
cell or tissue, then chromatographically separated and directly analyzed by MS. In the bottom-up approach 
(right), the extraction is followed by a proteolysis step of the protein. The most common enzyme used for pro-
teolysis is trypsin. The resulting peptides are then chromatographically separated and analyzed via MS (adapted 
from Gregorich et al. 47). 
 
1.3.2 Targeted Proteomics  
The procedure in this thesis followed the targeted bottom-up approach, and  
Figure 5 (adapted from Uchida et al. 50) gives an overview of a typical workflow. In 
the first step, the target proteins are selected. Since the analysis is performed at the 
peptide level, a target peptide has to be chosen as a representative for each protein. 
The next steps include the synthesis of non-labeled synthetic standard target pep-
tides (ENs), the examination of their MS detection compatibility, and method devel-
opment. After the successful generation of the assays, samples have to be prepared, 
i.e., tryptic proteolysis and immunoprecipitation (IP). Afterward, the analysis by liq-
uid chromatography-mass spectrometry (LC-MS), as well as the data evaluation and 
quantification of target analytes, follows. Targeted proteomics applications are gen-
erally termed selected reaction monitoring (SRM) or multiple reaction monitoring 
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(MRM), as well as parallel reaction monitoring (PRM), depending on the mass spec-
trometer. Pre-filtration at MS1 level results in higher sensitivity. The isolated pep-
tides are then fragmented, and the specificity is increased by the detection of the 
fragment ions at MS2 level, thus ensuring unambiguous identification.51-53 
All steps are described in more detail in the following sections.  
 
 
Figure 5. Overview of a typical targeted bottom-up approach. It comprises the selection of target proteins fol-
lowed by the selection of respective target peptides. After target non-labeled standard synthetic peptides (ENs) 
are synthesized, their MS detection compatibility is checked, and the method development is performed. After 
digesting the samples, an immunoprecipitation (IP) is done, followed by the LC-MS analysis. The last step in-
cludes the data evaluation and quantification of target analytes (Scheme was adapted by Uchida et al. 50). 
 
1.3.3 Immunoaffinity-Based Mass Spectrometry 
One challenge with bottom-up strategies is the concentration of low abundant pro-
teins, which in most cases, cannot be detected. In order to detect these proteins, an 
additional sample preparation step has to be implemented. In this step, the analyte 
of interest is enriched, or the matrix complexity is reduced. This can be achieved, for 
example, by immunoaffinity chromatography 54 (IAC) or immunoprecipita-
tion 55 (IP). For instance, Anderson et al. introduced a method in 2004, called stable 
isotope standards and capture by anti-peptide antibodies 56 (SISCAPA). Here, stable 
isotope standards and anti-peptide antibodies are added to the proteolyzed sample. 
By using anti-peptide antibodies, the peptides to be investigated, as well as the iso-
topically labeled standard peptides, are pulled out of the sample, which leads to a 
drastically reduced matrix complexity.  
A reduced matrix complexity has several positive effects regarding LC-MS detection. 
First, ion suppression effects are reduced during the ionization at the ion source be-
fore the MS unit. Ion suppression affects the amount of charged ions and thus im-
pairs the detection, identification, and quantification of target analytes.57  
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Second, typical LC-MS approaches that focus on identification use chromatographic 
gradients of several hours 58. If the sample’s complexity is reduced by immune en-
richment or immune precipitation techniques, these gradients can be shortened ex-
ceedingly from 2-3-hour methods to 10-20-minute methods.59  
Third, sensitivity can be improved, while the conditions of the detection system 
(such as scan range, scan speed, or injection time) remain unchanged. If parameters 
of the detection system are changed, background signals may also increase, or the 
resolution of the MS instrument may be reduced.60 
Compared to ligand-binding assays, the immunoaffinity LC-MS application is able to 
differentiate interferences similar to the target, while the ability of the detection an-
tibody in a ligand-binding assay may be limited 61. In conclusion, immunoaffinity-
based LC-MS approaches offer fast, specific, selective, and reproducible methods 
that allow multiplexing.62,63 
Today, immunoaffinity enrichment or immunoprecipitation prior to mass spectro-
metric analyses is a widely used method for identifying and quantifying biomarkers 
such as peptide hormones 64, important markers in cardiac diseases 65 or cancer-
related research 66.  
 
1.3.4 Triple X Proteomics ‒ an Example of an Immunoaffinity-Based Mass 
Spectrometry Approach 
As described in the previous section, immunoaffinity enrichment or precipitation of 
targets is performed, so low abundant proteins can also be detected. Although many 
capture approaches, such as hydrazide chemistry-based enrichment 67 or immobi-
lized metal ion affinity chromatography 68 (IMAC), are available, polyclonal and 
monoclonal antibodies are the molecules of choice 69. The SISCAPA method is an ex-
ample of a one-target one-antibody approach, which means that one single target is 
enriched by a specific antibody. Therefore, a tremendous number of antibodies 
would have to be generated for the analysis of a whole proteome. Not only would 
that usher to enormous costs, but the number of animals immunized for the gener-
ation of antibodies would also increase dramatically. To address this issue, ap-
proaches that involve group-specific antibodies, such as context-independent motif-
specific 70 (CIMS) or triple X proteomics 71 (TXP), came to the fore. 
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In the TXP strategy, specific antibodies are generated towards four amino acid anti-
gens. Meaning, these particular antibodies do not bind to the whole sequence of the 
target peptide, but only the last four amino acids at the C-terminus. Since trypsin is 
used for proteolysis in this strategy, the TXP-antibodies enrich groups of tryptic pep-
tides that share the same short C-terminal tag. Thus, one particular antibody is able 
to enrich many different peptides, resulting in cost, as well as workload reduction. 
Furthermore, the number of animals required for the generation of antibodies can 
be reduced significantly.71,72 
The CYP450 superfamily already described in 1.2.1 consists of very homologous 
proteins. Therefore, the use of TXP antibodies is advantageous for the analysis of 
this family. Exemplarily, the anti-FSGR antibody, and the peptides, it can enrich, are 
shown in Figure 6. With this antibody it is possible to enrich at least five peptides 
simultaneously that are surrogates for CYP2B6, CYP2C8, CYP2C18, CYP2E1, and 
CYP2F1. 
 
 
AEAFSGR CYP2B6 
EALIDNGEEFSGR CYP2C8 
EALIDHGEEFSGR CYP2C18 
DEFSGR CYP2E1 
EALVDQGEEFSGR CYP2F1 
Figure 6. Anti-FSGR antibody with its respective targets. The anti-FSGR antibody is capable of enriching pep-
tides derived from several metabolizing enzymes of the CYP450 family, like CYP2B6, 2C8, 2C18, 2E1, or 2F1. 
 
Prior to the generation of TXP-antibodies, a bioinformatic approach is used to ana-
lyze theoretical fragments in silico. With this strategy, it is possible to further reduce 
the total number of group-specific antibodies recognizing the same C-terminal tag. 
In conclusion, the TXP approach, in combination with the bioinformatics strategy, is 
capable of reducing the total number of capture antibodies, thus minimizing the 
massive workload and costs of the one-target one-antibody approach.72 
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1.3.5 Mass Spectrometric Analysis Methods 
In a typical mass spectrometric bottom-up approach, the proteolysis is performed 
after the extraction of proteins. As described before, this can either be done with 
in-gel digestion or in-solution protocols. Most extraction buffers contain detergents 
that are incompatible with the LC-MS application, such as sodium dodecyl sulfate 
(SDS) or Triton X-100 73. To address this issue, in-gel digests are usually performed 
to shed interfering detergents. Afterward, proteolyzed samples can be directly in-
jected to the LC-MS device, and with a full-scan approach (Full-MS / ddMS²; data-
dependent tandem mass spectrometry), identification of proteins present in the 
sample can be performed. This procedure is commonly known as shotgun prote-
omics.74,75 
For research projects, where not the identification of analytes but rather quantifica-
tion of prior chosen analytes is in focus, targeted approaches are the application of 
choice. Since proteolyzed samples are much more complex than the corresponding 
protein sample (about 50 times more complex 41), peptides of low abundance get 
lost in a non-targeted approach. Therefore, targeted approaches such as targeted 
selected ion monitoring (tSIM) or parallel reaction monitoring (PRM) methods are 
used. Besides the full-scan (Full-MS) method, these targeted approaches are availa-
ble for the QExactive plus mass spectrometer (Thermo Fisher Scientific, Waltham, 
USA). Depending on the interrogation, one specific mode is chosen. In the following 
sections, the modes Full-MS / ddMS², tSIM, and PRM will be explained in detail. 
 
1.3.5.1 Full-scan MS 
For the analysis of complex samples, mass spectrometers are typically used, which 
combine different mass filters and mass analyzers. In the first unit (Q1), a  
pre-filtering can be performed according to different mass-to-charge ratios. In the 
second unit (commonly abbreviated with Q2), these precursor ions can be frag-
mented using different fragmentation methods such as higher-energy collisional 
dissociation 76 (HCD) or electron transfer dissociation 77 (ETD). In the last unit, the 
detection of either precursor or fragment ions is achieved by a mass detector like 
the Orbitrap mass analyzer. As described in the previous section (1.3.4), the full-
scan (Full-MS) strategy is often used in identification projects (shotgun proteomics), 
to identify novel biomarkers 78,79. In this mode, no prior knowledge of the analytes 
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within a sample is required, so no isolation list needs to be used. This means that in 
the quadrupoles of the mass spectrometer, no pre-filtering of the ions takes place. 
In the first step, all ionizable peptides reach the Orbitrap mass analyzer, and a scan 
is performed at the MS1 level (precursor ions). For each scan event, the most intense 
peptide ion mass-to-charge ratios (usually Top 10 or Top 15) are selected for frag-
mentation, and an MS2 level scan (fragment ions) is performed. Hence, the method 
is called Full-MS / ddMS². The analytes are then identified by comparing the mass 
spectra obtained with databases. Figure 7 shows the principle of the Full-MS meas-
urement mode.  
 
 
Figure 7. Principle of Full-MS. After chromatographic separation, all ionized peptides enter the first quadru-
pole (Q1) without filtering. Without being fragmented, these peptides enter the Orbitrap mass analyzer and are 
detected there.  
 
1.3.5.2 Targeted selected ion monitoring 
In targeted modes such as targeted selected ion monitoring (tSIM) shown in  
Figure 8, it is important to know that not all ionized analytes are detected by the 
Orbitrap mass analyzer because a pre-filtering is performed in the first quadrupole. 
This means that prior knowledge of the sample or the analytes is required, and this 
information is made available to the instrument via an isolation list. By using filters, 
the sensitivity of the measurement can be increased, since only specific masses are 
selected, which can pass the first quadrupole. The filtered ions that have passed the 
first quadrupole directly reach the Orbitrap mass analyzer where they are detected. 
An advantage compared to the Full-MS mode is that the sensitivity can be strongly 
increased. This mode is used for experiments, where the target and its mass are al-
ready known.80,81 
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Figure 8. Principle of tSIM. All ions enter the first quadrupole (Q1), which serves as a filter. Only ions with a 
specific mass can pass it. Without fragmentation, the masses of interest enter the Orbitrap mass analyzer and 
are detected there. 
 
1.3.5.3 Parallel reaction monitoring 
Parallel reaction monitoring, also known as PRM, is also a targeted mass spectro-
metric approach available on a QExactive Plus mass spectrometer. After the  
pre-filtering step in Q1, these filtered ions are fragmented in the higher-energy col-
lisional dissociation (HCD) cell. There, they collide with nitrogen atoms leading to 
fragmentation of the respective precursor ion. After fragmentation, all fragment ions 
enter the Orbitrap mass analyzer and can be detected in parallel. This approach of-
fers excellent specificity by isolating specific masses and further fragmentation of 
the respective analyte 52,82. Figure 9 shows the PRM principle. Since the measure-
ment in tSIM is MS1 level-based and, therefore, prone to interferences, especially in 
complex matrices, PRM offers an excellent alternative with increased specificity 82. 
 
 
Figure 9. Principle of PRM. Ionized peptides enter the first quadrupole (Q1), where the filtering of specifically 
chosen masses is performed. Then, these precursor ions are fragmented in the higher-energy collisional disso-
ciation (HCD) cell by colliding with nitrogen atoms. These fragments enter the Orbitrap mass analyzer, where 
they are detected.  
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2 Aim of this Thesis 
People are exposed to various pesticide residues through the consumption of food. 
The possible intake routes are either directly through the consumption of crops and 
vegetables, or indirectly through the consumption of meat from animals that come 
into contact with pesticides in fields, soil, or drinking water (Figure 10). The toxico-
logical properties of these substances are only investigated at the individual level 
during the authorization procedure. Therefore, only limited data on potential mix-
ing effects are available so far. That means that the toxicological investigation of 
these mixing effects represents a central challenge for regulatory purposes and risk 
assessment. More than 450 active substances are approved in Europe, with many 
already being used as mixtures today. The investigation of toxicological properties 
during the authorization procedure includes a large number of animal experiments, 
such as short- and long-term toxicity or carcinogenicity. That means that the num-
ber of animal experiments would increase enormously if the mixing effects were in-
vestigated with the standard toxicological tests. This calls for an alternative that can 
be addressed by the development of in vitro methods.  
Therefore, the first goal of this thesis was to develop immunoaffinity-based mass 
spectrometry assays to investigate potential mixing effects of pesticides on toxico-
logically relevant liver proteins. The development first included a comprehensive 
database search for suitable peptides, which had already been identified as possible 
representatives to indicate hepatotoxicity at the mRNA level. With these selected 
peptides and specifically generated antibodies against these peptides, various pa-
rameters should be investigated to ensure the reliability of these assays. These in-
cluded the mass spectrometry (MS) detection compatibility of the peptides, the 
functionality of the antibodies, the optimization of the antibody-protein ratio, opti-
mal digestion time, linearity studies, as well as recovery and intra-/ interday varia-
tion tests. 
As a second goal, the influence of 30 pesticides on the protein profile in human cell 
culture samples should be investigated after successful method development. The 
cell line HepaRG was used as a test system, as it shows very similar characteristics 
to primary human hepatocytes, especially with regard to the protein profile of xe-
nobiotic-metabolizing enzymes such as cytochrome P450 (CYP). The results of this 
Aim of this Thesis 
20 
screening with the 30 pesticides should then be used to classify them according to 
their effect similarities. In addition, it should be investigated which mixtures were 
already available on the market. 
The third goal was to prepare mixtures of pesticides from the screening in different 
concentrations to investigate the influence on the target proteins. As a final step, not 
only the regulation of the proteins but also potential combinatorial effects, such as 
synergism or antagonism, should be evaluated using statistical methods. 
 
 
Figure 10. Routes of pesticide intake. Pesticides applied in agriculture can remain as residues in crops and thus 
enter the human body directly through consumption. In addition, these substances can enter animals from feed, 
drinking water, or soil and then indirectly enter the human organism through the consumption of meat. 
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3 Material and Methods 
3.1 Buffer 
Table 2. Buffer and Eluents 
Buffer/Eluents Ingredients 
Concentration/ 
Percentage share 
ABCC Buffer 
NH4HCO3 
CHAPS 
50 mmol L-1 
0.03% 
Eluent A (LC) 
FA 
Water, LC-MS grade 
0.1% 
 
Eluent B (LC) 
ACN 
FA 
Water, LC-MS grade 
80% 
0.1% 
 
Eluent C (LC) 
IPA 
Water, LC-MS grade 
10% 
 
Extraction Buffer (in-gel digest) 
ACN 
TFA 
50% 
0.05%  
Loading Buffer (LC) 
ACN 
TFA 
Water, LC-MS grade 
2% 
0.05% 
 
Lysis Buffer 
NP-40 
SDS 
NaCl 
Na2HPO4 x 2 H2O 
EDTA 
1% 
0.01% 
150 mmol L-1 
10 mmol L-1 
2 mmol L-1 
PBSC Buffer 
PBS 1x 
CHAPS 
 
0.03% 
Triethanolamine Triethanolamine 100 mmol L-1 
Washing Buffer A (in-gel digest) 
NH4HCO3 
ddH2O 
5 mmol L-1 
Washing Buffer B (in-gel digest) 
NH4HCO3 
ACN 
10 mmol L-1 
50% 
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3.2 Chemicals, Biochemicals, Reagents 
Table 3. Chemicals, Biochemicals, Reagents 
Substance Manufacturer 
3-[(3-Cholamidopropyl) dimethylammonio] -1-
propanesulfonate (CHAPS) 
Carl Roth, Karlsruhe, Germany 
Acetic acid 100% Carl Roth, Karlsruhe, Germany 
Acetone, ACS grade VWR, Darmstadt, Germany 
Acetonitrile, ROTISOLV ≥99.98%, Ultra LC-MS 
(ACN) 
Carl Roth, Karlsruhe, Germany 
Ammonia solution 25%, Rotipuran Carl Roth, Karlsruhe, Germany 
Ammonium bicarbonate (ABC) Sigma-Aldrich, St. Louis, USA 
Bicinchoninic acid protein assay reagents (BCA) Thermo Fisher Scientific, Waltham, USA 
Blocking reagent for ELISA Roche Diagnostics, Mannheim, Germany 
Customized polyclonal antibody sera Pineda GmbH, Berlin, Germany 
Customized synthetic isotopically labeled 
peptides (IS) 
Intavis AG, Tübingen, Germany 
Customized synthetic non-labeled peptides (ENs) Intavis AG, Tübingen, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
Dionex Cytochrome C Digest Thermo Fisher Scientific, Waltham, USA 
Disodium phosphate (Na2HPO4 x 2 H2O) Carl Roth, Karlsruhe, Germany 
Ethanol, >99.8%, p.a. Carl Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe, Germany 
Formic acid UHPLC-MS Optigrade (FA) LGC Standards, Teddington, United Kingdom 
Hydrochloric acid 37% fuming (HCl) Carl Roth, Karlsruhe, Germany 
InstantBlue Coomassie Protein Stain Expedeon, San Diego, USA 
Iodoacetamide (IAA) Sigma-Aldrich, St. Louis, USA 
Isopropyl alcohol, ROTISOLV ≥99.95%, Ultra  
LC-MS (IPA) 
Carl Roth, Karlsruhe, Germany 
LTQ Velos ESI Positive Ion Calibration Solution Thermo Fisher Scientific, Waltham, USA 
Methanol, ROTISOLV ≥99.98%, Ultra LC-MS Carl Roth, Karlsruhe, Germany 
NP40 Surfact Amps Detergent Solution Thermo Fisher Scientific, Waltham, USA 
NuPAGE Antioxidant Thermo Fisher Scientific, Waltham, USA 
NuPAGE LDS Sample Buffer (4X) Thermo Fisher Scientific, Waltham, USA 
NuPAGE MES SDS Running Buffer (20X) Thermo Fisher Scientific, Waltham, USA 
NuPAGE Sample Reducing Agent Thermo Fisher Scientific, Waltham, USA 
Phenylmethanesulfonyl fluoride (PMSF) Roche Diagnostics, Mannheim, Germany 
Phosphate buffered saline 10x (PBS) Thermo Fisher Scientific, Waltham, USA 
Pierce Bovine Serum Albumin Standard (BSA) Thermo Fisher Scientific, Waltham, USA 
Pierce Coomassie Plus Assay Kit Thermo Fisher Scientific, Waltham, USA 
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Substance Manufacturer 
Pierce Trypsin Protease, MS-Grade Thermo Fisher Scientific, Waltham, USA 
SeeBlue Plus2 Prestained Standard Thermo Fisher Scientific, Waltham, USA 
Sodium azide (NaN3) Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St. Louis, USA 
Sodium hydroxide ≥99% (NaOH) Carl Roth, Karlsruhe, Germany 
Technical buffer solution pH 4.01 Mettler Toledo, Columbus, USA 
Technical buffer solution pH 7.00 Mettler Toledo, Columbus, USA 
Technical buffer solution pH 9.21 Mettler Toledo, Columbus, USA 
Triethanolamine hydrochloride (TEA/TEA-HCl) Carl Roth, Karlsruhe, Germany 
Trifluoracetic acid, ULC/MS Optigrade (TFA) LGC Standards, Teddington, United Kingdom 
Tris(2-carboxyethyl) phosphine (TCEP) Carl Roth, Karlsruhe, Germany 
Water, ROTISOLV Ultra LC-MS Carl Roth, Karlsruhe, Germany 
 
3.3 Consumables 
Table 4. Consumables 
Consumables Manufacturer 
96-Well robotic full-skirted plate, 0.2 mL Thermo Fisher Scientific, Waltham, USA 
Acclaim PepMap RSLC C18, 75 μm I.D. x 150 mm,  
2 μm 
Thermo Fisher Scientific, Waltham, USA 
Acclaim PepMap RSLC C18,75 μm I.D. x 500 mm,  
2 μm 
Thermo Fisher Scientific, Waltham, USA 
Acclaim PepMap100 C18 μ-precolumn, 0.3 mm 
I.D. x 5 mm, 5 μm 
Thermo Fisher Scientific, Waltham, USA 
Axygen AxySeal sealing film  Corning Incorporated, Corning, USA 
Cellstar tubes, 15 mL, PP, graduated, conical  
bottom 
Greiner Bio-One, Frickenhausen, Germany 
Cellstar tubes, 50 mL, PP, graduated, conical  
bottom  
Greiner Bio-One, Frickenhausen, Germany 
Cellstar tubes, 50 mL, PP, graduated, 
self-standing 
Greiner Bio-One, Frickenhausen, Germany 
DURAN Laboratory bottle with DIN thread, GL 45, 
250 mL 
Duran Group GmbH, Wertheim/Mainz, Germany 
DURAN Laboratory bottle with DIN thread, GL 45, 
500 mL 
Duran Group GmbH, Wertheim/Mainz, Germany 
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Consumables Manufacturer 
DURAN Laboratory bottle with DIN thread, GL 45, 
1000 mL 
Duran Group GmbH, Wertheim/Mainz, Germany 
Dynabeads Protein G Thermo Fisher Scientific, Waltham, USA 
Easy Peel Heat Sealing Foil Thermo Fisher Scientific, Waltham, USA 
Eppendorf Tubes 3810X, 1.5 mL Eppendorf, Hamburg, Germany 
Eppendorf Tubes, 5.0 mL Eppendorf, Hamburg, Germany 
epT.I.P.S. Standard 0.1-10 µL Eppendorf, Hamburg, Germany 
epT.I.P.S. Standard 100-5000 µL Eppendorf, Hamburg, Germany 
epT.I.P.S. Standard 2-200 µL Eppendorf, Hamburg, Germany 
epT.I.P.S. Standard 50-1000 µL Eppendorf, Hamburg, Germany 
HiTrap NHS-activated HP GE Healthcare Life Sciences, Chicago, USA 
KingFisher 96 tip comb Thermo Fisher Scientific, Waltham, USA 
Micro insert, 0.1 mL, clear glass 15 mm, top VWR, Darmstadt, Germany 
Micro inserts glass, 250 μL, conical neoLab, Heidelberg, Germany 
Microplate, 96 well, PS, F-Bottom, clear Greiner Bio-One, Frickenhausen, Germany 
Mμlti-safety microcentrifuge tubes, 0.65 mL Carl Roth, Karlsruhe, Germany 
Nitrile gloves VWR, Darmstadt, Germany 
Novex WedgeWell 4-20% Tris-Glycine Gel Thermo Fisher Scientific, Waltham, USA 
PCR Tube Strips 0.2 mL Eppendorf, Hamburg, Germany 
pH indicator paper range 1-14 Carl Roth, Karlsruhe, Germany 
PipetteTips, SpaceSaver, LTS, 300 µL Mettler Toledo, Columbus, USA 
PipetteTips, StableRak, LTS, 10 µL Mettler Toledo, Columbus, USA 
PipetteTips, StableRak, LTS, 250 µL Mettler Toledo, Columbus, USA 
QUICKRACK Tip Transfer System, 1250 μL Biozym Scientific, Oldendorf, Germany 
Reaction tubes with screw thread, 1.5 mL, conical neoLab, Heidelberg, Germany 
Reaction tubes with screw thread, 1.5 mL, 
self-standing 
neoLab, Heidelberg, Germany 
Reaction tubes with screw thread, 2.0 mL, 
self-standing 
neoLab, Heidelberg, Germany 
Screw caps for reaction 1.5 mL and 2 mL tubes neoLab, Heidelberg, Germany 
Screw caps, 9 mm, natural rubber red-orange VWR, Darmstadt, Germany 
Vial short thread, 1.5 mL, amber glass with label VWR, Darmstadt, Germany 
Viper Inline Filter Thermo Fisher Scientific, Waltham, USA 
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3.4 Laboratory Equipment 
Table 5. Laboratory Equipment 
Apparatus Manufacturer 
ABgene Combi Thermo-Sealer Thermo Fisher Scientific, Waltham, USA 
Absorbance microplate reader, BioTek ELx808 BioTek, Winooski, USA 
Analytical balance CPA225D-0CE Sartorius Stedim Biotech, Göttingen, Germany 
Analytical balance XS205 DualRange Mettler Toledo, Columbus, USA 
Analytical balance, Explorer scale OHAUS Waagen, Bad Hersfeld, Germany 
Axyspin Mini Plate Spinner Centrifuge, Axygen Corning Incorporated, Corning, USA 
Ball mill, Micro-Dismembrator U Sartorius Stedim Biotech, Göttingen, Germany 
Centrifuge, Mini Star VWR, Darmstadt, Germany 
Chromatography system, ÄKTAxpress GE Healthcare Life Sciences, Chicago, USA 
Chromatography system, UltiMate 3000  
RSLCnano 
Thermo Fisher Scientific, Waltham, USA 
Electrophoresis Power Supply Power Ease 500 Thermo Fisher Scientific, Waltham, USA 
Electrophoresis System XCell SureLock Thermo Fisher Scientific, Waltham, USA 
Ice machine Scotman AF40 Frimont S.p.A., Pogliano Milanese, Italy 
Magnet Dynal MPF-96S Thermo Fisher Scientific, Waltham, USA 
Magnet DynaMag Spin Thermo Fisher Scientific, Waltham, USA 
Magnet KingFisher 96 PCR head Thermo Fisher Scientific, Waltham, USA 
Magnetic particle processor, KingFisher  
96-purification system 
Thermo Fisher Scientific, Waltham, USA 
Magnetic particle processor, KingFisher  
Flex-purification system 
Thermo Fisher Scientific, Waltham, USA 
Mass spectrometer, QExactive Thermo Fisher Scientific, Waltham, USA 
Mass spectrometer, QExactive Plus Thermo Fisher Scientific, Waltham, USA 
Microcentrifuge 5415D  Eppendorf, Hamburg, Germany 
Mixer, Vortex-Genie 2 Scientific Industries, Bohemia, USA 
Multichannel Electronic Pipette, E4 XLS,  
100–1200 µL 
Mettler Toledo, Columbus, USA 
Multichannel pipette 50–1200 μL, Eppendorf 
Research Pro 
Eppendorf, Hamburg, Germany 
Multichannel pipette, Pipet-Lite XLS, 2–20 μL Mettler Toledo, Columbus, USA 
Multichannel pipette, Pipet-Lite XLS, 20–300 μL Mettler Toledo, Columbus, USA 
Multichannel pipette, Pipet-Lite XLS, 5–50 μL Mettler Toledo, Columbus, USA 
Multi-syringe infusion pump SP220i World Precision Instruments, Sarasota, USA 
pH-meter, 766 Calimatic Knick, Berlin, Germany 
Pipette 0.1–2.5 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
Pipette 10–100 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
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Apparatus Manufacturer 
Pipette 100–1000 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
Pipette 2–20 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
Pipette 20–200 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
Pipette 50–5000 μL, Eppendorf Research plus Eppendorf, Hamburg, Germany 
Refrigerated microcentrifuge 5417R Eppendorf, Hamburg, Germany 
Sample mixer, HulaMixer  Thermo Fisher Scientific, Waltham, USA 
Single Channel Electronic Pipette, E4 XLS,  
20–300 µL 
Mettler Toledo, Columbus, USA 
Spectrophotometer, NanoDrop 2000c  Thermo Fisher Scientific, Waltham, USA 
SWC Safety Weighing Cabinet Sartorius Stedim, Biotech, Göttingen, Germany 
Thermomixer C Eppendorf, Hamburg, Germany 
ThermoMixer, Comfort Eppendorf, Hamburg, Germany 
Ultrasonic bath, Sonorex  Bandelin electronic, GmbH, Berlin, Germany 
Water purification system, Milli Q Plus Sartorius Stedim, Biotech, Göttingen, Germany 
 
3.5 Databases and Software 
Table 6. Databases and Software 
Software Distributor 
Gen 5.1.10.8 BioTek, Winooski, USA 
Chromeleon 6.8 Thermo Fisher Scientific, Waltham, USA 
Endnote x8 Thomson Reuters, Philadelphia, USA 
Microsoft Office Home and Business 2016 Microsoft, Redmond, USA 
Nanodrop 2000/2000c 1.5 Thermo Fisher Scientific, Waltham, USA 
Origin 2017G OriginLab, Northampton, USA 
Proteome Discoverer 2.1 Thermo Fisher Scientific, Waltham, USA 
ProteomicsDB TUM, München, Germany 
RStudio v.1.0.153 R Consortium, Boston, USA 
Skyline 4.2.0.19072 
MACOSS Lab, Department of genome sciences, 
University of Washington, Seattle, USA 
Tune 2.8 Thermo Fisher Scientific, Waltham, USA 
TXP-Tools 
Dr. Hannes Planatscher, Signatope GmbH, Reut-
lingen, Germany 
Unicorn 5.11 GE Healthcare Life Sciences, Chicago, USA 
UniProtKB Protein knowledgebase UniProt Consortium 
Xcalibur 4.0 Thermo Fisher Scientific, Waltham, USA 
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3.6 Samples 
The workgroup of Prof. Dr. Ulrich Rothbauer (University of Tübingen) kindly pro-
vided human cell culture (human blend: human embryonic kidney (HEK), human 
colon tumor (HCT), and hepatoma G2 (HepG2)), as well as mouse cell culture 
(NIH3T3) samples. 
The German Federal Institute for Risk Assessment (BfR) in Berlin (Dr. Albert  
Braeuning) kindly provided treated and untreated HepaRG cells. For the screening, 
the pesticide concentrations used were chosen as high as possible without being 
toxic for the cells. The cells for the method development were treated with 
10 µmol L-1 prochloraz.  
The samples to be analyzed after the method development were treated with differ-
ent pesticides and pesticide mixtures (shown in 3.6.1 as well as in 3.6.2). 
Dr. Almut Mentz (Center for Biotechnology (CeBiTec), Universität Bielefeld) kindly 
provided mRNA results measured with quantitative real-time polymerase chain re-
action (qPCR). 
Cryopreserved primary human hepatocytes (PHHs; donors 1, 2, and 3) were pur-
chased from hepacult GmbH in Martinsried.  
 
3.6.1 Pesticides 
Table 7. Pesticides of the screening  
Substance Chemical class 83 Function 84 
WHO 
Category 20 
(Table 1) 
Concentration 
in µmol L-1 
Azoxystrobin Strobilurin Fungicide U 100 
Boscalid Carboxamide Fungicide U 500 
Captan Phthalimide Fungicide U 50 
Carbendazim  Benzimidazole Fungicide U 250 
Chlormequat 
Quarternary ammo-
nium compound 
Plant growth  
regulator 
II 1000 
Chlorpyrifos Organophosphate 
Acaricide,  
Insecticide 
II 200 
Cyproconazole Triazole Fungicide II 80 
Cyprodinil Anilinopyrimidine Fungicide - 100 
Difenoconazole Triazole Fungicide II 25 
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Substance Chemical class 83 Function 84 
WHO 
Category 20 
(Table 1) 
Concentration 
in µmol L-1 
Dimethomorph Morpholine Fungicide U 500 
Epoxiconazole Triazole Fungicide - 80 
Ethoprophos Organophosphate 
Insecticide, 
Nematicide 
Ia 500 
Fenhexamid Hydroxyanilide Fungicide U 250 
Fenpyroximate Pyrazolium Acaricide II 5 
Fipronil Phenylpyrazole Insecticide II 50 
Fludioxonil Phenylpyrrole Fungicide U 250 
Flusilazole  Triazole Fungicide II 80 
Fluxapyroxad Pyrazolium Fungicide - 250 
Imazalil Imidazole Fungicide II 50 
Iprodione Dicarboximide 
Fungicide,  
Nematicide 
III 200 
Maneb Carbamate Fungicide U 200 
Metalaxyl Acylalanine Fungicide II 1000 
Myclobutanil Triazole Fungicide II 250 
Prochloraz Imidazole Fungicide II 80 
Propiconazole Triazole Fungicide II 80 
Pyraclostrobin Strobilurin 
Fungicide, 
Plant growth  
regulator 
- 25 
Tebuconazole Triazole Fungicide II 80 
Thiacloprid Neonicotinoid Insecticide II 500 
Thiamethoxam Neonicotinoid Insecticide - 1000 
Thiram Carbamate Fungicide II 100 
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Table 8. Single pesticides for treatment kinetics 
Substance 
Treatment duration 
in h 
Concentration 
in µmol L-1 
Difenoconazole 24, 72 10 (72 h), 25 (24 h) 
Fenpyroximate 24, 72 2.5 (72 h), 5 (24 h) 
Flusilazole 24, 72 80 
Imazalil 24, 72 50 
 
Table 9. Single pesticides for comparison with mixtures 
Substance 
Treatment duration 
in h 
Concentration 
in µmol L-1 
Azoxystrobin 24, 48, 72 10, 25, 35, 50, 70 
Cyproconazole 24, 48, 72 35, 55, 70, 110, 140 
Difenoconazole 24, 48, 72 4, 6, 8, 10, 12 
Propiconazole 24, 48, 72 20, 30, 40, 60, 80 
Thiacloprid 24, 48, 72 250, 375, 500, 750, 1000 
 
3.6.2 Pesticide Mixtures 
Table 10. Mixtures with different treatment durations and concentrations 
Mixture # Substances 
Treatment 
time in h 
Concentration 
in µmol L-1 
Total concentration 
in µmol L-1 
Product 
1 
Propiconazole, 
Difenoconazole 
24, 48, 72 
5, 1 
10, 2 
20, 4 
30, 6 
40, 8 
6 
12 
24 
36 
48 
TASPA 
2 
Azoxystrobin, 
Difenoconazole 
24, 48, 72 
5, 1 
10, 2 
15, 3 
25, 5 
35, 7 
6 
12 
18 
30 
42 
ASKON 
3 
Thiacloprid, 
Azoxystrobin 
24, 48, 72 
25, 2.5 
125, 12.5 
250, 25 
375, 37.5 
500, 50 
27.5 
137.5 
275 
412.5 
550 
 
- 
Material and Methods 
31 
Mixture # Substances 
Treatment 
time in h 
Concentration 
in µmol L-1 
Total concentration 
in µmol L-1 
Product 
4 
Azoxystrobin, 
Cyproconazole 
24, 48, 72 
2.5, 5 
10, 20 
17.5, 35 
27.5, 55 
35, 70 
7.5 
30 
52.5 
82.5 
105 
Various 
 
3.6.3 Induction Controls 
Table 11. Prototypical Inducers 
Substance Chemical class Function 
Concentration 
in µmol L-1 
Benz[a]pyrene 
Polycyclic aromatic  
hydrocarbon 
AhR agonist 1.25, 2.5, 5 
6-(4-Chlorophenyl)imid-
azo[2,1-b][1,3]thiazole-5-
carbaldehyde O-(3,4-di-
chlorobenzyl)oxime 
(CITCO) 
Imidazothiazole  
derivative 
CAR agonist 2.5, 5, 10 
Rifampicin Ansamycin PXR agonist 1.25, 2.5, 5 
 
3.7 Antibody Purification 
For the generation of polyclonal triple X proteomics (TXP) antibodies, rabbits were 
immunized with the respective antigens by Pineda GmbH (Berlin, Germany). The 
required KLH-peptide conjugate was generated according to Hoeppe et al.72 The 
rabbit sera (approximately 10 mL each) containing the antibodies were purified 
with an affinity chromatography device (ÄKTAx-pressTM). The sera were first fil-
tered through a 0.2 µm sterile filter. Affinity columns with peptides as a stationary 
phase, which served as ligands for the antibodies, were prepared. The mobile phase 
consisted of a phosphate-buffered saline solution (PBS). The peptides immobilized 
on the column captured only the antibodies with the appropriate paratope, and 
other components were washed away. Elution was performed using 100 mmol L-1 
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citric acid buffer at a pH of 2.5. The eluted sample was re-buffered in PBS and de-
salted by using three consecutive 5 mL filtration columns. After the antibodies were 
purified, their concentration was determined. The Nanodrop 2000c spectrometer 
(Thermo Fisher Scientific, Waltham, USA) was used for this purpose. The absorption 
of the antibody solution was measured at 280 nm. Then, the concentration was cal-
culated according to the law of Beer-Lambert:  
 
𝐴 = 𝜀 ∙ 𝑐 ∙ 𝑑  (41) 
A= absorption 
ε= extinction coefficient of an immunoglobulin G antibody 
c= concentration of the antibody to be determined 
d= path length of the nanodrop device 
 
The standard molecular mass of an immunoglobulin G antibody (IgG antibody) is 
≈ 1.5·105 g mol-1, and the extinction coefficient ε is 2.1·105 L mol-1 cm-1. The path 
length of the nanodrop device and the extinction coefficient could be regarded as 
constants so that the formula of the Beer-Lambert law can be adapted as follows: 
 
𝐴280 𝑛𝑚
1 𝑚𝑔 𝑚𝐿−1 = 1.4  (85) 
 
To preserve the antibody solution, 0.05% sodium azide (NaN3) was added, and the 
antibody solutions were stored in the refrigerator at 4°C until further use. 
 
3.8 Sample Preparation 
3.8.1 Peptide Standards 
The synthetic peptide standards were synthesized by INTAVIS AG (Tübingen, Ger-
many). Not only non-labeled synthetic standard peptides (ENs) but also isotopically 
labeled synthetic standard peptides (IS) were generated. The isotopically labeled 
synthetic peptides were used as internal standards for method development and 
analysis of samples. Both ENs and IS have the same sequence, the only difference 
being the isotope-labeled (13C/15N) C-terminal arginine or lysine. This label results 
in a mass shift of eight for lysine and ten for arginine when the analyte is singly 
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charged. Due to the same sequence of both peptides, they have the same physico-
chemical properties and therefore elute at the same time during the chromato-
graphic separation step. Before the peptides could be used, they had to be dissolved. 
About 1.5 mg of each peptide was weighed, pure dimethyl sulfoxide (DMSO) solu-
tion and ultrapure water (LC-MS grade) were added to obtain a final concentration 
of 5 mmol L-1 DMSO. The peptide solutions were stored at -20°C until further use. 
 
3.8.2 Cell Lysis and Protein Determination 
The whole sample preparation included several steps. First, the samples were lysed, 
then digested, and before the mass spectrometry measurement, immune precipita-
tion was performed. Lysis was done for one hour on ice with a lysis buffer containing 
Na2HPO4 + 2 H20 (0.01 mol L-1), NaCl (0.15 mol L-1), NP-40 (1%), SDS (0.01%), and 
EDTA (0.002 mol L-1). After lysis, the samples were centrifuged for 10 minutes at 
13 000 g and 4°C. To determine protein concentration, the bicinchoninic acid (BCA) 
protein assay kit (Thermo Fisher Scientific, Waltham, USA) was used. First, the dilu-
tion of the standard curve was performed (initial bovine serum albumin (BSA) con-
centration was: β=2 mg mL-1). Table 12 shows the dilution steps of the standard 
curve. 
 
Table 12. Dilution of the BSA standard curve for BCA assay. The initial concentration of bovine serum albumin 
(BSA) was β=2 mg mL-1. The standard curve consisted of eight concentration levels and an additional blank.  
Dilution 
Concentration 
in µg mL-1 
A 2000 
B 1500 
C 1000 
D 750 
E 500 
F 250 
G 125 
H 62.5 
I (blank) 0 
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After preparing the standard curve, HepaRG samples were diluted with lysis buffer 
(1:5). To rule out measurement errors of the instrument, each dilution, including 
that of the dilution curve, was pipetted twice onto the sample plate (microplate, 
96-well; Greiner Bio-One, Frickenhausen, Germany). In each well, 25 µL sample and 
200 µL working solution (BCA protein assay reagents A and B in a ratio of 50:1) were 
pipetted. To check the accuracy of the measurement, four quality control (QC) sam-
ples (prepared and verified BSA dilutions) were also pipetted onto the plate. These 
QC samples had the following concentrations: 50 µg mL-1, 150 µg mL-1, 300 µg mL-1, 
and 800 µg mL-1. To consider the protein determination as valid, the measured con-
centration of the QC samples must not deviate by more than 20% from the theoret-
ical concentration. After the samples and the working solution were pipetted onto 
the plate, the plate was sealed with a PlateMax-AxySeal Sealing Film (Corning Incor-
porated, Corning, USA) and the samples incubated at 37°C and 650 rpm for 
30 minutes on a thermomixer (Eppendorf, Hamburg, Germany). After incubation, 
air bubbles formed during incubation were removed, and the plate cooled to room 
temperature. As a readout, the absorbance microplate reader BioTek ELx808 (Bio-
Tek, Winooski, USA) was used, and the absorbance at 562 nm measured.  
 
3.8.3 Enzymatic Proteolysis and Immunoprecipitation 
The mass spectrometric measurement of proteins was performed indirectly at the 
peptide level. Therefore, the proteins had to be digested in order to obtain the pep-
tides of interest (procedure shown in Figure 11). Triethanolamine (TEA; final con-
centration 0.05 mol L-1) and lysis buffer (3.1 Buffer) were added to the respective 
sample amounts. A subsequent denaturation step for five minutes at 99°C followed. 
Samples were then cooled down to room temperature, and 0.2 mol L-1 tris(2-carbox-
yethyl) phosphine (TCEP) was added (final concentration 0.005 mol L-1). After shak-
ing for 30 seconds, samples were alkylated with 0.4 mol L-1 iodoacetamide (IAA; fi-
nal concentration 0.01 mol L-1) for 30 minutes at room temperature in the dark. For 
initiating the digestion, trypsin was added (trypsin:protein ratio was 1:40), and the 
temperature set to 37°C. To stop digestion, 0.042 mol L-1 phenylmethanesulfonyl 
fluoride (PMSF; final concentration 0.001 mol L-1) was used. After inactivation, the 
digested samples were centrifuged for 10 min at 13 000 g and then stored at -20°C 
until further use.   
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Figure 11. Workflow tryptic proteolysis. In the first step, TEA and lysis buffer were added to the samples, and 
then they were denatured at 99°C for five minutes. Reduction and alkylation of the sample were achieved by 
adding TCEP and IAA. With trypsin, proteins were fragmented down to peptides. Inactivation of trypsin was 
achieved by the use of PMSF. 
 
For immunoprecipitation in 96-well format, PBS containing CHAPS (3-[(3-Chol-
amidopropyl) dimethylammonio] -1-propanesulfonate), sample, internal isotopi-
cally labeled standard peptide, and the corresponding amount of antibodies were 
mixed. An incubation step of one hour followed, during which the samples were 
mixed six times for two minutes with an eight-minute pause between the mixing 
steps. During this time, the antibody-peptide complex (both non-labeled synthetic 
standard or endogenous peptide and isotopically labeled standard peptide) was 
formed. The first incubation step was followed by a second incubation step in which 
magnetic microspheres coated with protein G (Dynabeads Protein G; Thermo Fisher 
Scientific, Waltham, USA) were added. The second incubation step was performed 
according to the first. Five washing steps followed, with the first two washing solu-
tions consisting of PBSC and the last three solutions consisting of CHAPS-containing 
ammonium bicarbonate (ABCC). Finally, the peptides were eluted with formic acid 
(FA; 1%). To remove bead residues, the eluates were first transferred into a new 
96-well microtiter plate and then into glass vials for liquid chromatography-mass 
spectrometry (LC-MS) measurement. The entire TXP workflow is shown in  
Figure 12. 
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Figure 12. TXP-workflow. The TXP workflow consists of several steps. First, the sample preparation, where 
cells are lysed and then digested with trypsin. After that, isotopically labeled standard peptides and antibodies 
are added during the immunoprecipitation step. With protein G coated microspheres, the antibody-peptide com-
plexes are pulled out of the matrix. The analysis is then performed with LC-MS. 
 
3.9 Assay Development 
3.9.1 Database Search for Suitable Peptides 
This project aimed to investigate several toxicologically relevant liver proteins. In a 
previous study by Seeger et al.39, potential toxicologically relevant target genes have 
already been identified at mRNA level by quantitative real-time polymerase chain 
reaction (qPCR). These targets were used as a basis for the selection of analytes at 
the protein level. Table 13 gives an overview of the 44 target genes from the opti-
mized PCR array. 
 
Table 13. Overview of the target genes of the PCR array. Here, the 44 target genes identified and measured by 
qPCR are shown. 
# Gene # Gene # Gene # Gene 
1 ABCC2 12 COX1 23 HRG 34 POR 
2 ABCC3 13 CYP1A1 24 HSD11B2 35 PRKDC 
3 ACOX2 14 CYP2A13 25 HULC 36 S100P 
4 ADH1B 15 CYP2C9 26 IL6 37 SCARA3 
5 ALDH3A1 16 CYP2D6 27 INSIG1 38 SCD 
6 ANXA10 17 CYP2E1 28 LMNA 39 SLCO1B1 
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# Gene # Gene # Gene # Gene 
7 ARG1 18 CYP3A5 29 LY6D 40 SREBF1 
8 CCL20 19 CYP7A1 30 MLXIP 41 SULT1B1 
9 CD36 20 FASN 31 NEAT1 42 SYT1 
10 CES2 21 G6PC 32 NQO1 43 TNFRSF12A 
11 CGA 22 GZMB 33 NR1I3 44 UGT2B7 
 
Before a database search was performed, the list was modified. For example, 
UGT1A1, UGT1A3, and UGT2B15 were added to this list. No database search was 
performed for targets such as CYP2C9 or CYP2D6 for which mass spectrometric im-
munoassays have already been established 86. In total, the list of target analytes that 
should be analyzed at the protein level comprised 52 analytes. Table 14 shows all 
analytes to be investigated for possible combinatorial effects of pesticide mixtures. 
 
Table 14. Modified list of potential target analytes. This list comprises 52 potential target markers for the anal-
ysis of pesticide mixtures in HepaRG cells and whether already assays existed. 
Targets Targets Targets 
# Analyte 
Already 
developed 
# Analyte 
Already  
developed 
# Analyte 
Already 
developed 
1 ACOX2 N 19 CYP2E1 Y 37 MLXIP N 
2 ADH1B N 20 CYP2F1 Y 38 NCPR Y 
3 ALDH3A1 N 21 CYP3A4 Y 39 NQO1 N 
4 ANXA10 N 22 CYP3A5 Y 40 NR1I3 N 
5 ARG1 N 23 CYP3A7 Y 41 PRKDC N 
6 CCL20 N 24 CYP3A43 Y 42 S100P N 
7 CD36 N 25 CYP7A1 N 43 SCARA3 N 
8 CES2 N 26 FASN N 44 SCD N 
9 CGA N 27 G6PC N 45 SREBF1 N 
10 COX1 N 28 GAPDH N 46 SULT1B1 N 
11 CYP1A1 Y 29 GZMB N 47 SYT1 N 
12 CYP1A2 Y 30 HRG N 48 TNFRSF12A N 
13 CYP2B6 Y 31 HSD11B2 N 49 UGT1A1 N 
14 CYP2C8 Y 32 IL6 N 50 UGT1A3 N 
15 CYP2C9 Y 33 INSIG1 N 51 UGT2B7 N 
16 CYP2C18 Y 34 LMNA N 52 UGT2B15 N 
17 CYP2C19 Y 35 LY6D N    
18 CYP2D6 Y 36 MDR1 Y    
Y= Assays already developed; N= No existing assays 
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The selection of suitable peptides included a comprehensive database search, 
whereby first, the target protein was fragmented with trypsin in silico. Afterward, it 
was examined whether the peptides were proteotypic for the respective analyte, 
and only peptides with a sequence of 6-20 amino acids were selected. Then the 
amino acid composition was checked. Peptides containing methionine or an  
N-terminal glutamic acid were excluded. Peptides containing natural sequence var-
iants and amino acid modifications such as glycosylation were also removed. Next, 
the hydrophobicity factor was investigated. Peptides with a factor of less than 2.8 
were preferred. Finally, the Proteomics database (proteomicsDB 87) was used to 
check whether the respective peptides were already detected by mass spectrome-
try. If possible, two synthetic non-labeled standard peptides (ENs) were ordered for 
each analyte. 
 
3.9.2 Peptide Detection Compatibility with Mass Spectrometry 
Once the synthetic non-labeled standard peptide solutions had been prepared (3.8.1 
Peptide Standards), it was essential to investigate their detection compatibility by 
LC-MS. For this purpose, the charge state and the collision energy (CE), which should 
be used to achieve the optimal results, were determined. Peptides of each analyte 
were diluted with loading buffer from their initial concentration of 1 nmol µL-1 to 
the final concentration of 10 fmol µL-1 per peptide. The injection volume was 5 µL 
meaning that 50 fmol of each peptide was applied to the chromatographic column. 
As an analytical column, an Acclaim PepMap RSLC C18 (75 μm I.D. x 150 mm, 
2 μm, Thermo Fisher Scientific, Waltham, USA) and as a trapping column an Acclaim 
PepMap 100 C18 μ-precolumn (0.3 mm I.D. x 5 mm, 5 μm, Thermo Fisher Scientific, 
Waltham, USA) was used. Two different eluents for the LC gradient were prepared. 
Eluent A (aqueous phase) consisted of LC-MS-grade water containing 0.1% formic 
acid (FA). Eluent B (organic phase) consisted of 80% acetonitrile (ACN) and 
LC-MS-grade water with 0.1% FA. To load the samples onto the trapping column, a 
third buffer containing 2% ACN, LC-MS-grade water, and 0.05% trifluoroacetic acid 
(TFA) was used. The mass spectrometric analysis was performed by use of a QExac-
tive Plus mass spectrometer (Thermo Fisher Scientific, Waltham, USA). In a first  
45-minute full-scan (Full-MS / ddMS²) method run (Figure 13 (A)), it was deter-
mined which charge state led to higher peak intensities.   
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A 
 
B 
 
Figure 13. Standard full-scan 45-min and standard 10-min PRM gradient. In (A) the 45 min full-scan (Full-MS) 
and in (B), the standard PRM 10-min gradient is shown. In both cases, the column was equilibrated at 4% of 
eluent B and increased to 55% and 45%, respectively. The column was rinsed at 99% eluent B. 
 
Once the ideal charge state had been identified, various CEs were tested. The stand-
ard PRM method (Figure 13 (B)) was used, and four different collision energies were 
examined for each analyte. The normalized collision energy (NCE) was set to either 
15, 20, 25, or 30. The results were then compared, and the optimal NCE was selected 
for each analyte. The parameters that were set for the respective mass spectromet-
ric detection are shown in Table 15 below. 
 
Table 15. Mass spectrometric parameters for the 45-min standard full-scan and standard 10-min PRM method. 
The settings for the full-scan (Full-MS / ddMS²) are shown on the left, PRM settings on the right. Since PRM is an 
MS2 level-based method, ddMS² parameter setting is not applicable.  
Parameter Full-MS / ddMS² PRM 
Resolution 70 000 35 000 
AGC target 3·106 2·105 
Maximum IT in ms 100 60  
Loop Count  10 1 
MSX count  2 2 
Isolation window in m/z 2.0 1.5 
NCE 25 15, 20, 25, or 30 
ddMS² set na 
na= not applicable 
 
3.9.3 Full-Scan Mass Spectrometry Measurement of In-Gel Digested HepaRG Cells 
In this part, in-gel digestion of HepaRG cells and a full-scan (Full-MS) measurement 
was performed. An in-house revised protocol of the in-gel digestion described in 
Shevchenko et al. was used 88. In-gel digestion was performed for three negative 
Material and Methods 
40 
controls (DMSO-treated) and three prochloraz-treated (10 µmol L-1) HepaRG cells. 
This was followed by a full-scan (Full-MS / ddMS²) measurement with a 130-minute 
gradient. The in-gel digestion procedure is shown in Table 16.  
 
Table 16. In-gel digestion protocol. In the following table, the workflow of the in-house revised in-gel digestion 
protocol after Shevchenko et al. is shown 88.  
Step Performance 
1 Dilute samples with 2x LDS buffer (1:2) 
2 Heat samples for 5 min at 90°C 
3 Centrifugation for 5 min at 16 000 g 
4 Gel electrophoresis for 15 min (4-20% Tris-Glycine SDS-PAGE gel) 
5 Staining of protein bands with Coomassie brilliant blue for approx. 40 min at RT 
6 Wash gel with ddH2O for approx. 2 h at RT 
7 Cut the protein bands out of the gel 
8 
Destain the gel bands alternately for 15 min with buffer A and B (A: 5 mM L-1 ABC 
in ddH2O; B: 10 mM L-1 ABC in 50% ACN). Repeat four times 
9 Remove liquid and dry gel bands in Speed Vac for approx 1 h 
10 Add trypsin in a 1:15 (enzyme:protein) ratio 
11 Incubate gel bands for 16 h at 37°C in trypsin solution 
12 
Add extraction buffer (100% ACN and 0.1% TFA in a 1:1 mixture) and sonicate for 
15 min on ice. Repeat two times 
13 Dry the samples using Speed Vac for approx. 1 h 
14 Resuspend peptides in 1% FA 
 
After in-gel digestion, the total protein and peptide concentration of each sample 
was determined by use of the Nanodrop 2000c spectrometer (Thermo Fisher Scien-
tific, Waltham, USA). A volume of 2 µL of each sample was applied to the sensor, and 
the absorption at 280 nm was measured. The concentration was calculated using 
the approximation 1 Abs ≈ 1 mg mL-1 89. 
Samples were diluted to the same concentration of 48 ng µL-1, then 15 µL each, re-
sulting in a total of 720 ng enzymatically proteolyzed sample, was injected for full-
scan (Full-MS / ddMS²) analysis. The analytical column was an Acclaim PepMap 
RSLC C18 (75 μm I.D. x 500 mm, 2 μm, Thermo Fisher Scientific, Waltham, USA) and 
as a trapping column, an Acclaim PepMap 100 C18 μ-precolumn (0.3 mm I.D. x 
5 mm, 5 μm, Thermo Fisher Scientific, Waltham, USA) was used. A linear gradient 
from 2% to 30% of eluent B was used to separate peptides. The oven temperature 
Material and Methods 
41 
was set to 55°C, the flow to 0.25 µL min-1. The gradient for the full-scan 
(Full-MS / ddMS²) measurement of in-gel-digested samples is shown in Figure 14.  
 
 
Figure 14. Liquid chromatography gradient for full-scan measurement of in-gel digested samples. Columns 
were equilibrated at 2% of eluent B. The separation of in-gel digested samples was performed by increasing 
eluent B from 2% to 30%. The total method duration was 162 min.  
 
For this experiment, a full-scan (top 15 Full-MS / dd-MS²) data acquisition method 
was used. The resolution was set to 140 000 with an automatic gain control (AGC) 
target of 3·106, a maximum injection time (IT) of 40 milliseconds (ms), and the scan 
range was set to 200-2000 m/z. The dd-MS² resolution was set to 17 500 while the 
AGC target was set to 1·105 and the maximum IT to 55 ms. The isolation window of 
dd-MS² was set to 4.0 m/z and the normalized collision energy (NCE) to 25. Addi-
tionally, unassigned, single charged, fivefold- up to eightfold-charged peptides were 
excluded. The dynamic exclusion time was 30.0 seconds.  
Evaluation of results was performed with Proteome Discoverer 2.1 (Thermo Fisher 
Scientific, Waltham, USA) and Skyline 4.2.0.19072 (MACOSS Lab, Department of ge-
nome sciences, University of Washington, Seattle, USA). In order to identify the pro-
teins and peptides, a search against the HumanRefUP201611 database using 
masquot and sequest was started via Proteome Discoverer. Trypsin was set as pro-
teolysis enzyme, miss cleavage to one, and precursor mass tolerance to 10 ppm. In 
addition, a dynamic modification (oxidation of methionine) and a static modification 
(carbamidomethylation of cysteine) were specified. The confidence of the peptide 
identification was determined by the percolator validation node integrated into Pro-
teome Discoverer. If the false detection rate of the identified peptides was above 1%, 
the results were discarded. This was determined by the q-value (q-value >0.01).  
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3.9.4 Comparison of Targeted Mass Spectrometry Methods for Better Suitability 
of Target Analyte Analysis 
As described in 1.3.5, several measurement modes are available for the LC-MS de-
vice. To decide, whether targeted selected ion monitoring (tSIM) or parallel reaction 
monitoring (PRM) should be used for the method development and the analysis of 
pesticide-treated samples, test samples (prochloraz-treated HepaRG cells; 
20 µmol L-1) were measured with the existing CYP 17-plex assay in tSIM, as well as 
in PRM. The already developed and optimized LC gradient for the CYP 17-plex was 
used for the analysis. The separation was obtained by a two-step gradient starting 
at 4% to 10% and then continuing from 10% to 40% eluent B. The method duration 
was 18 minutes, and the flow rate was 0.3 µL min-1 while the temperature was kept 
constant at 40°C. An Acclaim PepMap RSLC C18 (75 μm I.D. x 150 mm, 
2 μm, Thermo Fisher Scientific, Waltham, USA) was used as the analytical column, 
and an Acclaim PepMap 100 C18 μ-precolumn (0.3 mm I.D. x 5 mm, 5 μm, Thermo 
Fisher Scientific, Waltham, USA) was used as the trapping column. Figure 15 shows 
the chromatographic gradient of the CYP 17-plex.  
 
 
Figure 15. Liquid chromatography gradient of the CYP 17-plex. Columns were equilibrated at 4% of eluent B. 
The separation of the analytes was performed by a two-step gradient from 4% to 10% and then continuing from 
10% to 40% of eluent B. The total method duration was 18 minutes.  
 
The parameter for the analyte’s detection in the Orbitrap with either tSIM / ddMS² 
or PRM is compared in Table 17. The NCE for the PRM measurement was optimized 
prior to this experiment for all analytes, according to 3.9.2. Since PRM is a method 
based on fragmentation, no ddMS² (data-dependent tandem mass spectrometry) 
parameters could be set. For the tSIM method, the ddMS² parameters were set as 
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follows: Resolution to 17 500, AGC target 2·105, maximum IT to 60 ms, isolation win-
dow to 2.0 m/z, and dynamic exclusion to 2.0 seconds.  
 
Table 17. Comparison of PRM and tSIM parameters for the CYP 17-plex. Here, the parameters set for each data 
acquisition method are shown. NCE was optimized for each analyte in PRM mode. Data-dependent-MS² param-
eters are not applicable for PRM.  
Parameter PRM tSIM / ddMS² 
Resolution 35 000 35 000 
AGC target 2·105 5·106 
Maximum IT in ms 60  60 
Loop Count  1 1 
MSX count  2 2 
Isolation window in m/z 1.5 2.0 
NCE various 30 
ddMS² na set 
na= not applicable 
 
3.9.5 Testing the Antibody Functionality 
In order to characterize the antibodies, their respective binding motif, and their abil-
ity to enrich target analytes from a complex matrix were tested. As a complex matrix, 
a mixture of three human cell lines (human embryonic kidney (HEK), human colon 
tumor (HCT), and hepatoma G2 (HepG2)) in the ratio of 1:1:1 was prepared (the 
cultivation of each cell line was performed by Dr. Bettina Keller; in the workgroup 
of Prof. Dr. Ulrich Rothbauer, University of Tübingen, Germany). For each TXP-tag, 
two rabbits were immunized with the respective antigen. For the determination of 
the epitope binding motif, three full-scan (Full-MS) runs (45 min) were performed 
for all antibodies (including both animals of each TXP-tag), and the results were 
evaluated using Proteome Discoverer 2.1 and the in-house developed TXP tool of 
Dr. Hannes Planatscher (Signatope GmbH, Reutlingen, Germany). 
For the investigation of whether the antibody was able to enrich the target peptide 
sufficiently, immunoprecipitation of the human blend with spiked-in ENs peptides 
and the respective antibody was performed. The analysis was carried out in PRM 
mode.   
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3.9.6 Antibody-Protein Ratio Optimization 
In this part, it was determined which minimum antibody-protein ratio was neces-
sary to provide reliable and stable peptide signals. Several antibody-protein ratios 
were investigated for each analyte. Either 1 µg, 2 µg, or 5 µg antibody were com-
bined with 10 µg, 20 µg, or 40 µg lysate. Immunoprecipitation was performed with 
these different combinations and subsequently measured with LC-MS. For the anal-
ysis, prochloraz-treated (10 µmol L-1) HepaRG cells were used. Each combination 
was examined in a single determination. 
 
3.9.7 Examination of Proteolysis over Time 
In order to investigate the ideal duration of tryptic proteolysis for each protein of 
interest, a time series experiment was performed. Prochloraz-treated (10 µmol L-1) 
HepaRG cells were proteolyzed for 2, 6, 16, 18, 24, 48, 72, or 96 hours with the tryp-
tic proteolysis protocol (3.8.3). The digestions were performed in triplicates, fol-
lowed by immunoprecipitation and LC-MS analysis. Not only the peptides of interest 
but also missed cleavage peptides (one miss cleavage on the N-terminal side) were 
analyzed. Therefore, the protein sequence was checked using the UniProt data-
base 90, and the mass (double and triple charge) of the peptide containing one miss 
cleavage site was included in the PRM method (data of miss cleavages not shown).  
 
3.9.8 Conversion from Singleplex to Multiplex Assays 
The availability of samples is often limited and therefore, it would be challenging to 
analyze each antibody and its peptide separately. For the compilation of multiplex 
assays, three criteria should be considered. First, the total antibody amount in an 
assay should not exceed 7 µg. For each microgram antibody, it was necessary to use 
5 µL of the magnetic bead solution. The amount of microspheres per assay is limited 
by the transfer efficiency of the magnetic particle processor. Second, the minimum 
amount of lysate required to obtain reliable and stable results should be in line with 
the analytes to be compiled. Third, the duration of proteolysis should be the same 
for each analyte within a multiplex.  
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3.9.9 Optimization of Chromatographic Separation 
After compiling multiplex assays, the chromatographic gradient was optimized for 
each assay. Standard peptides were diluted, and several gradients were tested in 
replicate measurements (n=3). Since only ENs peptides were used, no proteolysis 
and immunoprecipitation were performed prior to the LC-MS analysis. After meas-
uring these different gradients, it was decided which gradient should be used for the 
investigation of further method development parameters. Not only the optimal sep-
aration but also the intensity of analytes for each gradient and the repeatability were 
considered. The gradients described in Table 18 were tested. 
 
Table 18. Tested gradients to optimize the chromatographic separation. Five different gradients were tested 
for each multiplex. The respective percentage of eluent B is shown. The column was equilibrated at 4% and 
washed at 99% of eluent B.  
Time 
in min 
Tested gradients with eluent B in % 
Standard 10-45 10-40 10-30 10-20 
0 4 4 4 4 4 
0.25 4 10 10 10 10 
5.75 45 45 40 30 20 
6 99 99 99 99 99 
8 99 99 99 99 99 
8.25 4 4 4 4 4 
10 4 4 4 4 4 
 
3.9.10 Dynamic Ranges 
For the determination of the dynamic range, dilution series of ENs peptides in their 
respective IS peptide solution was performed while IS was kept constant. The line-
arity was investigated in the range from 0 to 1000 fmol ENs (for some high abundant 
analytes, the investigation of linearity was upscaled to 3000 fmol ENs). The dilution 
was done sequentially in 1:3 dilution steps. The dilution series was performed three 
times to cover the accuracy and precision for each dilution step. After the LC-MS 
measurement, linearity plots were prepared, and the limit of detection (LOD) for 
each analyte was calculated using the following, adapted formula, which was de-
scribed and compared with other methods by Mani et al.91   
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𝐿𝑂𝐷 = µ𝐵 +  𝑧(1−𝛼)
(𝜎𝐵+ 𝜎𝑠)
√𝑛
   (91) 
 
µB= estimated mean value of blank samples 
σB= standard deviation of blank samples 
σS= standard deviation of low concentration samples (where S/N > 3; own criterion) 
√n= square root of the number of replicates (n=3) 
z(1-α)= z-value with α of 0.05; inserted value = 1.645 
 
The linear equations obtained by evaluating the data with Origin 2017G (OriginLab, 
Northampton, USA) were used to calculate the accuracy of each analyte. The meas-
ured values should be within 80-120%, and the coefficient of variation (C.V.) within 
one replicate measurement ≤ 20%. The lower limit of quantification (LLOQ) was de-
fined as the least concentration, where both described criteria were met.  
 
3.9.11 Identification of Recovery Efficiency 
The recovery experiment was performed using spike-in experiments. A complex 
matrix that preferably did not contain the peptide of interest was used. The mouse 
cell line NIH3T3 was selected. After cell harvesting and lysis, the lysates were di-
gested and used as a matrix for immunoprecipitation. In addition, recovery experi-
ments should be performed at three different concentrations. Hence, three different 
amounts of non-labeled standard synthetic peptides (15 fmol, 250 fmol, and 
500 fmol) were spiked into the matrix, while the isotopically labeled peptide 
amount was kept constant. Each experiment was performed three times. Besides the 
spiked samples, also unspiked samples (blanks) were measured. The ratios of 
ENs/IS were corrected with the linear equations obtained during the linearity ex-
periment (3.9.10 Dynamic Ranges), and then the calculation of the recovery was per-
formed using the following formula: 
 
𝑅′(%) =
(?̅?′− ?̅?)
𝑥𝑠𝑝𝑖𝑘𝑒
∙ 100  (92) 
 
R‘(%)= relative spike recovery 
x̅′= mean value of the spiked sample 
x̅= mean value of the unspiked sample 
xspike= the added amount of non-labeled synthetic peptide (ENs)   
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3.9.12 Investigation of Repeatability 
To perform the intra- and interday repeatability, three different samples were used: 
Non-treated HepaRG cells, prochloraz-treated (10 µmol L-1) HepaRG cells, and a  
cryopreserved primary human hepatocyte (PHH; donor 1) sample. For the determi-
nation of intraday repeatability, every sample type was digested five times each day. 
This was performed on three different days to determine the interday repeatability. 
For the evaluation, it was decided that the coefficient of variation should be ≤ 20% 
for intraday (n=5) and interday (n=3). 
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4 Results 
4.1 Assay Development for the Quantification of Toxicologically 
Relevant Proteins in HepaRG Cells 
4.1.1 Peptide Selection for the Detection and Quantification of Target Analytes 
As described in 3.9.1, database search was performed for 36 target proteins. For 16 
analytes, mass spectrometric assays have already been developed previously 86. It 
was checked whether all set criteria, like proteotypicity, absence of natural vari-
ants/modifications within the sequence, or low hydrophobicity factors were met. If 
possible, two potential peptides per analyte were chosen. For analytes from which 
only peptides that did not fulfill all criteria were found, it was decided that peptides 
should still be tested despite unfavorable properties such as cysteine occurrence or 
a high hydrophobicity factor. For example, only two proteotypic peptides with a hy-
drophobicity factor greater than 2.8 were found for glucose-6-phosphatase (G6PC). 
Despite that, both peptides were tested. The results for the database search are 
shown in Table 31 in the appendix (9 Supplementary Data). For those 36 proteins, 
standard non-labeled synthetic peptides (ENs) were synthesized, and the detection 
compatibility with mass spectrometry investigated.  
 
4.1.2 Detection Compatibility of Selected Peptides with Mass Spectrometry 
With dilutions of each ENs peptide, ideal charge state and collision energy were de-
termined. The charge state that led to higher signal intensities in a full-scan 
(Full-MS) experiment was chosen, and after that, the collision energy with these par-
ticular charge states was investigated by use of parallel reaction monitoring (PRM) 
mode. Several collision energies were tested. Therefore, the normalized collision en-
ergy (NCE) was set to either 15, 20, 25, or 30. Due to the different analyte charge 
states, it was possible that not only single but also double or triple charged fragment 
ions could arise. Therefore, they were also selected in Skyline 4.2.0.19072 (MACOSS 
Lab, Department of genome sciences, University of Washington, Seattle, USA) and 
evaluated. Depending on where the peptide was fragmented, different daughter ions 
were formed. Due to the use of isotopically labeled standard peptides at the  
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C-terminal arginine or lysine, it was decided that only y-ions should be evaluated to 
distinguish between the analyte and the standard. The most intense y-ion was con-
sidered as the quantifier. For the quantification, only the area of the quantifier ion 
was used. Figure 16 shows the collision energy optimization of cytochrome 
P450 1A1 (CYP1A1) and arginase-1 (ARG1 with C-terminus: YILK) exemplarily. Re-
maining data are shown in 9 Supplementary Data, Figure 45. For CYP1A1, a steady 
decrease in the peak area by increasing NCE could be observed. The peak area of 
ARG1 increased from 15 up to the highest area at NCE 25. By use of 30 NCE, the peak 
area decreased drastically. 
 
ARG1(YILK) 
 
CYP1A1 
 
Figure 16. Normalized collision energy comparison. Results for arginase-1 (ARG1 with C-terminus: YILK) and 
cytochrome P450 1A1 (CYP1A1) are shown. The framed collision energy was selected, i.e., NCE of 25 for 
ARG1(YILK) and NCE 15 for CYP1A1. 
 
In the case of proteins for which two ENs peptides were synthesized initially, one 
was selected based on the results with which the method development was further 
carried out. Table 32 (9 Supplementary Data) shows the results for all these analytes 
that have passed the compatibility test for mass spectrometric detection, as well as 
the CYP 17-plex, as this assay has only been established in targeted selected ion 
monitoring (tSIM) so far 86. The table shows the analyte’s particular peptide se-
quence, the determined precursor with charge state, the chosen quantifier ion with 
its mass, and the optimized NCE. For each analyte, at least one peptide was detected 
by mass spectrometry, so the method development was continued with each protein 
of interest (37 peptides representing 36 proteins of interest for which new assays 
should be developed).  
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4.1.3 Can Analytes be Detected in HepaRG Cells Directly after In-Gel Digestion 
and Full-Scan Mass Spectrometry Analysis? 
Three negative controls (dimethyl sulfoxide (DMSO)-treated) and three prochloraz-
treated (10 µmol L-1) HepaRG cell samples were prepared as described in 3.9.3. Af-
ter proteolysis, the sample concentration was determined with the Nanodrop 2000c 
spectrometer (Thermo Fisher Scientific, Waltham, USA), diluted to the same concen-
tration of 48 ng µL-1 and then measured by liquid chromatography-mass spectrom-
etry (LC-MS). Full-scan analysis (Full-MS / ddMS²) was used as data acquisition 
method, whereby the separation of peptides was performed with a 130-minute gra-
dient. Figure 17 shows the total ion current chromatogram (TIC) of one of the pro-
chloraz-treated samples (PT3).  
 
 
Figure 17. Total ion current chromatogram of a prochloraz-treated HepaRG cell sample. Shown is the third rep-
licate of prochloraz-treated HepaRG cells (PT3). In this sample, 2907 proteins with 13125 peptide groups were 
identified by Proteome Discoverer. The analytes were separated by a 130-minute gradient. 
 
At least 2570 proteins have been identified in all samples. The highest protein iden-
tification rate was observed in the third replicate of prochloraz-treated samples 
(PT3). Here, 2907 proteins and 13125 peptide groups were identified with Prote-
ome Discoverer 2.1. A summary of identified proteins and peptide groups is shown 
in Table 19.   
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Table 19. Number of identified proteins and peptide groups after in-gel digestion. 
Sample  Identified Proteins Identified Peptide groups 
SC1 2739 12074 
SC2 2570 12175 
SC3 2647 12665 
PT1 2674 11705 
PT2 2832 11952 
PT3 2907 13125 
 
After data processing with Proteome Discoverer 2.1 (settings and search criteria de-
scribed in 3.9.3), the list of identified proteins and peptides was screened for the 
analytes of interest. The first step was to check whether the protein to be investi-
gated was present. If the protein was found, it was further investigated whether the 
peptide, selected based on the database search and mass spectrometric detection 
compatibility (4.1.2), was observed, too. Table 33 in the appendix (9 Supplementary 
Data) shows the results for the screening. If both a protein and its desired peptide 
were found, the corresponding retention time was included in the table. Not all pep-
tides were identified in all six samples. As an example, the peptide DVDPGEHYILK of 
ARG1 was identified in each sample in contrast to TIGIIGAPFSK of the same protein, 
which was only found in PT3. For some analytes such as glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), DNA-dependent protein kinase catalytic subunit 
(PRKDC) or UDP-glucuronosyltransferase 1-1 (UGT1A1), the protein, but not the 
peptide of interest was found. The analysis showed that 15/36 proteins were iden-
tified after in-gel digestion, while only 8/37 (for ARG1 two peptides were investi-
gated) peptides of interest were found. In case of 16 proteins comprised in the 
CYP 17-plex assay, only 5 of 17 peptides (two peptides for CYP3A5) were identified 
by full-scan MS analysis.  
 
4.1.4 Selection of Mass Spectrometry Detection Mode for Most Sensitive 
Detection of Target Analytes 
Prochloraz-treated (20 µmol L-1) HepaRG cells were measured in targeted selected 
ion monitoring (tSIM), as well as in parallel reaction monitoring (PRM) mode. In  
Figure 18, the results for CYP2B6 and CYP2C9 in both measurement modes are 
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shown exemplarily. (A) and (B) show CYP2B6, measured in tSIM and PRM, respec-
tively. (C) and (D) show the results for CYP2C9. The upper chromatogram in each 
case displays the signal of the endogenous peptide (EN); the lower chromatogram 
displays the internal isotopically labeled standard peptide (IS).  
 
A 
 
B 
 
C 
 
D 
 
Figure 18. PRM and tSIM comparison for CYP2B6 and CYP2C9. (A) and (B) represent CYP2B6 in targeted se-
lected ion monitoring (tSIM) and parallel reaction monitoring (PRM), respectively, and (C), (D) represent 
CYP2C9. In tSIM, the three most prominent precursor isotopes are shown, in PRM all detected transitions of the 
precursor ion. The upper chromatogram shows the endogenous peptide signal, the lower chromatogram the 
signal of the corresponding internal isotopically labeled standard peptide.  
 
The tSIM results show the first (blue), second (violet), and third (red) isotopes of 
the precursor. In the PRM chromatograms, all detected transitions of the precursor 
mass are shown. For the results measured in tSIM, it can be clearly seen that inter-
ferences were present that made the evaluation for the CYP2B6 peptide in tSIM (A) 
impossible. The endogenous signal was influenced by other compounds with the 
same mass as the analyte under investigation. In (C; CYP2C9), several signals were 
obtained in the endogenous chromatogram. Without the use of the internal standard 
peptide, the assignment of the correct signal would not be possible. In addition, it 
can also be seen here that interferences were present in the IS chromatogram at MS1 
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level. The additional fragmentation in PRM (D) after the filtering of the precursor 
ion in the first quadrupole led to a clear chromatogram in which no interference was 
present. Based on these measurements, it was decided to use the PRM mode for fur-
ther method development steps. 
 
4.1.5 Determination of Antibody Epitope Binding Motifs and Functionality in 
Complex Matrix 
A mixture of human embryonic kidney (HEK), human colon tumor (HCT), and hepa-
toma G2 (HepG2) cells in a ratio of 1:1:1 was used to test the antibody's functional-
ity. In this experiment, the binding motif of the antibodies (AB) on the one hand, and 
on the other hand, the ability to enrich the target peptide from a complex matrix was 
investigated. Enzymatic proteolysis was performed for 16 hours, followed by im-
munoprecipitation (IP). In this case, no synthetic non-labeled standard (ENs) or iso-
topically labeled standard (IS) peptides were spiked into the proteolyzed samples 
before the IP. A 45-minute full-scan (Full-MS) mass spectrometry measurement was 
then performed to examine the epitope binding motif (n=3). The evaluation was 
done using Proteome Discoverer 2.1, and the in-house developed triple X prote-
omics (TXP)-tool (Dr. Hannes Planatscher, Signatope GmbH, Reutlingen, Germany). 
Both animals of each TXP-tag were analyzed. Only the results of the antibodies used 
for further method development are shown in Figure 19. Besides, epitope motifs 
were only generated for newly generated antibodies. For the antibodies of the 
CYP 17-plex, epitope motifs have already been generated in an earlier project 86.  
Figure 19 shows that at least one epitope binding motif from two polyclonal anti-
bodies could be generated for each analyte. For the tryptic fragment derived from 
histidine-rich glycoprotein (HRG), the TXP tag sequence is GFC(CAM)R. One anti-
body was capable of enriching peptides comprising amino acids matching the anti-
gen at positions one, two, and four, but no cysteine was visible at position three in 
the graph. The second antibody enriched only peptides not related to the initially 
used antigen GFC(CAM)R. Hence, only the first antibody was used for further 
method development because the third position has a rather unspecific binding site, 
and it is highly probable that the analyte of interest is enriched.   
Results 
55 
 
Anti-ALQR_rbt1 
 
Anti-ANPK_rbt2 
 
Anti-ATAR_rbt1 
 
Anti-DLDK_rbt1 
 
Anti-EPLR_rbt2 
 
Anti-EQAR_rbt2 
 
Anti-FFLR_rbt2 
 
Anti-FHNK_rbt1 
 
Anti-GCFK_rbt2 
 
Anti-GEAK_rbt2 
 
Anti-GEFK_rbt1 
 
Anti-GFCR_rbt1 
 
Anti-GGAK_rbt1 
 
Anti-GGFK_rbt2 
 
Anti-HLGK_rbt2 
 
Anti-HSAR_rbt2 
 
Anti-HWIK_rbt1 
 
Anti-IPQK_rbt1 
 
Anti-LDPK_rbt1 
 
Anti-LEVR_rbt3 
 
Anti-LLIR_rbt_2 
 
Anti-LNIR_rbt2 
 
Anti-PEER_rbt1 
 
Anti-PFQR_rbt2 
 
Anti-PFSK_rbt1 
 
Anti-PSEK_rbt2 
 
Anti-PTYK_rbt1 
 
Anti-PVYK_rbt2 
 
Anti-QLEK_rbt2 
 
Anti-QLSK_rbt1 
Results 
56 
 
Anti-QSGK_rbt2 
 
Anti-QVLK_rbt1 
 
Anti-TLEK_rbt1 
 
Anti-TPLR_rbt1 
 
Anti-TVNK_rbt1 
 
Anti-VDNK_rbt2 
 
Anti-YILK_rbt2 
   
Figure 19. Epitope binding motifs of TXP antibodies. The in-house developed triple X proteomics (TXP) tool was 
used to generate epitope binding motifs. Only graphs of antibodies used for further method development are 
shown ‒ one out of two. Furthermore, graphs were only generated for new analytes. For the CYP 17-plex assay, 
epitope binding motifs were already generated in a previous project 86.  
 
The second part was to investigate the antibody’s ability to enrich the target pep-
tides from a complex matrix. Here, the human blend sample was also used as the 
matrix. Target ENs peptides were spiked into the proteolyzed human blend sample, 
and the IP was performed. The results are shown in Table 34 in the appendix  
(9 Supplementary Data). The measurement was performed with a 10-minute PRM 
method (n=3). Antibodies that did not enrich the target peptide were not used fur-
ther. The analysis was not performed for the CYP 17-plex. For all analytes, at least 
one antibody enriched the target from the complex matrix. Method development 
was continued for all 36 proteins. 
 
4.1.6 Least Optimal Antibody-Protein Extract Ratio for Reliable Target Analysis  
In chapter 4.1.5, it was described how suitable antibodies were for enriching the 
peptides of interest from a complex matrix. With these antibodies, a further analysis 
was performed to determine the least antibody amount in combination with the 
ideal sample protein amount. Different antibody-protein ratios were investigated, 
with either 1, 2, or 5 micrograms of each antibody combined with either 10, 20, or 
40 micrograms protein extract. The analysis was performed using protein extracts 
from prochloraz-treated (10 µmol µL-1) HepaRG cells. For all analytes, 50 fmol IS 
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peptide was used as an internal control. For those analytes, where 50 fmol IS pep-
tide led to low signal intensities, the experiment was repeated, and either 100 fmol 
or 200 fmol of IS peptide was added. The results for the minimal antibody-protein 
ratio, leading to stable and reliable results, are shown in Table 20. For analytes, 
where both antibodies enriched the peptide of interest out of the complex matrix, 
both antibodies were tested. Only the antibody, which led to better results, in terms 
of fragmentation pattern and peak shape, is shown. In this experiment, 20 peptides 
had to be excluded from further method development, since no signals for endoge-
nous peptide or even no internal standard signal were obtained. This means that 
17/37 peptides were used for further analysis. The analysis was not performed for 
the CYP 17-plex.  
 
Table 20. Least required antibody-protein ratio. Here, the analyte, its peptide sequence, the used antibody 
(AB), as well as the determined AB amount, lysate amount, and amount of substance of each internal isotopically 
labeled (IS) peptide are shown. Only the antibodies showed in this table will be used for further method devel-
opment. The analysis was not performed for the CYP 17-plex.  
Analyte Peptide Sequence 
Antibody 
# 
AB amount 
in µg 
Lysate amount 
in µg 
n(IS) 
in fmol 
ADH1B GAVYGGFK 317_2 2 20 200 
ALDH3A1 IQQLEALQR 318_1 2 20 100 
ARG1 TIGIIGAPFSK 169_1 2 20 50 
ARG1 DVDPGEHYILK 313_2 1 10 50 
CYP7A1 LSSASLNIR 293_2 2 40 50 
FASN TGTVSLEVR 272_3 2 10 100 
HSD11B2 VSIIQPGCFK 308_2 1 10 50 
LMNA LEAALGEAK 295_2 2 10 50 
NQO1 FGLSVGHHLGK 297_2 1 10 50 
PRKDC LGLPGDEVDNK 311_2 1 20 50 
S100P ELPGFLQSGK 312_2 2 20 50 
SULT1B1 TSGIEQLEK 300_2 2 20 50 
TNFRSF12A GSSWSADLDK 303_1 2 40 50 
UGT1A1 TYPVPFQR 322_2 2 20 100 
UGT1A3 YLSIPTVFFLR 323_2 2 20 50 
UGT2B7 ANVIASALAQIPQK 302_1 5 20 100 
UGT2B15 SVINDPVYK 325_2 2 20 100 
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4.1.7 Analysis of Optimal Proteolysis Time 
Since the proteolysis time for the different analytes may vary, and multiplex assays 
should be generated, it was essential to investigate the respective optimal digestion 
times 93. For this investigation, protein extracts from prochloraz-treated 
(10 µmol L-1) HepaRG cells were proteolyzed using trypsin for 2, 6, 16, 18, 24, 48, 
72, or 96 hours (n=3). After the analysis, mean values were calculated. To compare 
all analytes, the mean values for each analyte were normalized to the respective 
peak value. Figure 20 gives an overview of all analytes. It was observed that the pep-
tide release for ARG1(PFSK), UGT1A1, and UGT1A3 differed considerably compared 
to all other analytes. In addition, no endogenous signals were obtained for CYP7A1. 
The analysis was not performed for the CYP 17-plex since this analysis was already 
conducted by Weiss et al.86 
 
 
Figure 20. Normalized target peptide release by enzymatic fragmentation from HepaRG protein extracts over 
time. The normalized peptide release in percent (%) was plotted against the digestion time in hours (h). Peptide 
release for ARG1(PFSK), UGT1A1, and UGT1A3 differed significantly compared to the other analytes. No endog-
enous signals were obtained for CYP7A1. The analysis was not performed for the CYP 17-plex. Proteolysis was 
performed three times for each timepoint in prochloraz-treated (10 µmol L-1) HepaRG cells.  
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Since no endogenous signals were obtained for CYP7A1 during the determination of 
the ideal digestion time, it was decided to test another sample as a matrix. For this 
purpose, a mixture of DMSO-treated HepaRG cells and cyclosporin A-treated  
HepaRG cells was prepared and processed according to the enzymatic proteolysis 
protocol and the immunoprecipitation workflow (3.8.3).  
 
 
Figure 21. Normalized peptide release of CYP7A1 by enzymatic fragmentation from HepaRG protein extracts 
over time. The normalized peptide release in percent (%) was plotted against the digestion duration in 
hours (h). Proteolysis was performed three times in a mixture of DMSO-treated HepaRG cells and cyclo-
sporin A-treated HepaRG cells.  
 
In addition to Figure 20 and Figure 21, additional evaluation and visualization were 
carried out. Results are shown in Figure 22. In (A), mean values were calculated for 
each time point comprising all analytes (except ARG1(PFSK), CYP7A1, UGT1A1, and 
UGT1A3) to obtain a more unobstructed view. The same calculation was performed 
for ARG1(PFSK), UGT1A1, and UGT1A3, shown in (B).  
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A 
 
B 
 
Figure 22. Mean normalized peptide release by enzymatic fragmentation from HepaRG protein extracts over 
time. In (A), the mean normalized peptide release in percent (%) over time in hours (h) is shown. For the calcu-
lation, all analytes except ARG1(PFSK), CYP7A1, UGT1A1, and UGT1A3 were used. (B) shows the mean normal-
ized peptide release for ARG1(PFSK), UGT1A1, and UGT1A3. 
 
Figure 20 shows that there is not one optimal incubation time for all analytes. How-
ever, Figure 22 (A) indicates that the best compromise is between 6 and 24 hours 
except for ARG1(PFSK), UGT1A1, and UGT1A3. The digestion time for the 
CYP 17-plex (16 h) was determined in an earlier project 86, and thus, the digestion 
time was also set to 16 hours for all analytes (A) and to two hours for ARG1(PFSK), 
UGT1A1, and UGT1A3 (B). During this investigation of the optimal proteolysis time, 
no peptide was excluded from further method development (17 peptides represent-
ing 16 proteins were further used). 
 
4.1.8 Compiling of Multiplex Assay Panels 
Multiplex assays were compiled on the basis of the results obtained in sections 4.1.6 
and 4.1.7. The minimum amount of proteolyzed sample required, the antibody 
amount required, and the optimal digestion time were taken into account. It was 
also considered that the total antibody amount within a multiplex should not exceed 
7 µg due to limitations with regard to magnetic microsphere transfer efficiency dur-
ing the automated immunoprecipitation. As shown in Figure 22 (B), the digestion of 
ARG1(PFSK), UGT1A1, and UGT1A3 followed different kinetics. Therefore, these 
three analytes were combined into one multiplex. A total of six multiplex assays 
were compiled (Table 21). Digestion for multiplex 2-5 was set to 16 hours, for mul-
tiplex 1 to two hours. The lysate amount of all multiplexes except multiplex 5 was 
set to 20 µg. Multiplex 5 required 40 µg lysate.  
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Table 21. Multiplex assays for proteins of interest. Six multiplex assays were generated. These are shown here 
with the respective total antibody (AB) amount in microgram (µg), the minimal lysate amount needed (µg), as 
well as the digestion duration. 
Multiplex 
# 
Analyte 
Total AB amount 
in µg 
Lysate amount 
in µg 
Digestion  
duration  
in h 
MpCombi1 
ARG1(PFSK) 
6 20 2 UGT1A1 
UGT1A3 
MpCombi2 
FASN 
6 20 16 LMNA 
TNFRSF12A 
MpCombi3 
ALDH3A1 
4 20 16 
UGT2B15 
MpCombi4 
SULT1B1 
7 20 16 
UGT2B7 
MpCombi5 
ARG1(YILK) 
5 40 16 CYP7A1 
S100P 
MpCombi6 
ADH1B 
5 20 16 
HSD11B2 
NQO1 
PRKDC 
 
4.1.9 Effect of Chromatographic Separation on Signal Intensity and Repeatability 
In Figure 23, the optimized chromatographic gradient, as well as the area compari-
son amongst the different gradients, are shown. The measurement was repeated 
three times for each gradient. The black boxes in (B), (D), (F), (H), (J), (L) indicate 
the gradient that was chosen for each multiplex, and these specific gradients are de-
picted in (A), (C), (E), (G), (I), and (K). 
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Figure 23. Chromatographic separation and area comparison of the different gradients. (A) shows the gradient 
of multiplex 1; (B) the area comparison of multiplex 1; (C) and (D) show multiplex 2; (E) and (F) multiplex 3; (G) 
and (H) multiplex 4; (I) and (J) multiplex 5; (K) and (L) multiplex 6. The black boxes in (B), (D), (F), (H), (J), and 
(L) indicate the selection for the individual multiplex. The chromatogram with the selected gradient is shown in 
(A), (C), (E), (G), (I), and (K). 
 
4.1.10 Determination of Assay Linearity and Accuracy to Discover Dynamic Ranges 
The determination of linearity and accuracy was performed, as described in 3.9.10. 
As mentioned before, the dilution was performed sequentially in 1:3 dilution steps 
in phosphate-buffered saline (PBS) with CHAPS (3-[(3-Cholamidopropyl) dime-
thylammonio] -1-propanesulfonate), except values above 1000 fmol ENs. There, an 
additional dilution step of 2000 fmol ENs was integrated. The limit of detection 
(LOD) was calculated using the formula described by Mani et al.91 Experiments were 
performed for all multiplex assays in PRM mode (MpCombi1-6, as well as the 
CYP 17-plex assay). In order to generate the linearity graphs, the ENs/IS area ratios 
were plotted against the theoretically expected ratios. Linear regression equations 
were calculated. Only data points, where also the range of the standard deviation 
was above the detection limit were taken into account. Using the obtained slope and 
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intercept from the determined linear equations, the respective accuracy was calcu-
lated, and accuracy plots were generated. Figure 24 shows the linearity plot for 
CYP1A1 as an example. The dashed horizontal line indicates the LOD. The graph 
shows that the analyte CYP1A1 was linear over a concentration range of five orders 
of magnitude. The coefficient of determination (R²) was 0.99935, and the LOD was 
0.015 fmol. Graphs for all other analytes can be found in Figure 46 (9 Supplementary 
Data). 
 
 
Figure 24. Linearity of CYP1A1 in PBSC. The ratio of the area (non-labeled synthetic standard/internal isotopi-
cally labeled standard; ENs/IS) was plotted against the expected ratio of ENs/IS. The dashed horizontal line in-
dicates the limit of detection (LOD). A logarithmic scale was used due to the broad concentration range investi-
gated. Dilutions were done in triplicates. 
 
Figure 25 shows the accuracy plot of CYP1A1, where the two horizontal lines indi-
cate the limits of the acceptance criterion (accuracy 80-120%). The accuracy in per-
centage was plotted against the theoretical amount of ENs. The linear range was de-
fined where the accuracy was between 80-120%, and the coefficient of variation 
(C.V.) within one concentration level (n=3) was ≤ 20% (these criteria were based on 
the U.S. Food and Drug Administration (FDA) guideline 94). The lowest value meet-
ing these criteria was determined as the lower limit of quantification (LLOQ). The 
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blue frame in Figure 25 indicates the linear range for CYP1A1, where the LLOQ is 
0.15 fmol, and the upper limit of quantification (ULOQ) is 1000 fmol. Results for all 
other analytes can be found in Figure 47 (9 Supplementary Data).  
 
 
Figure 25. Accuracy plot of CYP1A1 in PBSC. The accuracy in percentage (%) was plotted against the theoretical 
ENs amount of substance in femtomole (fmol). Analyses were done in triplicates. Both horizontal lines mark the 
limit values of 80% and 120%. The blue frame indicates the linear range were all evaluation criteria were met 
(accuracy between 80-120%; coefficient of variation (C.V.) ≤ 20%).  
 
All linear equations with the corresponding coefficients of determination (R²), the 
determined LODs, and LLOQs are shown in Table 22. Here, the analytes in the table 
were sorted by the multiplexes. All analytes showed a linear relationship between 
the ENs/IS area ratio and the theoretical amount of substance ratio of ENs/IS over 
several orders of magnitude. The coefficients of determination ranged from 0.97458 
for protein S100-P (S100P) to 0.99999 for sulfotransferase family cytosolic 1B mem-
ber 1 (SULT1B1). The lowest LLOQ was determined for CYP3A4 with 0.05 fmol, the 
highest for aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) with 
12.35 fmol. 
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Table 22. Linear equations of all analytes in PBSC as well as the coefficient of determination (R²), the calculated 
limit of detections (LOD), and the determined lower limit of quantification (LLOQ). 
Multiplex Analyte Linear equation R² 
LOD 
in fmol 
LLOQ 
in fmol 
CYP 17-plex 
CYP1A1 y= 0.54665x-0.000150 0.99935 0.015 0.15 
CYP1A2 y= 0.55626x-0.00123 0.99971 0.009 0.15 
CYP2B6 y= 0.67992x+0.00687 0.99984 0.267 4.12 
CYP2C8 y= 0.62282x-0.0000917 0.99986 0.024 0.46 
CYP2C9 y= 0.66665x+0.00674 0.99957 0.314 4.12 
CYP2C18 y= 0.55175x-0.000216 0.99597 0.018 1.37 
CYP2C19 y= 1.10319x+0.01086 0.99515 0.586 0.46 
CYP2D6 y= 0.17323x-0.00395 0.98589 0.025 4.12 
CYP2E1 y= 0.67925x-0.0012 0.99886 0.027 0.46 
CYP2F1 y= 0.78655x+0.00597 0.99913 0.155 4.12 
CYP3A4 y= 0.74543x+0.00227 0.99916 0.126 0.05 
CYP3A5 (FIPK) y= 0.41002x+0.01109 0.99994 0.334 4.12 
CYP3A5 (LPNK) y= 0.55173x+0.00233 0.99987 0.237 4.12 
CYP3A7 y= 0.62158x+0.0039 0.99959 0.452 4.12 
CYP3A43 y= 0.57262x-0.01326 0.99928 0.274 4.12 
MDR1 y= 0.5472x-0.000151 0.99986 0.030 1.37 
NCPR y= 0.49608x-0.00148 0.99982 0.033 0.46 
MpCombi1 
ARG1(PFSK) y= 0.57461x+0.01076 0.99952 4.553 1.37 
UGT1A1 y= 0.998x-0.00387 0.99762 0.053 4.12 
UGT1A3 y= 2.64329x+0.01596 0.99823 0.694 1.37 
MpCombi2 
FASN y= 1.59593x-0.01567 0.99342 1.127 4.12 
LMNA y= 1.5014x+0.00355 0.99973 0.948 1.37 
TNFRSF12A y= 1.19786x-0.00604 0.99625 0.079 1.37 
MpCombi3 
ALDH3A1 y= 1.17059x-0.03643 0.99602 0.460 12.35 
UGT2B15 y= 2.00952x-0.06011 0.99571 0.247 4.12 
MpCombi4 
SULT1B1 y= 1.38987x-0.00198 0.99999 0.043 0.46 
UGT2B7 y= 1.16501x-0.01165 0.99807 0.039 1.37 
MpCombi5 
ARG1(YILK) y= 1.89879x-0.01273 0.99322 0.088 1.37 
CYP7A1 y= 1.01451x-0.00937 0.99803 0.103 1.37 
S100P y= 1.77549x-0.00229 0.97458 0.078 1.37 
MpCombi6 
ADH1B y= 1.29341x-0.00701 0.99975 0.316 4.12 
HSD11B2 y= 1.24041x-0.00435 0.99829 0.048 0.46 
NQO1 y= 1.54318x+0.00258 0.99923 0.125 1.37 
PRKDC y= 1.39809x-0.01149 0.99830 0.250 1.37 
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4.1.11 Determination of the Target Analyte Yield ‒ Recovery 
As described in 3.9.11, the mouse cell line NIH3T3 was used as a matrix for recovery 
experiments. In the literature, it is recommended to use different concentrations to 
determine recovery 94. Therefore, either 15 fmol, 250 fmol, or 500 fmol ENs were 
spiked into the sample for each analyte. The formula described in chapter 3.9.11 was 
used to calculate the recovery. Besides, the measured ENs/IS ratios were corrected 
using the linear equations determined in chapter 4.1.10 before the formula was ap-
plied. Table 23 shows the results for multiplex assays 1-6 at different spike-in levels. 
For the results marked with a star, a high base level of the mouse matrix has already 
been measured. No recovery experiments were performed for the CYP 17-plex.  
 
Table 23. Recovery of analytes out of NIH3T3 cell samples by use of three different spike-in amounts of ENs 
(15 fmol, 250 fmol, and 500 fmol). Recovery in percentage (%), as well as the coefficients of variation (C.V.), are 
shown for each spike-in level. Only multiplex 1-6 were investigated. 
Multiplex Analyte 
Recovery 
in % 
(15 fmol 
spike-in) 
C.V. 
in % 
Recovery 
in % 
(250 fmol 
spike-in) 
C.V. 
in % 
Recovery 
in % 
(500 fmol 
spike-in) 
C.V. 
in % 
MpCombi1 
ARG1(PFSK) 80 3 74 1 80 5 
UGT1A1 107 2 108 3 113 6 
UGT1A3 60 1 80 1 94 2 
MpCombi2 
FASN 79 8 86 3 88 6 
LMNA 66* 12 92 4 100 2 
TNFRSF12A 71 2 82 2 100 8 
MpCombi3 
ALDH3A1 91 7 104 10 99 8 
UGT2B15 88 10 112 2 115 6 
MpCombi4 
SULT1B1 98 3 103 3 104 1 
UGT2B7 77 3 80 1 90 1 
MpCombi5 
ARG1(YILK) 103 5 113 9 108 5 
CYP7A1 102 2 100 2 96 3 
S100P 78 5 82 6 101 10 
MpCombi6 
ADH1B 70 13 81 1 85 3 
HSD11B2 101 0 99 2 102 2 
NQO1 128* 0 80 0 79 3 
PRKDC 110 5 113 4 111 2 
*= Due to high base level in the matrix, 15 fmol spike-in is within the measurement error range and, therefore, 
cannot be determined. 
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Table 23 reveals that the recoveries were between 60.47±1.49% for UGT1A3 
(marked with orange) at 15 fmol ENs spike-in to 127.60±0.42% at 15 fmol ENs 
spike-in for NAD(P)H dehydrogenase [quinone] 1 (NQO1). The results for all ana-
lytes at each concentration level were precise and reproducible with a maximum 
C.V. of 13.4% for alcohol dehydrogenase 1B (ADH1B) at 15 fmol ENs spike-in. 
 
4.1.12 Intra- and Interday Precision 
For the assessment of intra- and interday precision, three different samples were 
used. First, a negative HepaRG control (DMSO-treated), second a prochloraz-treated 
(10 µmol L-1) HepaRG sample, and third a cryopreserved primary human hepato-
cyte sample (PHH; donor 1). Each sample was digested five times per day, and this 
procedure was repeated for three days. For intraday precision, the mean value for 
the five single determinations was used. For the interday precision, one random 
value was chosen for each day. Table 24 on the next two pages shows the results. 
Only multiplex 1 to multiplex 6 were investigated. The table shows that for both in-
tra- and interday results, C.V.s with less than 20% could be obtained. The smallest 
C.V. was obtained for ARG1(PFSK) with 0.5% in the PHH sample (interday), the high-
est for corticosteroid 11-beta-dehydrogenase isozyme 2 (HSD11B2) with 19.6% in 
the negative control (intraday). CYP7A1 and S100P were only detected and quanti-
fied in the PHH sample. On the other hand, ALDH3A1, HSD11B2, NQO1, and tumor 
necrosis factor receptor superfamily member 12A (TNFRSF12A) were identified 
only in the HepaRG cells and not in the hepatocyte sample. 
In summary, it can be said that the method development was completed successfully 
with regard to the investigated parameters for six new multiplexes containing a to-
tal of 17 peptides (representative of 16 proteins). In combination with the 
CYP 17-plex, the analysis of pesticide-treated HepaRG cells was performed for 34 
peptides (representative of 32 proteins). 
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Table 24. Intra- and interday precision of multiplex assays 1-6, where intraday variance was determined with n=5 replicates and interday variance with n=3 replicates. For the assessment, 
a negative HepaRG cell sample (DMSO-treated), a prochloraz-treated (10 µmol L-1) HepaRG cell sample, and a cryopreserved primary human hepatocyte (PHH; donor 1) sample were used. 
Shown are the mean values in fmol µg-1 and the respective coefficient of variation (C.V.) in percent (%). 
  Intraday variance (n=5) Interday variance (n=3) 
Mp Analyte 
Control 
Prochloraz-
treated 
PHH.1 Control 
Prochloraz-
treated 
PHH.1 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
1 
ARG1 
(PFSK) 
2.5 6 1.9 5 69.8 11 2.5 6 1.7 5 66.3 1 
UGT1A1 6.8 9 5.6 6 10.9 12 6.8 12 5.4 4 9.1 15 
UGT1A3 1.1 4 0.8 9 3.0 6 1.1 3 0.8 1 3.1 10 
2 
FASN 18.6 10 19.0 12 4.4 6 20.3 11 23.0 16 4.0 5 
LMNA 28.4 7 6.6 7 0.3 17 29.8 3 6.5 7 0.4 9 
TNFRSF12A 0.2 11 0.2 7 n.d. na 0.2 18 0.2 11 n.d. na 
3 
ALDH3A1 15.2 8 10.1 6 n.d. na 15.3 4 12.0 15 n.d. na 
UGT2B15 30.6 7 27.0 15 117.1 12 34.2 12 29.0 15 121.7 17 
4 
SULT1B1 0.9 4 0.6 4 3.3 3 1.0 8 0.7 16 3.4 3 
UGT2B7 2.8 6 1.4 7 52.1 6 3.0 13 1.5 7 54.3 2 
5 
ARG1(YILK) 0.8 8 0.8 12 20.9 8 0.8 3 1.0 19 19.9 7 
CYP7A1 <LLOQ na n.d. na 0.1 9 <LLOQ na n.d. na 0.1 18 
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  Intraday variance (n=5) Interday variance (n=3) 
Mp Analyte 
Control 
Prochloraz-
treated 
PHH.1 Control 
Prochloraz-
treated 
PHH.1 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
mean 
in 
fmol µg-1 
C.V. 
in % 
S100P <LLOQ na <LLOQ na 0.1 4 <LLOQ na <LLOQ na 0.1 3 
6 
ADH1B 58.5 12 49.4 3 172.5 7 59.8 9 52.4 13 173.4 3 
HSD11B2 0.1 20 0.1 12 n.d. na 0.1 2 0.05 9 n.d. na 
NQO1 0.5 7 0.4 11 n.d. na 0.5 13 0.4 14 n.d. na 
PRKDC 4.9 8 4.1 18 1.0 19 5.6 15 4.3 10 1.0 9 
n.d.= not detected; na= not applicable; <LLOQ= below the lower limit of quantification 
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4.2 Analysis of Pesticide-Treated HepaRG Cells with 
Immunoaffinity-Based Mass Spectrometry 
4.2.1 Determination of the Fold Change’s Significance Levels 
For the analysis of induction or repression effects, it was necessary to determine 
what the threshold would be to distinguish between the variations due to experi-
mental errors and a significant change referred to the control. To address this issue, 
RStudio v.1.0.153 (R Consortium, Boston, USA) was used, and in cooperation with 
Dr. Hannes Planatscher (Signatope GmbH, Reutlingen, Germany), a script for a sim-
ulation with random fold change values (transformed to log2 values) was written. It 
was considered that each pesticide treatment was measured three times, as well as 
the control samples. Also, α was set to 0.05, which means the observed fold change 
is not a random product with a probability of 5%. To obtain a more accurate result, 
alpha was divided by the number of analytes for which the evaluation was per-
formed (alpha was divided by 27). As a further criterion, the tested coefficient of 
variation (C.V.) was set to 20%, since interday variation did not exceed 20% (see 
Table 24).  
With these parameters set, the simulation was performed with 100, 1000, 10 000, 
and 100 000 random fold change (log2 transformed) values. Figure 26 shows that 
with an increased number of test samples, the histograms approximated a perfect 
Gaussian distribution. The simulation revealed that a fold change (log2 transformed) 
must be less than -0.56 or higher than +0.56 to be considered as significant. This 
transforms into 1.5-fold and 0.7-fold in absolute values. 
  
Results 
72 
A 
 
B 
 
C 
 
D 
 
Figure 26. Histogram of randomly generated fold changes. The simulations were performed with 100 (A), 1000 
(B), 10 000 (C), and 100 000 (D) randomly generated fold changes (log2 transformed). The simulation revealed 
that the log2 transformed fold changes must be less than -0.56 or greater than +0.56 to be considered as signifi-
cant. The simulations were run with RStudio v.1.0.153. 
 
Since the effects of pesticide treatments on toxicologically relevant proteins in  
HepaRG cells were determined using fold changes, quadratic error propagation was 
used to calculate the errors of these fold changes. The following equation shows the 
general formula of the quadratic error propagation law. 
 
∆𝐹 = √(
𝜕𝐹
𝜕𝑥
∙ ∆?̅?)
2
+ (
𝜕𝐹
𝜕𝑦
∙ ∆?̅?)
2
+ ⋯ (95) 
 
This formula has been modified for the calculation of fold change errors as follows: 
 
∆𝐹 = (√(
𝜎𝑡𝑟
?̅?𝑡𝑟
)
2
+ (
𝜎𝑛𝑐
?̅?𝑛𝑐
)
2
) ∙ (
?̅?𝑡𝑟
?̅?𝑛𝑐
) 
σtr= standard deviation of treated samples 
x̅tr= mean value of treated samples 
σnc= standard deviation of the negative control 
x̅nc= mean value of the negative control   
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4.2.2 Analysis of HepaRG Cells Treated with Single Pesticides ‒ Screening 
Before the analysis of potential mixture effects was investigated, a screening of 30 
different pesticides, comprising acaricides, fungicides, insecticides, nematicides, 
and plant growth regulators, was performed. Treatment of HepaRG cells was per-
formed with each pesticide in three replicates. The concentration of the particular 
pesticide was the highest non-toxic concentration determined with a cell viability 
test performed by Dr. Dajana Lichtenstein (German Federal Institute for Risk As-
sessment (BfR)). After the measurement, mean values were calculated for each an-
alyte. Fold changes were determined, and results were transformed to log2 data.  
Figure 27 shows a heatmap of the results. On the y-axis, all 27 quantified peptides 
(7/34 peptides were either below the quantification limit or not detectable) are pre-
sented, on the x-axis all pesticide treatments. A gray field indicates that no evaluable 
data point has been obtained. At first glance, the heatmap shows that weak changes 
can be observed for most analytes across all pesticides (only 28.1% of all data points 
showed a significant change). The effects, however, are more towards down-regula-
tion. Nevertheless, for a few proteins, stronger changes were observed. For example, 
CYP1A1 shows a strong induction effect, with a 695 or 322 fold change after treat-
ment with cyprodinil (CDN) or fludioxinil (FDO), respectively. Strong induction ef-
fects were also observed for CYP1A1 after treatment with iprodione (IPR; 188-fold), 
carbendazim (CBZ; 158-fold), chlorpyrifos (CLP; 80-fold), or pyraclostrobin 
(PCL; 67-fold). In contrast to CYP1A1, CYP2C19 shows a partially strong down-reg-
ulation. These effects are mainly observed after the treatment of CLP (0.08-fold), 
azoxystrobin (AOS; 0.10-fold), ethoprophos (ETP; 0.12-fold), or thiram (TRM; 0.13). 
Looking at the pesticide treatments across all analytes, it can be observed that the 
treatment with ethoprophos (ETP) produced a significant effect (greater than 0.56 
and less than -0.56 or 1.5-fold and 0.7-fold) in 18 out of 27 analytes. Significant 
changes were observed for 14 analytes each when treated with fludioxonil (FDO), 
maneb (MAN), and thiram (TRM). On the other hand, only two analytes showed a 
significant change after treatment with captan (CPT) and thiacloprid (THI). When 
treated with chlormequat (CMQ), it was even only one analyte. Table 25 summarizes 
the 30 pesticides used for the screening. It contains both the substance name and 
the abbreviation (abbrev.) used in Figure 27, as well as the treatment concentration 
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in µmol L-1 applied. It also displays how many significant up- or down-regulations 
were observed during the screening.  
 
Table 25. Pesticides of the screening. The table shows the pesticides of the screening with the corresponding 
abbreviations and concentrations used. It also shows the number of significant up- or down-regulation of the 
respective pesticide treatment.  
Substance Abbrev. 
Concentration 
in µmol L-1 
Significant 
up-regulation # 
Significant 
down-regulation # 
Azoxystrobin AOS 100 0 8 
Boscalid BOS 500 2 6 
Captan CPT 50 1 1 
Carbendazim CBZ 250 5 2 
Chlormequat CMQ 1000 1 0 
Chlorpyrifos CLP 200 5 5 
Cyproconazole  CC 80 4 1 
Cyprodinil CDN 100 6 3 
Difenoconazole DIF 25 2 5 
Dimethomorph DIM 500 2 5 
Epoxiconazole  EPC 80 5 1 
Ethoprophos ETP 500 2 16 
Fenhexamid FHM 250 0 6 
Fenpyroximate FPX 5 2 5 
Fipronil  FIP 50 4 1 
Fludioxonil FDO 250 6 8 
Flusilazole  FLZ 80 6 1 
Fluxapyroxad FLP 250 2 10 
Imazalil IMZ 50 4 5 
Iprodione IPR 200 5 2 
Maneb MAN 200 2 12 
Metalaxyl MTX 1000 1 5 
Myclobutanil MCB 250 6 2 
Prochloraz  PCZ 80 2 2 
Propiconazole  PPC 80 9 0 
Pyraclostrobin PCL 25 3 3 
Tebuconazole  TBC 80 6 1 
Thiacloprid THI 500 0 2 
Thiamethoxam TMX 1000 2 1 
Thiram TRM 100 4 10 
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Figure 27. Heatmap of screening results. Here, data for all analytes after the treatment with 30 different single 
pesticides are shown. Measurement of each treatment was performed in triplicates. Abbreviations of the treat-
ments are shown in Table 25. Gray fields indicate that no evaluable data point has been obtained. 
 
4.2.3 Time-Dependency of Effects after Varying Pesticide Incubations 
Since the results of the screening showed only few significant changes at the protein 
level, it was decided that the time dependency on the effects of a small selection of 
pesticides should be re-analyzed. Hence the treatment duration was extended from 
24 to 72 hours. Four different pesticides and a prototypical inducer were selected. 
Results of the 72-hour treatment were then compared to the already obtained data 
after 24 hours of treatment. HepaRG cells were treated with difenoconazole, fenpy-
roximate, flusilazole, and imazalil. Rifampicin was used as a prototypical inducer. 
Concentrations of flusilazole (80 µmol L-1), imazalil (50 µmol L-1), and rifampicin 
(5 µmol L-1) were the same for both treatment durations. Due to cytotoxicity data, 
the concentration of difenoconazole and fenpyroximate had to be adjusted 
(25 µmol L-1 to 10 µmol L-1 and 5 µmol L-1 to 2.5 µmol L-1, respectively). Heat maps 
were generated from the obtained data using mean log2 data (n=3; errors not dis-
played), and results are shown in Figure 28. The analytes were plotted on the y-axis 
while the four pesticides and the prototypical inducer were plotted on the x-axis. In 
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addition, the scales of both heat maps were set to the same values to allow a visual 
comparison. Gray fields indicate that no evaluable data point has been obtained 
since values were below the lower limit of quantification (LLOQ), or no endogenous 
signal was detected.  
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Figure 28. Heatmap comparison of 24 h and 72 h treatment. HepaRG cells were treated with difenoconazole, 
fenpyroximate, flusilazole, imazalil, and rifampicin for 24 h (upper graph) and 72 h (lower graph). The concen-
tration of flusilazole, imazalil, and rifampicin (80 µmol L-1, 50 µmol L-1, and 5 µmol L-1, respectively) remained 
unaltered. Difenoconazole and fenpyroximate had to be adjusted based on cytotoxicity data (25 µmol L-1 to 
10 µmol L-1 and 5 µmol L-1 to 2.5 µmol L-1). Each treatment was performed three times, and measurements were 
performed in single determinations. Mean values were then calculated; errors are not displayed. Gray fields 
indicate that no evaluable data point has been obtained. For visual comparison, the scales were set to the same 
values. 
 
Figure 28 clearly shows differences between the results from cell cultures treated 
for 24 hours and 72 hours. Due to cytotoxic effects after 72 hours of treatment, the 
concentration for difenoconazole and fenpyroximate had to be reduced and ad-
justed. Therefore, a direct comparison could only be made for flusilazole, imazalil, 
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and rifampicin. In general, the effect of flusilazole and imazalil was more pro-
nounced after 72 hours than after 24 hours. While 11 proteins showed a significant 
change (less than -0.56 or more than 0.56; or 0.7-fold and 1.5-fold) after the 24-hour 
treatment with flusilazole and imazalil, 25 proteins showed a significant change af-
ter 72 hours. In addition to the higher number of significant protein changes, the 
amplitude of some analytes also increased. S100P, for example, showed a stronger 
induction after 72 hours. The fold changes of S100P after treatment with flusilazole 
and imazalil for 24 hours were 7.5 and 6.4, respectively, whereas these protein 
changes were 118.6 and 17.7 after 72 hours. Moreover, CYP2C8, CYP2C9, or 
CYP2C19 showed stronger repression effects after 72 hours. 
Interestingly, the results after 24-hour treatment with rifampicin indicate a trend 
towards up-regulation. Comparing the results with the 72-hour treatment, it is no-
table that the direction of regulation of many proteins switched towards down-reg-
ulation. Moreover, 17 protein concentrations were below LLOQ after 24 hours, while 
only 12 data points were below LLOQ after 72 hours of treatment (characterized by 
gray fields, which is particularly visible after treatment with flusilazole and rifam-
picin). 
 
4.2.4 HepaRG Cell Viability after Treatment with Single Pesticides and Mixtures 
thereof 
Once the screening was completed, the data were used to decide which substances 
should be combined to investigate potential mixing effects. The composition of the 
mixtures should be based on the potency of the substance and not on concentra-
tions. One challenge was that typically, only one effect (i.e., on a specific endpoint, 
e.g., a single protein) is considered when calculating the potency. In this case, how-
ever, it was necessary to consider the effect on all proteins to be investigated. It was 
therefore decided to calculate a multiple potency factor of the individual pesticide 
effects on the proteins in order to obtain relative potency factors (RPFs) of the treat-
ments by relating them to each other. This calculation was performed at the protein 
level and to compare the data obtained, the calculation was also performed with Ad-
ipoRed data (test for the intracellular enrichment of triacylglycerides; the measure-
ment and calculation was performed by Dr. Dajana Lichtenstein, BfR) and at the 
Results 
79 
mRNA level (assay and calculation was performed by Dr. Almut Mentz at the Center 
for Biotechnology (CeBiTec)). 
To calculate the RPFs at the protein level, confidence intervals for all analytes were 
determined respectively and normalized to the concentration used. In order to ob-
tain RPFs, all calculated values were related to each other. The results are shown in 
Figure 29. The encircled values show the RPFs of the substances that were used for 
the generation of mixtures. 
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Figure 29. Relative potency factor matrix. For each substance, a multiple potency factor was calculated, which contains the effects of the respective substance on all measured analytes. For 
this purpose, confidence intervals were determined, which were normalized to the concentration of the respective pesticide used. In order to obtain relative potency factors (RPFs), all 
calculated values were related to each other. The matrix shows the calculation at the protein level. The RPFs of the substances used to generate the mixtures are encircled in black. 
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This matrix showed how the potency of a treatment behaved in comparison to the 
referenced one. In order to distinguish the similarities of the effects, a Pearson cor-
relation was performed with the mRNA data only, since here, stronger effects were 
observed. The mixtures should represent four different classes: very strong, strong, 
moderate, and weak. The values of these classifications were: >0.9, 0.6-0.9, 0.3-0.6, 
and <0.3, respectively. In addition, it was investigated which of these substances are 
commercially available as combination products. Table 26 shows the information 
about the selected mixtures. The reference column shows to which particular sub-
stance the mixing partner was normalized.  
 
Table 26. Selection of mixtures for the analysis of potential mixture effects. The mixtures were classified into 
four different groups based on their Pearson scores (mRNA). In addition, the RPFs were calculated using Adi-
poRed, mRNA, and protein data. The reference corresponds to the single substance to which the normalization 
was performed. The last column shows the products available on the market as mixtures. 
Similarity 
Pearson 
Score 
Refer-
ence 
Mixing 
partner 
Relative potency 
Product 
AdipoRed mRNA Protein Applied 
Very strong 0.95 PPC DIF 5.2 3.2 6.6 5 TASPA 
Strong 0.89 AOS DIF 5.8 6.5 4.0 5 ASKON 
Moderate 0.48 THI AOS 9.1 11.4 10.4 10 - 
Weak 0.23 AOS CC 0.3 0.6 0.7 0.5 Several 
 
The results of the RPFs using the three different calculations with AdipoRed, mRNA, 
and protein data, showed slight differences. Therefore, it was decided to use the po-
tencies closest to all three calculation paths. These are for the mixture PPC/DIF= 5; 
AOS/DIF= 5; THI/AOS= 10 and AOS/CC= 0.5. With these calculated values, an equi-
potent ratio between the substances in the respective mixture should be obtained. 
Since the results of the treatment kinetics (4.2.3 Time-Dependency of Effects after 
Varying Pesticide Incubations) showed that after 24-hour treatment only few signif-
icant changes were observed and the number of significant changes was increased 
after 72 hours, it was decided that the duration of treatment to determine potential 
mixing effects should not only be 24 hours but additionally 48 and 72 hours. In ad-
dition, not only one concentration of the individual substance and the mixtures but 
concentration series should be investigated in order to determine concentration de-
pendencies. The results of the individual treatment should be used as a reference 
for the mixture treatment. Hence, five different concentrations were prepared for 
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each substance and each mixture. The highest concentration should be the highest 
non-toxic concentration for the HepaRG cells.  
Therefore, the cytotoxicity of these individual substances, as well as in combination, 
were investigated. This was done, so changes in protein levels based on the cytotox-
icity of the substance could be ruled out. To determine cytotoxic effects, a viability 
test was performed by Dr. Lichtenstein (BfR) as described in Luckert et al.96 The cells 
were treated for either 24, 48, or 72 hours with the respective concentration series 
of the individual substances or mixtures. The measurements for each concentration 
were repeated nine times. The data were kindly provided by Dr. Lichtenstein. These 
data are shown in Figure 30. For the mixtures, the first concentration on the x-axis 
stands for the first substance in the legend. 
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Figure 30. HepaRG cell viability after pesticide treatment. In (A), the viability after 24 hours of single treatment 
is shown. (B) shows the respective mixtures after 24 hours. (C) and (D) represent the 48-hour treatments and 
(E), (F) the 72-hour treatments. In the case of mixtures, the first concentration on the x-axis stands for the first 
respective substance in the legend. The dashed horizontal line indicates 100% viability, which represents the 
solvent control. Data were referred to the solvent control. Measurements for each treatment was performed 
nine times.  
 
The data of the 24-hour treatment (A and B) showed no evidence of cytotoxic effects 
on the cells if 80% viability was set as threshold. This applies both to the individual 
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substances and to the mixtures thereof. Nevertheless, a trend towards cytotoxic ef-
fects can be observed after treatment with an increasing concentration of PPC. In 
contrast to the 24-hour treatment, cytotoxic effects can be observed at high concen-
trations after 48 hours of treatment with AOS and 72 hours of treatment with PPC 
and PPC/DIF. After 48 hours of treatment with 70 µmol L-1 AOS, cell viability de-
creased to 56%. For single treatment with PPC (72 h), the viability decreased to 82% 
at 70 µmol L-1 and to 54% at 80 µmol L-1. In the mixture PPC/DIF (40+8 µmol L-1), 
the viability decreased to 66%. Interestingly, no cytotoxic effects were observed af-
ter 72 hours of treatment with AOS. 
 
4.2.5 Analysis of HepaRG Cells Treated with Pesticide Mixtures 
In Chapter 4.2.4 HepaRG Cell Viability after Treatment with Single Pesticides and 
Mixtures thereof, the selection of mixtures to be investigated was described. In ad-
dition to the mixtures, the individual substances were also examined with different 
concentrations in order to obtain reference values. Therefore, a concentration series 
consisting of five different concentrations were prepared for each mixture as well 
as for each substance, and HepaRG cells were treated for either 24, 48, or 72 hours. 
Experiments were independently performed three times with the respective pesti-
cides and mixtures. As a prototypical inducer 6-(4-Chlorophenyl) imidazo 
[2,1-b][1,3] thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime (CITCO), and as 
a negative control, DMSO-treated HepaRG cells were used. The total number in one 
replicate experiment was 141 (135 pesticide-treated samples, three CITCO-treated 
samples, and three negative controls). Table 9 and Table 10 (3.6 Samples) show the 
concentrations of the individual substances or the mixtures, respectively. Mean val-
ues were calculated from each of the three individual measured values, and then fold 
changes with respect to the negative control were determined. Afterward, the data 
were log2 transformed. With these log2 transformed data, four heat maps were gen-
erated as an overview for the four different mixtures with corresponding single sub-
stances covering all 27 quantified analytes. Each heat map contains all three treat-
ment durations of 24, 48, and 72 hours and the five different concentrations, in as-
cending order from left to right, measured at each timepoint. The analytes were plot-
ted on the y-axis, the treatments on the x-axis. Gray fields indicate that the values 
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for the respective protein were below the LLOQ, or no signal was detected. The re-
sults after 48 hours of treatment with the highest AOS concentration and the highest 
concentration after 72 hours of treatment with PPC and PPC/DIF showed cytotoxic 
effects on cell viability (viability below 80%, Figure 30). These results are shaded in 
gray in the following graphs.   
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Figure 31. Protein abundance analysis in HepaRG cells treated with the mixture of AOS/CC and AOS/DIF. The 
upper graph shows the heatmap for the mixture of AOS/CC and respective single treatments; the lower graph 
the results for AOS/DIF. The concentrations at each timepoint are shown in ascending order from left to right 
(n=3). Gray fields indicate that no evaluable value was obtained (either no endogenous signal or below lower 
limit of quantification). Shaded gray fields indicate that for this concentration, the cell viability was below 80%. 
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Figure 32. Protein abundance analysis in HepaRG cells treated with the mixture of AOS/THI and PPC/DIF. The 
upper graph shows the heatmap for the mixture of AOS/THI and respective single treatments; the lower graph 
the results for PPC/DIF. The concentrations at each timepoint are shown in ascending order from left to right 
(n=3). Gray fields indicate that no evaluable value was obtained (either no endogenous signal or below lower 
limit of quantification). Shaded gray fields indicate that for this concentration, the cell viability was below 80%.   
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Figure 31 and Figure 32 show the log2 transformed data of the mixtures with the 
respective individual substances as a heatmap. The data of single substances such 
as azoxystrobin are the same for every heatmap. The scales were set to the same 
range so that a comparison could be made according to the intensity of colors. At 
first glance, it can be observed that the treatment with azoxystrobin generally had a 
stronger effect on protein abundance than the other single substances. In particular, 
CYPs show a stronger trend towards down-regulation. This is evident in CYP2C8, 
CYP2C9, CYP2C19, and CYP3A4. On closer examination of the results for CYP3A4 
after treatment with AOS, it can be seen that there was a concentration dependency. 
With increasing pesticide concentration, the down-regulation becomes stronger. In 
addition, stronger repression could be observed after longer treatment times. An-
other interesting observation is the fact that S100P appears to be the only analyte 
that shows a strong trend towards up-regulation across all treatments. Treatment 
with AOS/CC, AOS/DIF, AOS/THI, and the respective single substances showed for 
CYP1A1 that only a few changes were observed. For most conditions except CC and 
DIF after 24 hours, no quantifiable results for CYP1A1 (marked by gray fields) were 
obtained. Interestingly, there was a strong induction effect after treatment with PPC 
and the mixture of PPC/DIF. For single treatment with PPC, the effect became 
weaker by increasing the duration of treatment. 
Besides these four heatmaps, log2 graphs were also generated for each analyte to 
provide a more in-depth insight into the regulation. The results for CYP3A4 and 
prelamin-A/C (LMNA) are shown in Figure 33 and Figure 34 as examples. The re-
maining graphs can be found in Figure 48-Figure 60 in the appendix (9 Supplemen-
tary Data). These two proteins were chosen because they clearly show time and con-
centration effects after pesticide treatment.  
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Figure 33. Results of potential mixture effects on CYP3A4 protein abundance in HepaRG cells. Log2 transformed fold changes of single as well as mixture treatment with azoxystrobin and 
difenoconazole is shown in (A), azoxystrobin and cyproconazole in (B), azoxystrobin and thiacloprid in (C), and propiconazole and difenoconazole in (D); n=3. Concentrations of treatments 
can be found in Table 9 and Table 10. 
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Figure 34. Results of potential mixture effects on LMNA protein abundance in HepaRG cells. Log2 transformed fold changes of single as well as mixture treatment with azoxystrobin and 
difenoconazole is shown in (A), azoxystrobin and cyproconazole in (B), azoxystrobin and thiacloprid in (C), and propiconazole and difenoconazole in (D); n=3. Concentrations of treatments 
can be found in Table 9 and Table 10. 
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Figure 33 shows the results for CYP3A4. The concentration dependency indicated in 
the heatmap can also be clearly seen in this additional illustration. A concentration-
dependent effect was present after the treatment with azoxystrobin (A1 lowest con-
centration; A5 highest concentration). The higher the concentration, the more the 
enzyme was down-regulated. This observation could also be made after treatment 
with propiconazole (P1-P5) and difenoconazole (D1-D5). In azoxystrobin- and pro-
piconazole-treated samples, a change in the direction of regulation was detected af-
ter all treatment durations, for difenoconazole only after the 72-hour treatment. 
This change of effect direction could also be observed with the mixture treatment of 
AOS/DIF (72 h), AOS/CC, AOS/THI, and PPC/DIF (48 h; 72 h). Furthermore, the ef-
fect of different treatment durations could be observed in the treatment of 
azoxystrobin. The longer the treatment, the stronger was the down-regulation com-
pared to the shorter periods. In total, the data for CYP3A4 revealed that out of 135 
data points, 89 showed a significant change (less than -0.56 or greater than 0.56). 
In comparison, the results of LMNA show a lower concentration dependency. More 
notable is the effect of treatment time. After the 24-hour treatment, in most cases, 
hardly any effect is visible, whereas these effects become stronger with longer treat-
ment. This can be seen particularly in Figure 34 (Part D). While 89 values for CYP3A4 
indicated a significant change, only 21 values were found for LMNA. Of these 21 val-
ues, 20 were observed after 72 hours of treatment.  
Both substances were chosen to show that not only the different concentrations 
used but also the treatment duration had an influence on protein abundance and 
direction of change. While significant changes in protein abundance for CYP3A4 
were already observed after 24 hours of treatment, these effects could only be ob-
served after 72 hours for LMNA. These results demonstrate that it was important 
not only to investigate one treatment timepoint, but several timepoints since the 
change in protein abundance was different for the analytes measured.  
 
4.2.6 Multiple Linear Regression Analysis for the Determination of Combinatorial 
Effects 
In order to discover whether combinatorial effects of pesticide treatments could be 
observed, the data obtained were used and further evaluated. Various models are 
used in the literature to determine whether there is a combinatorial effect, such as 
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antagonism, additivity, or synergism. A distinction is made between mixtures that 
follow the same mode of action (MOA) and mixtures that follow different MOAs. The 
most common and widely applied models are Loewe Additivity 97 (same MOA) and 
Bliss Independence 98 (dissimilar MOA), which are used in pharmacology to investi-
gate mixing effects of drugs. The following formula describes the Loewe Additivity 
of a binary mixture. The effect concentration (ECx) of a mixture is determined. For 
the determination, the respective concentrations of substances A and B, which lead 
to an x% effect of the individual substances (ECxA and ECxB), are taken into account. 
If substance A and B are additive, the term for ECxmix becomes 1. The formula was 
adapted from Cedergreen 99. 
 
𝐸𝐶𝑥𝑚𝑖𝑥 =
𝑐𝐴
𝐸𝐶𝑥𝐴
+
𝑐𝐵
𝐸𝐶𝑥𝐵
 (adapted from Cedergreen 99) 
 
ECx= effect concentration of either mix, substance A or substance B causing an x% effect 
cA= concentration of substance A  
cB= concentration of substance B 
 
If the substances in a mixture follow a different MOA, the Bliss Independence for-
mula can be applied. Which is (formula adapted from Bliss 98): 
 
𝐸𝑚𝑖𝑥 = 𝐸𝐴 + 𝐸𝐵 − 𝐸𝐴 ∙ 𝐸𝐵  (adapted from Bliss 98) 
 
The mixing effect (Emix) is calculated by the sum of the individual effects of substance 
A (EA) and B (EB) and the subtraction of the product of both effects. 
However, these methods are based on the availability of dose-response curves. 
When determining dose-response dependencies, receptors are often explicitly tar-
geted 100. In this thesis, proteins were used as a readout for potential combinatorial 
effects. Compared to a specific receptor, this is a complex system that depends on 
different time-shifted processes: mRNA synthesis, presence of microRNA, biosyn-
thesis of these proteins as well as protein degradation. 
Due to this fact, both models are not practicable for the analytes used in this work, 
as the following example shows. In Figure 35, the graph for the analyte LMNA is 
shown after 24 hours of treatment with azoxystrobin. The mean amount in fmol µg-1 
was plotted against the azoxystrobin concentration used. The graph clearly shows 
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that after 24-hour treatment with AOS, no dose-response dependency could be ob-
served, but that the values fluctuated around the value 30 fmol µg-1. That means no 
effect concentration that causes an x% effect can be defined. 
 
 
Figure 35. Dose-response plot of LMNA after 24-hour treatment with azoxystrobin. The mean amount in 
fmol µg-1 was plotted against the concentration in µmol L-1 of azoxystrobin (AOS) used. The treatment duration 
was 24 hours. 
 
Since, in these cases, neither the Loewe Additivity nor the Bliss Independence could 
be applied, and because it is desirable to have an evaluation system with which all 
analytes can be evaluated equally, it was decided to conduct the evaluation in an-
other way. Multiple linear regression analysis was used as the basis for this. Thus, a 
model prediction was made for all analytes based on the results of the individual 
substances, which is composed as follows: 
 
𝑦 = 𝑝1𝑐(𝐴𝑂𝑆) + 𝑝2𝑐(𝐶𝐶) + 𝑝3𝑐(𝐷𝐼𝐹) + 𝑝4𝑐(𝑇𝐻𝐼) + 𝑝5𝑐(𝑃𝑃𝐶) + 𝑝6𝑡𝑖𝑚𝑒 + 𝑏𝑎𝑠𝑒 𝑙𝑒𝑣𝑒𝑙 
 
p1-5= coefficients for the respective treatments 
c(substance)= applied concentration during a single treatment 
base level= instrument noise consideration 
time= treatment time of single substances (24, 48, or 72 hours) 
 
If, for example, the model for the AOS/CC mixture is considered, the formula would 
change as follows, since the terms for c(DIF), c(THI) and c(PPC) have a value of zero: 
 
𝑦 = 𝑝1𝑐(𝐴𝑂𝑆) + 𝑝2𝑐(𝐶𝐶) +  𝑝6𝑡𝑖𝑚𝑒 + 𝑏𝑎𝑠𝑒 𝑙𝑒𝑣𝑒𝑙   
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This model prediction was performed for each analyte using RStudio v.1.0.153. It 
needs to be mentioned that the highest concentrations of AOS after 48-hour treat-
ment and PPC after 72-hour treatment were not considered for the modeling be-
cause the viability of the cells was below 80%. These multiple linear regression 
models were then used to compare them with the actual measured value of the mix-
ture. This was done using the Model Deviation Ratio (MDR) described by 
Belden et al., where the predictive value was divided by the measured value 101. For 
the determination of the MDR, the concentration causing a given effect (ECx) is usu-
ally used. Cedergreen applied the MDR for the evaluation of combinatorial effects 
and classified the MDR into the three following groups: MDR<0.5 antagonism, 
0.5<MDR<2 additivity, and MDR>2 synergism 99. This could not directly be trans-
ferred to our data since no ECx was determined by multiple regression analysis. 
However, the boundaries for the characterization of the effects were adopted. Thus, 
if the MDR was between 0.5 and 2, it was defined as an additive effect. Once the value 
was below 0.5 or above 2, it was either a synergistic or antagonistic effect. A distinc-
tion between the effects could only be made after considering the sign of the slope 
of the multiple regression parameters. This becomes apparent with the following 
schematic illustration (Figure 36).  
 
A 
 
B 
 
Figure 36. Two different schematic cases for determining a combinatorial effect. In the graphs, the red and black 
lines are the regression lines of the individual substances. The blue lines are the model predictions of the re-
spective mixture. The green stars represent measured values after mixing treatments. In (A), all slopes are pos-
itive. This means that values smaller than 0.5 indicate a synergism. In (B), all slopes are negative, which means 
that values greater than 2 indicate a synergism. 
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In (A), the case is shown where both individual substances have a positive slope. 
This results in a model prediction for the mixture, which also increases with increas-
ing concentration. The green stars represent theoretical measuring points after mix-
ing treatment where the upper star indicates a synergism, the lower star an antago-
nism. Thus, if the MDR equation is used, an MDR for the upper value (synergism) of 
0.5 is obtained (predicted value divided by the measured value). In example (B), the 
slopes of the regression lines are all negative. If the lower measured data point is 
considered, it also shows that there is a model deviation (synergism), but the MDR 
assumes a value of 2 in this case. In order to distinguish the effects of the values 
below 0.5 and above 2 for the respective analytes, the slopes of the regression line 
were taken into account. A limitation of the analysis by mixture model predictions 
was that some protein abundance values were below the respective LLOQ of the as-
says. In these cases, the value half of the LLOQ was used for the calculations. This 
was done for the following reasons. Firstly, this ensured that no negative MDR val-
ues were obtained, and secondly, this procedure was also applied to the evaluation 
of the raw data. Otherwise, MDRs across all analytes could not be obtained. The fol-
lowing table (Table 27) shows the slope directions of the regression lines for each 
analyte in the respective mixtures. Furthermore, it was entered whether a syner-
gism or antagonism was present at values above 2 or below 0.5. In orange marked 
fields, the slopes have negative and positive values after single pesticide treatment. 
In these cases, a decision whether a synergistic or antagonistic effect was present is 
not applicable. It can only be said that MDR values greater than 2 or less than 0.5 
indicate a significant deviation from an additive model.  
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Table 27. Slopes of regression lines and effects in the respective mixtures. For the ten analytes with values outside the boundaries, the directions of the regression line slopes were 
determined. These slopes were then used to decide which effect was present for the respective values. In orange fields, the calculated slopes for the single analytes had positive and negative 
values. In these cases, the decision of whether a synergistic or antagonistic effect was present is not applicable. 
Analyte 
AOS/CC AOS/DIF AOS/THI PPC/DIF 
Slope Syn Anta Slope Syn Anta Slope Syn Anta Slope Syn Anta 
ARG1(PFSK) - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 
CYP1A1 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 + / - na na 
CYP1A2 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 
CYP2B6 - / + na na - / - >2 <0.5 - / + na na - / - >2 <0.5 
CYP2C8 - / - >2 <0.5 - / - >2 <0.5 - / + na na - / - >2 <0.5 
CYP2C9 - / + na na - / - >2 <0.5 - / + na na - / - >2 <0.5 
CYP2C19 - / - >2 <0.5 - / - >2 <0.5 - / + na na - / - >2 <0.5 
CYP3A4 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 
CYP7A1 - / + na na - / - >2 <0.5 - / - >2 <0.5 - / - >2 <0.5 
S100P + / + <0.5 >2 + / + <0.5 >2 + / + <0.5 >2 + / + <0.5 >2 
  Syn= Synergism; Anta= Antagonism; na= not applicable 
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To get a first impression of the distribution, all obtained MDRs were used to create 
a histogram. The class width was set to 0.1. Figure 37 depicts the histogram contain-
ing the MDRs of all measured analytes.  
 
 
Figure 37. Histogram of Model Deviation Ratios. Predicted model values were divided by measured values of 
mixtures. The distribution of the determined Model Deviation Ratios (MDR) for all measured analytes are shown 
in this histogram. The class width was set to 0.1.  
 
A total of 1486 data points were obtained. The results for the highest concentration 
after 72 hours of treatment with PPC/DIF were not considered, as viability was be-
low 80% (Figure 30). The distribution clearly shows that most values were between 
0.5 and 2, which means that most combinatorial treatments resulted in additive ef-
fects. There, most values were found between the class width of 0.9 and 1.0 
(339 data points). More interesting, however, are the values observed below 0.5 and 
above 2. Therefore, these results were examined more closely. A total of 65 values 
below 0.5 and 40 values above 2 were determined. The minimum value was 0.0005 
at the highest concentration of the AOS/THI mixture after 24 hours for CYP3A4. On 
the other hand, the highest value of 5.92 was observed at the highest concentration 
of AOS/THI after 24 hours for S100P. The mixture with most values outside these 
thresholds was AOS/DIF at the highest concentration level after 24 hours of treat-
ment. Of these seven values, six were below 0.5. Most model deviations outside the 
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thresholds were obtained for S100P with 29 values, followed by CYP2B6 with 21 
and CYP1A2 with 17 values. The values for S100P are distributed in approximately 
equal parts below and above both thresholds (16 values below 0.5; 13 values 
above 2). 
While the values of the model deviation for CYP1A2 and CYP3A4 are also distributed 
above 2 and below 0.5, there are other analytes, such as CYP2B6 and CYP7A1, for 
which only model deviations below 0.5 were obtained (21 and 6 respectively). In 
total, values outside the thresholds were observed in 10 of the 27 analytes exam-
ined. Of these ten analytes, eight were from the cytochrome P450 family. The MDRs 
for all analytes are shown in the following matrix (Figure 38). The mixtures are 
shown in rows, the MDRs of the respective analytes in columns. A red-white-blue 
color scale was used to identify trends in the respective mixtures. Blue fields indi-
cate trends towards values below 0.5, red fields towards values above 2. The results 
for the highest concentration of PPC/DIF after 72 hours of treatment were crossed 
out because the viability was below 80%. 
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Figure 38. Matrix of Model Deviation Ratios. The mixtures are displayed in rows. The concentrations are arranged in ascending order (1 lowest, 5 highest concentration). Furthermore, the 
treatment times are arranged in ascending order of the respective mixture. The Model Deviation Ratios (MDRs) of the respective analytes are shown in columns. A ranking is visualized via 
the color scale. Blue colors show a trend towards values below 0.5, red towards values above 2. Empty fields indicate that no evaluable data were available. The results for PPC/DIF after 
72 hours of treatment in the highest concentration are crossed out because the viability was below 80%. 
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Additionally, graphs for CYP3A4 and S100P are shown exemplarily as dot plots. The 
MDRs were plotted against the concentrations at the respective timepoint of treat-
ment. Thereby is one the lowest and five the highest concentration. The upper graph 
shows the results for CYP3A4, the lower graph for S100P. 
 
 
 
Figure 39. Model Deviation Ratios for CYP3A4 and S100P. The upper graph shows the results for CYP3A4, the 
lower graph for S100P. Model Deviation Ratios (MDRs) are plotted against the respective concentration at each 
timepoint of treatment. Values above the dashed horizontal line and values below the dotted line indicate either 
synergistic or antagonistic effects. Values between both thresholds show an additive effect. The data for the 
highest concentration after 72-hour treatment with PPC/DIF are shown but are not reliable as the viability was 
below 80%. 
 
These two analytes were selected as examples since, in both cases, the change in the 
MDRs over the different concentrations, as well as after different treatment times, 
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is clearly visible. Here it can be observed that combinatorial effects, such as syner-
gism and antagonism, can be concentration-dependent, and therefore it was neces-
sary to investigate several concentrations. Looking at the upper graph (CYP3A4), it 
can be seen that most values are between 0.5 and 2. These values indicate additivity 
between the two substances in the mixture. In addition, it can be observed that con-
centration dependencies exist. This can especially be seen in all mixtures after 
24-hour treatment. The higher the concentration, the lower the MDR. It can also be 
seen that the MDRs for the mixtures AOS/CC, AOS/THI, and PPC/DIF increase 
sharply at concentrations four and five, and are above the threshold of two. Consid-
ering the table of slopes (Table 27), it can be noted that values above 2 indicate syn-
ergistic effects, and values below 0.5 indicate antagonistic effects. This means that, 
after 24 hours of treatment, with increasing concentrations, the trend is towards an-
tagonism, while apparent synergistic effects can be seen at high concentrations after 
72 hours of treatment. 
Considering the lower graph (S100P), the concentration dependency after 24 hours 
of treatment is also recognizable. In this case, however, the direction of the MDRs is 
reversed. With increasing concentration, the values move in the upward direction. 
After 48 and 72 hours of treatment, this effect is reversed again. After longer treat-
ment times, the MDR decreases with the increasing concentration. Referring again 
to Table 27, it can be said that for all mixtures, all values above 2 indicate an antag-
onism, all values below 0.5 a synergism. This means that after 24 hours of treatment 
in the low concentrations, synergistic effects can be observed, which move towards 
antagonism with increasing concentration. However, this changes after 48-hour and 
72-hour treatment. After these treatment periods, the trend is towards synergism 
with increasing concentration, as observed for CYP3A4.   
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5 Discussion 
5.1 Development of Immunoaffinity-Based Mass Spectrometry 
Assays 
Before the analysis and quantification of toxicologically relevant liver proteins using 
immunoaffinity-based mass spectrometry assays, it was necessary to investigate 
method parameters to ensure the reliability of these assays. This includes, for exam-
ple, determination of the dynamic ranges, optimal proteolysis time, or the optimiza-
tion of the antibody-protein ratio. For the discovery of new biomarkers in prote-
omics approaches, shotgun experiments are usually performed 74. However, in this 
thesis, the selection of potential markers has already been made by the German Fed-
eral Institute for Risk Assessment (BfR) based on mRNA results discovered previ-
ously (e.g., in Seeger et al.39). Since some of these analytes, such as HULC 102 or 
NEAT1 103, which are non-protein-coding genes and therefore unsuitable for mass 
spectrometric analysis of toxicologically relevant liver proteins, this selection of an-
alytes was modified. The modified list of analytes is shown in Table 14.  
This list was used as a starting point for a detailed database search for suitable pep-
tides. Prior to the search, criteria were established that the peptides should meet in 
order to be considered reliable. The first criterion was that the peptide should be 
proteotypic, meaning that this peptide only exists in one protein and no other. The 
uniqueness of the peptide is essential to make reliable statements about the quanti-
fication. The sequence should also not contain methionine (prone to oxidation) 104, 
N-terminal glutamic acid (prone to cyclization) 105, and, if possible, cysteine (prone 
to oxidation) 106. The presence of modifications or natural variants within the se-
quence was also investigated. Another characteristic that was considered was the 
hydrophobicity factor. It was decided that only analytes with a factor less than 2.8, 
if possible, should be used to minimize or prevent potential problems within chro-
matographic separation. Krokhin et al. determined retention coefficients for indi-
vidual amino acids of tryptic peptides 107. Based on these results, hydrophobicity 
factors were calculated for each peptide. After all these parameters had been inves-
tigated, it was additionally checked whether the peptide had already been detected 
in other liquid chromatography-mass spectrometry (LC-MS) experiments. This was 
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done with the help of proteomicsDB, a database developed by a working group of 
the Technical University of Munich (TUM) 87. 
For the entire database search, UniProt 90, a TXP-tool (internal bioinformatics tool 
of Dr. Hannes Planatscher, Signatope GmbH, Germany; used for the investigation of 
peptide proteotypicity) and the proteomics database (proteomicsDB 87) were used. 
In order to test whether these analytes were directly measurable from HepaRG cells, 
in-gel digestion was performed, and the samples were measured with a full-scan 
method (Full-MS / ddMS²). Untreated and prochloraz-treated HepaRG cells were 
used as samples. The results in Table 19 show that in this experiment, between 2570 
and 2907 proteins and between 11705 and 13125 peptides could be identified using 
Proteome Discoverer 2.1 (Thermo Fisher Scientific, Waltham, USA). The number of 
identified proteins or peptides depends strongly on the sample to be examined, sam-
ple preparation, as well as on the mass spectrometers used and the parameters set. 
In an experiment by Tascher et al., a secretome analysis with HepaRG cells was per-
formed. This enabled the identification of 4394 intracellular proteins 108. However, 
the analysis was preceded by an additional albumin depletion, and the analysis was 
performed on a different instrument, making direct comparison difficult. Neverthe-
less, there were overlaps in the proteins identified by Tascher et al. and in this thesis. 
These include, for example, aldehyde dehydrogenase, dimeric NADP-preferring 
(ALDH3A1), several cytochrome P450 enzymes like CYP2E1, CYP2C9, CYP2C19,  
sulfotransferase family cytosolic 1B member 1 (SULT1B1), or UDP-glucuronosyl-
transferase 2B7 (UGT2B7).  
After analysis, the protein and peptide lists derived from Proteome Discoverer 2.1 
were used to investigate whether the target analytes could be identified directly af-
ter in-gel digestion. It was found that only 15 of the new 36 proteins (without 
CYP 17-plex) and even only 8 of the 37 target peptides (two for arginase-1; ARG1) 
could be found. In addition, the identification of peptides for the already developed 
CYP 17-plex assay was also investigated. This showed that only 5 out of 17 target 
peptides representing 16 proteins (two for CYP3A5) could be detected. In summary, 
only a small part (13 of 54 initial peptides) of these analytes were found directly by 
LC-MS in the HepaRG cell samples, although the detection compatibility experiment 
(4.1.2) showed that all selected peptides could be detected in the mass spectrome-
ter. This may, for example, be due to the fact that low abundant proteins are overlaid 
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by high-abundant proteins. Kim et al. have already described and compared differ-
ent enrichment strategies in their review, with which it is possible to analyze also 
low-abundant proteins by mass spectrometry 60. In order to increase the yield of the 
analytes for the measurement, it was therefore decided that antibodies (AB) should 
be generated and that immune precipitation should be used as an additional sample 
preparation step. Furthermore, since the analytes to be investigated were already 
known, it was decided to use a targeted MS method instead of the full-scan method 
to increase the sensitivity additionally 80.  
In order to decide which targeted method, targeted selected ion monitoring (tSIM) 
or parallel reaction monitoring (PRM), was more suitable for this purpose, prochlo-
raz-treated HepaRG cells were analyzed with the already developed CYP 17-plex. 
Figure 18 clearly shows that the analysis using the tSIM method was influenced by 
interferences. Since this measurement method is based on the detection of precur-
sor ions only, the probability that peptides with the same mass can be present in a 
complex sample is very high and thus interfere with unambiguous identification and 
quantification. In a study by Gallien et al., targeted mass spectrometric approaches 
were investigated, and they found that some peptides were affected by interferences 
in SIM mode, which influenced the limit of quantification (LOQ), while the LOQ re-
mained constant when measured with the PRM method 109. The additional fragmen-
tation in PRM and the associated evaluation at the MS2 level increases the specific-
ity, which leads to more specific results 52,82. By combining immune precipitation 
and PRM as a targeted measurement mode, the number of detectable CYP peptides 
could be increased from initially 5/17 after in-gel digestion and full-scan (Full-MS) 
measurement to 14/17 in HepaRG cells. Of these 14 peptides, ten peptides were 
quantifiable. Only for the analytes CYP2D6, CYP2F1, and CYP3A43, no endogenous 
signals could be observed. 
As described in chapter 1.3.4, no sequence-specific but tag-specific antibodies were 
generated. These enable the enrichment of whole peptide groups with the same 
C-terminal tag. This has not only the advantage that the number of animals to be 
immunized can be drastically reduced but also reduces the costs for the antibodies 
to be generated. Since polyclonal antibodies (pABs) usually consist of a heterogene-
ous mixture, their functionality was determined first. The aim was to determine 
whether they were able to recognize the target epitope against which they were gen-
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erated and whether they were able to enrich the target peptide from a complex ma-
trix. Two antibodies were tested for each tag. The results showed that for each ana-
lyte at least one of the two antibodies recognized the target from a tryptically di-
gested human cell mixture consisting of human embryonic kidney (HEK), human co-
lon tumor (HCT), and hepatoma G2 (HepG2) in a ratio of 1:1:1 (w:w:w). A total of 72 
antibodies were tested for the 37 peptides (for fatty acid synthase (FASN) with the 
LEVR-tag and acyl-CoA desaturase (SCD) with the PTYK-tag one animal each died 
during the 4-month immunization). Of these 72 antibodies tested, 69 epitope bind-
ing motifs were generated (protocol of Weiss et al. was used and modified 86). This 
showed that the immunization was successful for 96% of all antibodies. 
Nevertheless, it had to be investigated further whether the antibodies could enrich 
not only the appropriate tag but also the target peptide from a complex matrix. In a 
second experiment, the standard non-labeled synthetic (ENs) peptide was spiked 
into the human cell mixture, and the samples were measured in PRM. It was shown 
that each antibody that was able to enrich the appropriate epitope motif also en-
riched the spiked target peptide. 
Due to the varying performance of the antibodies and endogenous amounts of the 
respective analytes, the least optimal ratio between antibody and lysate used, which 
is required for reliable quantification, was determined in the next step. For this pur-
pose, prochloraz-treated (10 µmol L-1) HepaRG cells were used. The different anti-
body amounts of either 1, 2, or 5 micrograms were tested with either 10, 20, or 
40 micrograms lysate. The amounts used were based on previous experiments. Nine 
different combinations were tested for each antibody. Considering the high number 
of measurements, only one replicate each was measured, and the decision which 
antibody-protein ratio was used for further method development was made via the 
mass spectrometric fragment pattern. The optimization for two antibodies is illus-
trated in Figure 40. 
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1 µg AB with 
10 µg lysate 
2 µg AB with 
20 µg lysate 
5 µg AB with 
20 µg lysate 
UGT2B7_rbt1 
   
ARG1(YILK)_rbt2 
   
Figure 40. Antibody-lysate amount optimization for ARG1 and UGT2B7. In each graph, the upper chromatogram 
displays the endogenous signal (EN), the lower the internal isotopically labeled standard (IS) signal. Three of 
the nine different combinations are shown for UGT2B7_rbt1 (upper graphs) and ARG1(YILK)_rbt2 (lower 
graphs). The analysis was done in a single measurement per combination. For UGT2B7, the signal for EN and IS 
increases by increasing the antibody (AB) and lysate amount. To enable reliable and stable results, 5 µg AB and 
20 µg lysate are at least needed. For ARG1(YILK), EN and IS signal also increases by increasing AB and lysate 
amount, but quantification shows that the combination of 1 µg AB and 10 µg lysate already led to reliable and 
stable results.  
 
Three of the nine measured combinations for UDP-glucuronosyltransferase 2B7 
(UGT2B7; upper graphs) and ARG1(YILK; lower graphs) are shown. For UGT2B7, 
the combination of 1 µg AB with 10 µg lysate shows neither an endogenous signal 
(EN) nor a signal from the internal isotopically labeled standard (IS) peptide. In each 
graph, the upper chromatogram shows the signal of the EN peptide and the lower 
one the signal of the IS peptide. The signals become better for 2 µg AB with 20 µg 
lysate, but the peak shape and the signal intensity obtained are not yet stable. At 
5 µg AB and 20 µg lysate, not only the shape of the peak but also the intensity im-
proves by a five-fold factor. In contrast, the result of the second AB for ARG1(YILK) 
is shown. Here, an increase of the endogenous as well as of the standard signal can 
be seen with an increase of AB and lysate amount, but the results deliver almost 
similar values (approx. 2 fmol µg-1 in each case). Furthermore, the graph already 
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shows a clear fragment pattern and a signal height of the EN peptide of 2.0·105 for 
the combination of 1 µg AB with 10 µg lysate. During this investigation, many assays 
failed, and analytes had to be excluded from further method development since ei-
ther no endogenous signal or in some cases, even no isotopically labeled standard 
peptide signal was obtained. Antibodies that did not enrich either endogenous or 
standard peptide were excluded. Antibodies only enriching the standard were addi-
tionally tested whether an endogenous signal could be obtained from cryopreserved 
primary human hepatocytes (PHH). It was found that 3 of the 18 analytes investi-
gated could be detected in PHHs. Due to a lack of primary hepatocyte samples and 
the fact that the pesticide-treated samples to be examined later were HepaRG cells, 
the method development for these three analytes: Peroxisomal acyl-coenzyme A ox-
idase 2 (ACOX2), granzyme B (GZMB), and histidine-rich glycoprotein (HRG), de-
tected only in primary human hepatocytes, was not further pursued. In total, the 
method development was continued with 17 of the initial 37 peptides. 
Another essential aspect that can influence detection and quantification is digestion 
time. There are several reasons why digestion time varies between proteins. Pro-
teins have different properties due to their amino acid sequence. These include, for 
example, the folding due to intramolecular interactions, solubility, presence, and the 
number of disulfide bonds, et cetera. The localization of the target peptide within 
the protein sequence may also play a role. For this reason, it is not surprising that 
the use of different detergents or concentrations can also significantly influence pro-
teolysis what has already been shown by Proc et al. in a study in which they exam-
ined and compared different digestion protocols 93. 
Given the results from Figure 20, where the normalized peptide release in percent 
over time is shown, it can be said that for most analytes, an increase with increasing 
digestion time was observed at first, which then decreased to a greater or lesser ex-
tent over time. Exceptions are the results for ARG1(PFSK), UGT1A1, and UGT1A3. 
There the maximum was already reached after two hours of digestion. For these 
three analytes, it was therefore decided to perform two-hour digestion before the 
analysis. For the remaining analytes, the maximum value was reached between 
6 and 24 hours of digestion. In order to decide which digestion time should be used, 
a minimum percentage of 80% was set as a threshold for all analytes. For the 6- and 
16-hour digestion, all analytes were above 80%. As the digestion kinetics for the 
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CYP 17-plex had already been investigated, the digestion time of the new assays was 
set to the same digestion time of 16 hours. 
Since the LC-MS detection system enables multiplexing 110, i.e., the simultaneous de-
tection of several analytes, multiplex assays have been compiled. The results of the 
antibody-protein ratio, as well as the digestion kinetics, were taken into account. It 
was also considered that the total antibody amount of 7 µg within one multiplex 
must not be exceeded. The use of microspheres during the immunoprecipitation is 
limited due to the transfer efficiency of the KingFisher device. To increase the 
amount of microspheres, 3-[(3-Cholamidopropyl) dimethylammonio] -1-propane-
sulfonate (CHAPS) is used, which reduces the surface tension. However, CHAPS is a 
known mass spectrometric impurity (spreadsheet from supplementary data) 111, 
and therefore only small amounts can be used. Experience has shown that the max-
imum antibody limit per multiplex is 7 µg. After taking these factors into account, a 
total of six multiplex assays were established to minimize the amount of sample to 
be used and to shorten the analysis time. 
In order to increase the number of data points per analyte and to avoid possible 
interferences between the target analytes to be measured, it was necessary to con-
sider the chromatographic separation. It is desirable to achieve an optimal separa-
tion within a multiplex. However, it must be considered that the ionization capacity 
of the respective analytes changes with different solvent compositions 112. In order 
to investigate the optimal chromatographic separation, where reproducible and re-
liable results could be obtained, different gradients were tested. Each gradient was 
measured three times, mean values of the intensities were calculated, and then nor-
malized to the highest respective intensity obtained. Figure 23 shows the results. 
When looking at the graph for multiplex 1 (A and B), an evident influence of the dif-
ferent gradients, i.e., the different solvent compositions during ionization, can be 
seen. Comparing the gradient of 10-40% eluent B with the gradient of 10-20% B, the 
signals for ARG1(PFSK) and UGT1A3 decreased sharply. The normalized signal de-
creased from 82% to 27% and from 100% to 50%, respectively. The signal from 
UGT1A1 was reversed. The signal increased from 68% to 100%. Since the analytes 
were influenced differently, the decision which gradient should be used for each 
multiplex was based on a combined consideration of retention times, normalized 
intensities of the analytes, and the coefficient of variation (C.V.) of the triplicate de-
termination. 
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The criteria to be met in the study of linearity were that the accuracy for each con-
centration level should be between 80-120% and the precision below 20%. The re-
sults of the linearity test showed that the developed assays have a wide dynamic 
range. This is particularly advantageous because, for example, the protein profile of 
cytochrome P450 enzymes (CYPs) can vary between different sample types such as 
tissue or cells and between different species 38. Most of the analytes showed a dy-
namic range over several orders of magnitude. The least lower limit of quantifica-
tion (LLOQ) was obtained for CYP3A4, with 50 amol. The linear range of this analyte 
was over five orders of magnitude. On the other hand, an upper limit of quantifica-
tion (ULOQ) for alcohol dehydrogenase 1B (ADH1B) of 3 pmol was determined. Af-
ter pesticide treatment of HepaRG cells, partly strong repression and induction ef-
fects could be observed. Therefore, broad dynamic ranges were necessary to deter-
mine the target analytes quantitatively. From 34 peptides representative for 32 pro-
teins (two peptides for ARG1 and CYP3A5), 27 peptides could be quantified during 
the analysis of the effects of pesticides and pesticide mixtures in HepaRG cells. The 
concentrations of the analytes in the samples ranged from the attomolar range for 
CYP1A1 to the picomolar range for (ADH1B). 
According to the U.S. Food and Drug Administration (FDA) guidelines 94, three dif-
ferent concentrations in the assumed concentration range are to be tested each in 
five replicates for precision analysis by determining the intra- and interday vari-
ance. Since the amount of the different analytes measured so far in method develop-
ment differs considerably, it was difficult to find samples with low, medium, and 
high concentrations. In order to come close to the criteria of the FDA guidelines, it 
was therefore decided to use three different samples for the analysis. Firstly,  
untreated HepaRG cells (dimethyl sulfoxide (DMSO)-treated), secondly prochloraz-
treated HepaRG cells (10 µmol L-1), and thirdly a cryopreserved primary human 
hepatocyte sample (PHH; donor 1). Intraday variation was determined by calculat-
ing the mean value of the five individual measurements per day. The measurement 
was repeated on two further days, and for determining the interday variance, one 
random value was selected from each day (n=3). This was done because, in the later 
analysis of pesticide-treated HepaRG cells, only one single determination was to be 
measured of each treatment per substance set. The results in Table 24 clearly show 
that partly very different amounts were obtained for the analytes. Although three 
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different samples were examined instead of three different concentrations, the re-
sults showed that both the intraday and interday values were precise. Coefficients 
of variation below 20% were obtained for all analytes. For CYP7A1 and protein 
S100-P (S100P), no quantifiable results were obtained in the HepaRG cells. The val-
ues for S100P were all below LLOQ. No endogenous signals were obtained for 
CYP7A1 in prochloraz-treated HepaRG samples. However, since the results in the 
cryopreserved human hepatocyte sample met the criteria and the difficulty of using 
a sample suitable for all analytes, it was decided that the test was successful for these 
analytes. 
To investigate the recovery, the mouse cell line NIH3T3 was used as a matrix for 
spike-in experiments. The selection of this cell line, instead of HepaRG cells, was 
made because the target analytes should preferably not be present in the matrix. 
The spike-in experiments were performed according to the FDA guidelines 94. There 
it is suggested that three different spike-in concentrations should be used. In addi-
tion, unspiked samples were analyzed, and the experiment was performed three 
times. Since the measurements were performed in a different sample matrix and 
endogenous signals were already measured for some analytes in the blanks, the 
ENs/IS ratios obtained were corrected with the linear equations determined in the 
linearity experiment. The FDA guidelines of bioanalytical method validation state 
that the recovery of analytes does not have to be 100%, but the recoveries of analyte 
and internal standard should be consistent, precise, and reproducible 94. Table 23 
shows that the results were precise within each spike-in level. The coefficients of 
variation were between 0.3% for NAD(P)H dehydrogenase [quinone] 1 
(NQO1; 250 fmol spike-in) and 13.4% for ADH1B (15 fmol spike-in). Recovery 
ranged from 60% (UGT1A3; 15 fmol spike-in) to 128% (NQO1; 15 fmol spike-in). As 
mentioned before, for some analytes, signals were already obtained in the blank 
sample. The measured blank signal for prelamin-A/C (LMNA) was 253 fmol and 
74 fmol for NQO1. The literature search using UniProt 90 revealed that the peptide 
sequences for LMNA and NQO1 were identical for human and mouse. Therefore, a 
high base level for these analytes was measured in the NIH3T3 mouse cell line. Since 
the spike-in of 15 fmol synthetic non-labeled standard peptide is in the range of the 
measurement error, no accuracy determination was possible in these cases. On the 
other hand, sulfotransferase family cytosolic 1B member 1 (SULT1B1), for example, 
in which no endogenous blank signal was obtained, showed a very similar recovery 
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in all three spike-in concentrations between 98-104%. It can be concluded that the 
results for all analytes are precise and accurate, which is in concordance with the 
criteria set by the FDA 94.  
 
5.2 HepaRG Cells as a Suitable Model for the Analysis of Potential 
Mixture Effects after Pesticide Treatment 
The use of primary hepatocytes is limited due to their availability. Therefore, HepG2 
cell lines have often been used for in vitro toxicity studies. However, this cell line 
shows differences compared to human hepatocytes in both enzyme quantity and ac-
tivity.113,114 
Therefore, the number of experiments using HepaRG cells has increased in recent 
years. For example, in a recent study by Yokohama et al., the activities of CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGTs, and SULTs were measured and 
compared in human hepatocytes, HepG2 cells, and HepaRG cells. They found that 
the activities of these CYPs in HepaRG cells were comparable to those in human 
hepatocytes while activities in HepG2 were much lower.115 
In order to get a first impression of whether the HepaRG cells were useful for the 
analysis of the analytes to be investigated in this work, measurements of three hu-
man donors (cryopreserved primary human hepatocytes; in the following abbrevi-
ated with PHH.1; PHH.2; PHH.3) were performed. Results were compared with data 
from HepaRG cells after 24-hour DMSO treatment (results of the sample set from 
the mixture experiment). The obtained mean amounts in fmol µg-1 were corrected 
with the linear equations determined (4.1.10) since no fold changes were investi-
gated here. The results are displayed in Figure 41. 
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Figure 41.  Comparison of cryopreserved human hepatocytes with HepaRG cells. Three human donors (PHH.1, 
PHH.2, and PHH.3) and the results obtained in HepaRG cells are presented. For the HepaRG cell results, the val-
ues from the mixture experiment after 24-hour DMSO treatment were used. Each sample was digested three 
times. Mean values were calculated and corrected with linear equations determined in (4.1.10). The dashed 
horizontal line in the MpCombi1 and MpCombi6 graphs indicates that the values for ARG1(PFSK) and ADH1B 
were above the upper limit of quantification (ULOQ). In the graph for MpCombi5, the dashed horizontal line 
indicates half the lower limit of quantification (0.5∙LLOQ) for CYP7A1. For S100P and NQO1, only one value was 
obtained in the HepaRG cells (marked with I). For CYP3A5, only the results for the LPNK peptide are shown.   
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The graphs show that the measured protein amounts differ considerably in most 
cases. This also applies to the quantities obtained in the different donors (e.g., 
LMNA; MpCombi2 or UGT1A1 MpCombi1). For analytes such as UGT2B7 and 
UGT2B15, the amount obtained in the HepaRG cells is comparatively low. On the 
other hand, aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1), corti-
costeroid 11-beta-dehydrogenase isozyme 2 (HSD11B2), tumor necrosis factor re-
ceptor superfamily member 12A (TNFRSF12A), and NQO1 could only be detected in 
the HepaRG cells and in none of the three donors. The results for ARG1 in the donors 
indicate discrepancies. However, since the ULOQ was exceeded in the case of 
ARG1(PFSK), and the results are not in the linear range, no reliable statement can 
be made here. Looking at the results of the CYP multiplex assay, it can be observed 
that the amount of CYP450 proteins (in fmol µg-1) in the HepaRG cells was lower 
than in the primary hepatocytes, except for multidrug resistance protein 1 (MDR1). 
Besides, some CYP450 proteins show that the amounts differed depending on the 
donor (particular visible for CYP1A1 or CYP3A4). Since the analytes CYP2F1 and 
CYP3A43 were not detected in any of the samples, they were not included in the 
graph. The results of the HepaRG cells show that 10 of the 14 analytes were quanti-
fiable. For the analytes CYP2C18, CYP2D6, CYP3A5, and CYP3A7, the measured val-
ues were below the LLOQ. 
It can be summarized that although differences to cryopreserved primary human 
hepatocytes have been observed, the HepaRG cell model is suitable to investigate 
the potential mixture effect of pesticides on toxicologically relevant liver proteins 
for the following reasons. On the one hand, 32 of 34 peptides (two peptides for ARG1 
and two peptides for CYP3A5) were detected, of which 27 could be quantified in 
HepaRG cells and, on the other hand, the focus when studying the mixture effects is 
to determine the change in the respective treatment compared to the negative con-
trol (fold changes). 
 
5.3 Comparison of mRNA and Protein Data  
Although some pesticide studies with HepaRG cells have been published, only little 
data on the effect at protein level can be found in literature because most analyses 
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are performed at the mRNA level, or using enzyme activity tests 116-118. In addition, 
the pesticides used, and the concentrations applied differ strongly from these used 
in this study, which makes a comparison difficult. However, a comparison of mRNA 
data with protein data was performed. With the marker genes identified in the study 
of Seeger et al. 39, which indicate liver toxicity, the screening of the 30 pesticides was 
also carried out at the mRNA level by Dr. Almut Mentz (Center for Biotechnology 
(CeBiTec), Bielefeld). The cells were also treated with individual pesticides for 
24 hours. The 17 analytes that were quantified both at mRNA and protein level are 
shown in the heatmap in Figure 42, whereby the upper graph shows the mRNA re-
sults, and the lower graph shows the protein data. Gray fields indicate that no data 
point was obtained (not detected or below LLOQ).   
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Figure 42. Comparison of mRNA and protein data from the screening. Here the results of the screening at mRNA 
and protein level are shown. Only the data of the analytes obtained at both levels were plotted. The analytes are 
shown line by line, the treatments column by column. Each treatment was measured three times. The abbrevia-
tions of the treatments are shown in Table 25. Gray fields indicate that no data points were obtained. The mRNA 
data were obtained and kindly provided by Dr. Almut Mentz (Center for Biotechnology (CeBiTec), Bielefeld). 
 
The scales in both heatmaps were set to the same value to allow visual comparison. 
It can be seen that the effect at the mRNA level was stronger than the effect at the 
protein level. Interestingly, however, is that the trends of the respective analytes af-
ter the different treatments are very similar at both levels. This is particularly evi-
dent for the analytes CYP1A1, CYP7A1, S100P, and TNFRSF12A. Evaluation of the 
fold changes showed 380 significant changes (less than 0.7-fold and greater than 
1.5-fold) out of 506 data points at the mRNA level, while only 131 significant 
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changes of a total of 510 data points were obtained at the protein level. In percent-
age terms, this means that 75.1% of the mRNA data showed significant changes, 
whereas, at the protein level, it was only 25.7% (almost thrice as many values). This 
could, for example, be explained with the fact that the biosynthesis of protein and 
mRNA occurs with a time-delay. Moreover, protein and mRNA half-lives differ most 
probably, too.119,120 In addition to that, also effects of microRNA regulation might 
play a role. 
In order to investigate the effects of the time delay between mRNA and protein re-
sults, it was decided that four pesticides and a prototypical inducer should be inves-
tigated at an additional timepoint. HepaRG cells were treated for 72 hours and ana-
lyzed at the protein level. Afterward, the results of the 24-hour and 72-hour treat-
ment were compared. It was found that the treatment time had an influence on the 
regulatory strength and even the direction of regulation. The results are shown in 
Figure 28. A direct comparison was only possible for flusilazole, imazalil, and rifam-
picin treatment, as the concentration of difenoconazole and fenpyroximate had to 
be changed due to cytotoxic effects. If these three substances are considered, 16 sig-
nificant changes were observed after 24-hour treatment, and 29 after 72-hour treat-
ment (factor 1.8). For the analyte S100P, the inductive effect after 72 hours was 
2.4 times stronger for flusilazole and 1.5 times stronger for imazalil compared to the 
24-hour value. Based on these data, it was decided that further experiments should 
be performed with 24-, 48- and 72-hour treatment durations to study time depend-
encies. 
 
5.4 Combinatorial Effects of Pesticide Mixtures on Protein 
Profiles in HepaRG Cells 
There is a lack of data regarding potential mixture effects, since to date, the toxico-
logical properties of pesticides are only investigated on an individual basis during 
the authorization procedure. Mixture effects can either be antagonistic, additive, or 
even synergistic. The primary goal of this thesis was to develop immunoaffin-
ity-based mass spectrometry assays to investigate whether combinatorial effects 
can be observed at protein level after pesticide mixture treatment of HepaRG cell 
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cultures. The conventional methods of determining combinatorial effects, such as 
Loewe Additivity or Bliss Independence, were unsuitable for modeling such effects 
at the protein level. In general, both methods require the determination of the EC50 
(EC50; the concentration at which a half-maximum effect is achieved), and hence, if 
analytes showed no dose-dependency, they could not be included in the analysis. 
The example in Figure 35 makes this clear. The mean amount in fmol µg-1 of LMNA 
after 24-hour treatment with azoxystrobin is shown. The values fluctuate around 
30 fmol µg-1, and no dose-dependency can be observed. It was, therefore, necessary 
to establish an alternative evaluation method. We applied multiple linear regression 
analysis to determine potential combinatorial effects. The workflow of multiple lin-
ear regression analysis is illustrated in Figure 43 below.
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Figure 43. Workflow multiple linear regression analysis. This scheme shows the procedure of multiple linear regression. The results of the individual substances are used to obtain linear 
regressions of the respective substance (black and red fit). With these regressions, a predictive mixture model is generated (blue fit). If the measured value deviates from the prediction 
model, a non-additive effect can be assumed. Via the Model Deviation Ratio, where the predicted value is divided by the measured value, MDR scores are obtained. Values below 0.5 and 
above 2 are considered as a significant deviation from the additive model. Using the linear regression slopes, it can be determined as to whether it is an antagonistic or synergistic effect.
Discussion 
121 
With RStudio v.1.0.153, linear regression equations were calculated using the indi-
vidual results of pesticide treatments for each analyte. A model prediction was then 
calculated for the two functions of a binary mixture. This model prediction indicates 
an additive effect of the two substances in the mixture. The experimentally deter-
mined values were then compared with those of the model prediction. This was 
done using the Model Deviation Ratio (MDR), where the predicted value was divided 
by the measured value. Based on the thresholds described in Cedergreen, it was de-
cided that values less than 0.5 and greater than 2 indicate a significant deviation 
from the additive model, and thus a combinatorial effect, such as synergism or an-
tagonism 99. In addition, it was specified in R that half of the LLOQ was used for val-
ues below the respective LLOQ in the mixture model predictions. This was done for 
the following reasons. Firstly, this ensured that no negative MDR values were ob-
tained, and secondly, this procedure was also applied to the evaluation of the raw 
data. Thus, reasonable and consistent applicability across all analytes could be ob-
tained.  
Considering the histogram in Figure 37, it was found that most values were between 
the boundaries 0.5 and 2, which means that mostly additive effects of the test sub-
stances were observed according to the MDR model. A total of 1486 MDRs were ob-
tained, of which 105 indicate a significant deviation from the additive model. This 
corresponds to about 7.1%. Of these 105 values, 39 synergistic, 50 antagonistic, and 
16 further, not definable significant deviations from the additive model were iden-
tified with the defined criteria. Most of these values were obtained for cytochrome 
P450 enzymes (visible in Figure 38 Matrix of Model Deviation Ratios). The following  
Table 28 gives an overview of the number of antagonistic, synergistic, and the not 
definable significant changes from the additive model. Apart from ARG1(PFSK) and 
S100P, deviations from the additive model were only found for CYPs. It shows that 
most of the significant changes were found for S100P with 29 values, followed by 
CYP2B6 with 21 values and CYP1A2 with 17 values. 
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Table 28. Number of significant changes from the additive model. Here, all analytes are shown for which values 
outside the boundaries of 0.5 and 2 were found. It is also defined whether these effects were antagonistic, syn-
ergistic, or not definable. 
Analyte Antagonism Synergism Not definable Σ 
ARG1(PFSK) 0 1 0 1 
CYP1A1 3 0 3 6 
CYP1A2 7 10 0 17 
CYP2B6 14 0 7 21 
CYP2C8 1 4 1 6 
CYP2C9 2 1 0 3 
CYP2C19 2 1 3 6 
CYP3A4 4 6 0 10 
CYP7A1 4 0 2 6 
S100P 13 16 0 29 
 
Since cytochrome P450 enzymes play an essential role in the biotransformation of 
endogenous as well as xenobiotic substances, the results of this family are discussed 
in more detail. It has to be mentioned first that the CYPs can be regulated not only 
by one but by several receptors 121-123. These receptors include, for example, the aryl 
hydrocarbon receptor (AhR), the constitutive androstane receptor (CAR), or the 
pregnane X receptor (PXR). In parallel to the screening experiment, prototypical in-
ducers were also used for treating the cell cultures. These inducers consisted of 
benz[a]pyrene, 6-(4-Chlorophenyl) imidazo[2,1-b][1,3] thiazole-5-carbaldehyde O-
(3,4-dichlorobenzyl) oxime (CITCO), and rifampicin (concentration of each sub-
stance was 5 µmol L-1). In the literature, it can be found that benz[a]pyrene is an 
agonist for AhR, CITCO for CAR, and rifampicin for PXR. The following graph shows 
the fold change of eight CYPs after treatment with the particular substance, related 
to the negative control (DMSO-treated).  
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Figure 44. Fold change of CYPs after prototypical inducer treatment. Shown is the fold change of each respective 
prototypical inducer (benz[a]pyrene, CITCO, and rifampicin; each 5 µmol L-1) related to the negative control 
(DMSO-treated). HepaRG cell culture and treatment were done in triplicates; mean values and standard devia-
tions were calculated. The dashed horizontal line indicates the control value of 1.  
 
Rifampicin is described in the literature as an agonist of the PXR, which can primar-
ily induce CYP3A4 124. The data confirms this and shows an induction of CYP3A4 by 
a factor of 3.2. CITCO is often used as CAR agonist, and the induction of CYP2B6 is 
observed 125. This can also be confirmed. In addition, CYP2B6 is induced by rifam-
picin, as well as by benz[a]pyrene, suggesting regulation of this enzyme via CAR, as 
well as via AhR and PXR. The regulation of CYP1A1 and CYP1A2 is mainly associated 
with AhR 126. Results show a strong induction of these two enzymes after treatment 
with the AhR agonist benz[a]pyrene (fold change of 35.0 and 39.9, respectively). In 
addition, the two enzymes also show a strong induction by CITCO, which indicates 
regulation via CAR as well. However, it should be mentioned that no values for 
CYP1A1 and 1A2 could be obtained for the negative control in both cases, and thus, 
values were referenced to half of the lower limit of quantification (LLOQ). For the 
other CYPs, no significant changes could be observed after treatment with these 
three prototypical inducers, suggesting regulation by different routes. Looking at 
the results for CYP1A1, CYP1A2, CYP2B6, and CYP3A4, it can be concluded that the 
regulation system of the tested substances benz[a]pyrene, CITCO, and rifampicin 
worked as positive controls in HepaRG cells. 
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The results after propiconazole (PPC) treatment are consistent with the results of 
the positive controls. Knebel et al. showed that propiconazole acts not only as an 
agonist for CAR and PXR but also as an activator of AhR 127. Considering the results 
shown in Figure 32, this result can be confirmed. Not only CYP2B6 and CYP3A4, 
which are mainly regulated by CAR and PXR but also CYP1A1 and CYP1A2, show an 
induction after PPC treatment. However, the observed effects of CYP1A1/1A2 are 
more pronounced. In addition, it can be observed that CYP1A2, CYP2B6, and CYP3A4 
show concentration-dependent changes. With increasing concentration, the effect 
of induction switches to down-regulation. With CYP3A4, a repression effect can al-
ready be observed after 48 and 72 hours at high concentrations. 
Furthermore, it can be observed that the concentration of these proteins is also 
time-dependent. With more prolonged treatment, the observed inductive effects are 
weaker with CYP1A1 and CYP2B6. These observations could be explained by the 
cytotoxicity of PPC. Figure 30 shows that the viability after PPC treatment decreases 
sharply at high concentrations (after 72 hours). Also, a slight trend towards a de-
crease in viability at high concentrations can already be observed after 24 and 
48 hours of treatment. After the 72-hour treatment, the value at the highest concen-
tration is only 54%. Rose et al. came to similar conclusions 125. Propiconazole 
showed cytotoxicity at high concentrations (100 µmol L-1) after 24 and 72 hours. 
They also showed that CYP1A1/1A2, CYP2B6, and CYP3A4 were induced after PPC 
treatment. However, the effect was more pronounced in that study with CYP2B6 and 
CYP3A4. The analysis was performed in a human micropatterned coculture model 
(MPCC) with cryopreserved human hepatocytes, which may explain these differ-
ences compared to the analyses performed here in HepaRG cells. 
The results for CYP2C8, 2C9, and 2C19 in Figure 44 show no significant effects after 
treatment with the prototypical inducers. After 24 hours of treatment with PPC, also 
no significant changes (less than -0.56 and greater than 0.56) were observed for 
CYP2C8 and 2C9. After 48 and 72 hours, a down-regulation can be observed, which 
could also be explained by cytotoxicity at high concentrations. Since the trend of 
these three enzymes is towards down-regulation and no significant changes could 
be observed after treatment with the prototypical inducers for AhR, CAR, and PXR, 
it could be assumed that these enzymes follow a different regulatory pathway in 
HepaRG cells. 
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Difenoconazole (DIF), also from the triazole group, shows a similar regulatory pic-
ture to PPC. However, the effects are less intense than in PPC.  
Cyproconazole (CC; triazole), was investigated by Luckert et al. with regard to re-
ceptor regulation in HepG2 and HEK-293 cells, as well as protein levels in HepaRG 
cells 96. They showed that cyproconazole activated only one of the three receptors 
described so far, namely the PXR, but neither AhR nor CAR. Part of the protein data 
in HepaRG cells after 72 hours of treatment are shown as fold change (log2) in Table 
29 and are compared with the results of this thesis. 
 
Table 29. Comparison of cyproconazole protein data. Fold change (log2) protein values of cyproconazole-treat-
ment (72h) were taken from table S5 96.  
 
Analyte 
Cyproconazole (72h)  
in µmol L-1 
Cyproconazole (72h) 
in µmol L-1 (Luckert et al.96) 
 35 55 110 25 50 100 
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CYP2E1 -0.74 -1.10 -1.21 -0.16 -0.38 -0.76 
CYP3A4 1.30 1.17 1.13 1.9 2.04 2.21 
FASN 0.01 0.06 0.25 -0.1 -0.23 -0.78 
LMNA -0.49 -1.20 -0.60 0.04 0.02 -0.04 
NCPR/POR 0.55 0.35 0.53 0.29 0.25 0.14 
NQO1 -0.32 0.10 -0.30 -0.07 0.22 0.41 
SULT1B1 -0.19 -0.19 -0.13 -1.65 -1.28 -0.45 
UGT2B7 -0.05 -0.09 -0.03 -0.2 -0.4 -0.94 
Green field= significant up-regulation; blue field= significant down-regulation 
 
First of all, it should be mentioned that different concentrations were used in both 
studies. Nevertheless, results for the most similar concentrations applied are com-
pared in Table 29. Besides, the significance was determined in different ways. In this 
work, a simulation with 100 000 random fold changes (log2) was run by RStudio 
with α=0.05. Luckert et al. used an unpaired t-test with p<0.05 96. Comparing the 
data measured in both studies, it is notable that the total number of significant 
changes in this thesis was higher (8/24 vs. 4/24 fold changes) than in Luckert et al. 
Comparing the data where no significant change occurred, it can partly be observed 
that concentration dependencies were observed in both studies. This can be seen, 
for example, for CYP2E1 or SULT1B1. The values obtained decrease with increasing 
cyproconazole concentration. A concentration dependency is also recognizable for 
FASN, whereby the regulation direction is different. In this work, the value increased 
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with increasing concentration, whereas the values decreased in the other study. In 
both cases, CYP3A4 showed a significant inductive effect for all concentrations, 
which supports the findings that cyproconazole acts as a PXR activator. 
After thorough literature research, no data were found on thiacloprid metabolism 
regulated by these three receptors. Since CYP2B6 and CYP3A4 showed inductive ef-
fects, it can be assumed that thiacloprid could act via CAR or PXR or even both re-
ceptors. In order to verify this, further investigations would have to be conducted 
using gene reporter assays. 
In a study by Zahn et al., the individual substances azoxystrobin (AOS) and cypro-
conazole, as well as the mixture of these substances and a plant protection product 
already available on the market consisting of these two substances, were investi-
gated 128. Gene reporter assays in HepG2 cells and protein quantity changes after 
24-hour treatment of HepaRG cells were examined. They were able to show that 
both the product and the self-produced mixture (to a lesser extent than the product) 
induced the AhR. Furthermore, it was shown that after azoxystrobin treatment, con-
centration-dependent inhibition of CAR was present. This inhibition was also main-
tained after treatment with the mix and the product. On the other hand, CAR was 
induced by cyproconazole, whereby this effect became weaker with increasing con-
centration. No significant difference was observed at the highest concentration 
(13.7 µmol L-1). PXR was strongly induced by increasing AOS concentration, as well 
as the mixture and the product. Interestingly, the results show no induction after CC 
treatment. It must be mentioned that the concentrations chosen and used were 
much lower than in the work presented here. While the highest concentration for 
CC was 13.7 µmol L-1 and for AOS 3.97 µmol L-1, the lowest concentrations in this 
study were 35 µmol L-1 and 10 µmol L-1, respectively. Since the concentration differ-
ences are substantial, it is difficult to compare the results directly to this work. How-
ever, with increasing concentration of AOS, all CYPs observed in this study have been 
down-regulated. For CYP2B6, for example, only the lowest AOS concentration (after 
24 h or 72 h) was detectable. All other values were already below the LLOQ. A con-
centration-dependent down-regulation was also observed for CYP3A4, 2C8, 2C9, 
and 2C19. Since Zahn et al. discovered strongly induced PXR gene targets but 
strongly repressed CAR gene targets after AOS treatment with increasing concen-
tration, it could be assumed that the regulations in different directions balance each 
other out, and thus the regulated enzymes show only minor changes 128. However, 
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this is not the case. In order to find out what the transactivation of receptors actually 
looks like at the concentrations used, additional reporter gene assays would have to 
be performed to explain the regulatory mechanism. Moreover, only the transactiva-
tion after 24-hour treatment is usually investigated. It would be interesting to con-
duct a time-dependent experiment to find out whether the transactivation changes 
with more prolonged treatment periods and, thus, the enzyme regulation.  
Besides, Zahn et al. showed that differences between the mixtures they produced 
themselves, and the plant protection products were obtained 128. This suggests that 
the co-formulants and excipients in the products could have an additional effect.  
As a result, it is necessary to test not only the individual substances but also the mix-
tures and products available on the market. So far, only binary mixtures have been 
investigated in this thesis. However, since it is possible to get into contact with a 
variety of different pesticide residues at the same time, a further step would be to 
produce a multi-mixture of several individual substances below the no observed ad-
verse effect level (NOAEL) and to test whether the combination of this variety pro-
duces an adverse effect. At this point, it should be mentioned that the concentrations 
used so far are much higher than the residue concentrations on food with which the 
consumer comes into contact. The concentrations used were chosen in such a way 
that it was possible to investigate and define mode of actions or mixture effects, but 
not yet so high that cytotoxic effects could be observed. Also of interest is the analy-
sis of primary human hepatocytes after pesticide treatment. Therefore a further step 
would be the treatment of primary hepatocytes with pesticides and pesticide mix-
tures in order to compare the results with those of HepaRG cells. 
In summary, an applicable test system for the analysis of pesticide mixtures in  
HepaRG cells has been developed. New immunoaffinity-based mass spectrometry 
assays were developed for 16 analytes. In total, the influence of pesticides and pes-
ticide mixtures on 32 different marker proteins in HepaRG cells was tested. It could 
be shown that the cell model was suitable for these investigations and that the CYPs 
and S100P stood out in the analyses with regard to the Model Deviation Ratios (as 
shown in Table 28). Although results were obtained with all 32 proteins, S100P and 
the CYPs, especially CYP1A2 and CYP2B6, appear to be most sensitive to pesticide 
treatments and are therefore most suitable for future mixing studies. A total of 105 
significant combinatorial effects deviating from the additive model were identified 
using multiple linear regression analysis. As a result of this, the question arises on 
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how relevant a synergistic effect found in a mixture is and whether such a mixture 
may require additional regulation for use in pest control. Since not only one concen-
tration but a series was investigated in this work, the results of the other concentra-
tions should also be taken into account in the case of synergisms. If a synergistic 
effect is consistent across the investigated concentration range, consideration 
should be given to further studying this particular mixture. This includes, for exam-
ple, analyses that are necessary to understand the mechanisms behind the regula-
tion of the respective analytes, such as gene reporter assays, in order to investigate 
the transactivation of receptors that play an essential role in the metabolism of  
xenobiotics. 
However, not only the synergistic or antagonistic but also the additive effects are 
very interesting. It can partly be observed that the effects cancel each other out or 
that the direction of regulation can change with increasing concentration. This 
shows that it was necessary to investigate not only at a single concentration but at a 
series of concentrations. It was also shown that the results at the protein level were 
dependent on the duration of treatment. 
It needs to be mentioned that the assays developed here do not replace the manda-
tory animal tests for the market release of new active substances, but they represent 
an alternative to animal testing in the context of possible combinatorial effects after 
exposure to several pesticide residues. Nevertheless, a direct transfer to the in vivo 
situation is difficult with these developed in vitro tests. However, there is an im-
mense number of possible mixtures (in Europe alone, more than 450 individual sub-
stances are approved) that cannot be covered by animal testing alone. The devel-
oped in vitro tests can be used to prioritize mixtures that may cause synergistic ef-
fects, which can then be further investigated using animal models or other appro-
priate test systems. The results of in vitro studies can also be used to classify pesti-
cides into cumulative assessment groups in order to predict whether it might be a 
critical mixture that needs further investigation. Thus, the present work can help to 
reduce the number of animal experiments to a minimum.   
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6 Summary 
Pesticides are used worldwide to protect plants and fields as it is a necessity to pro-
vide sufficient and safe food. When these substances shall be approved, their toxico-
logical effects must be investigated first. However, as today, not only individual pes-
ticides but also pesticide mixtures are widely applied, consumers come into contact 
with a variety of pesticide residues. Therefore, it is essential to investigate potential 
mixture effects. If all potential mixtures were tested with the standard, mandatory 
toxicological tests that must be carried out for approval, the number of animal tests 
would increase dramatically. Hence, this work aimed to develop an in vitro test sys-
tem to investigate the influence of potential mixing effects on toxicologically rele-
vant liver proteins. Method development was initially started for 36 proteins. A total 
of six multiplex assays with 16 different proteins were successfully developed. In 
addition, a CYP 17-plex assay method already developed in targeted selected ion 
monitoring (tSIM) was transferred to the parallel reaction monitoring (PRM) like 
the six other multiplex assays. This resulted in the total number of 32 proteins used 
for the analysis of potential mixing effects in HepaRG cells. During method develop-
ment, it was shown that immune precipitation and the use of targeted mass spectro-
metric methods could significantly increase the number of analytes detected (espe-
cially for the CYPs from 5/17 to 14/17) compared to full-scan analysis. These assays 
were used to investigate the effect of 30 individual pesticides on 32 proteins in  
HepaRG cells. These pesticides were also investigated at the mRNA level by a collab-
oration partner. Similarities have been observed between the two molecule species, 
but the effect was more pronounced at the mRNA level after 24 hours of treatment. 
By a similarity analysis using Pearson correlation, the pesticides were classified into 
four groups, and then four mixtures of five single substances were prepared. Based 
on the mRNA/protein expression result comparison, it was additionally decided 
that the treatment periods should be extended to 24, 48, and 72 hours. A novel math-
ematical model was developed to determine whether combinatorial effects such as 
antagonism, additivity, or synergism were observed after mixture treatment. For the 
very first time, multiple linear regression analysis was used to identify combinato-
rial effects after pesticide treatment. The results of the individual treatments were 
used to obtain theoretical model values of the respective mixture. These proposed 
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values were then compared with the measured values from the mixture experi-
ments. According to this model, the results showed that most mixtures had an addi-
tive effect on the different proteins analyzed. However, in some cases, synergistic or 
antagonistic effects were observed. Most model deviations that indicate synergis-
tic/antagonistic effects were obtained for the three analytes S100P, followed by 
CYP2B6, and CYP1A2, suggesting them as the most sensitive sensors for detecting 
these effects.   
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7 Zusammenfassung 
Pestizide werden weltweit zum Schutz von Pflanzen und Feldern eingesetzt, da eine 
ausreichende und sichere Versorgung mit Lebensmitteln unerlässlich ist. Bei der Zu-
lassung dieser Stoffe müssen zunächst ihre toxikologischen Auswirkungen unter-
sucht werden. Da heutzutage jedoch nicht nur einzelne Pestizide, sondern auch Pes-
tizidmischungen eingesetzt werden, können Verbraucher mit einer Vielzahl von 
Pestizidrückständen in Berührung kommen. Daher ist es unerlässlich, diese poten-
ziellen Mischeffekte ebenfalls zu untersuchen. Würden alle potenziellen Mischun-
gen mit den üblichen, obligatorischen toxikologischen Untersuchungen, die zur Zu-
lassung durchgeführt werden müssen, getestet, würde sich die Zahl der Tierversu-
che drastisch erhöhen. Daher zielte diese Arbeit darauf ab, ein in vitro Testsystem 
zu entwickeln, um den Einfluss möglicher Mischungseffekte auf toxikologisch rele-
vante Leberproteine zu untersuchen. Die Methodenentwicklung wurde zunächst für 
36 Proteine begonnen. Insgesamt wurden sechs Multiplex-Assays für 16 verschie-
dene Proteine erfolgreich entwickelt. Darüber hinaus wurde der bereits im targeted 
selected ion monitoring (tSIM) entwickelte CYP 17-plex Assay zum parallel reaction 
monitoring (PRM) Modus transferiert, um ihn gleich wie die sechs Multiplex-Assays 
messen zu können. Daraus ergab sich die Gesamtzahl von 32 Proteinen, die für die 
Analyse möglicher Mischeffekte in HepaRG Zellen verwendet wurden. Bei der Me-
thodenentwicklung konnte gezeigt werden, dass durch die Immunpräzipitation und 
den Einsatz gezielter massenspektrometrischer Methoden die Anzahl der detektier-
ten Analyten, im Vergleich zur Full-Scan Analyse, deutlich erhöht werden konnte 
(insbesondere für die CYPs von 5/17 zu 14/17 Peptiden). Mit diesen Assays wurde 
die Wirkung von 30 einzelnen Pestiziden auf 32 Proteine in HepaRG-Zellen unter-
sucht. Diese Pestizide wurden von einem Kooperationspartner auch auf mRNA-
Ebene untersucht. Es wurden Ähnlichkeiten zwischen den beiden Molekülspezies 
beobachtet, wobei der Effekt nach 24-stündiger Behandlung auf mRNA-Ebene stär-
ker ausgeprägt war. Durch eine Ähnlichkeitsanalyse mittels Pearson-Korrelation 
wurden die Pestizide in vier Gruppen eingeteilt und anschließend vier Mischungen 
aus fünf Einzelsubstanzen hergestellt. Basierend auf dem mRNA/Protein-Vergleich 
wurde zusätzlich entschieden, dass die Behandlungszeiten auf 24, 48 und 72 Stun-
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den erweitert werden sollten. Ein neuartiges mathematisches Modell wurde entwi-
ckelt, um festzustellen, ob kombinatorische Effekte wie Antagonismus, Additivität 
oder Synergismus nach Mischungsbehandlung beobachtet werden konnten. Zum 
ersten Mal wurde die multiple lineare Regression verwendet, um kombinatorische 
Effekte nach der Pestizidbehandlung zu identifizieren. Die Ergebnisse der einzelnen 
Behandlungen wurden dabei genutzt, um theoretische Modellwerte der jeweiligen 
Mischung zu erhalten. Diese Vorhersagewerte wurden dann mit den Messwerten 
aus den Mischungsversuchen verglichen. Laut diesem Modell zeigten die Ergeb-
nisse, dass die meisten Mischungen einen additiven Effekt auf die verschiedenen 
analysierten Proteine hervorriefen. In einigen Fällen wurden jedoch synergistische 
oder antagonistische Effekte beobachtet. 
Die meisten Modellabweichungen, die synergistische/antagonistische Effekte an-
zeigten, wurden für die drei Analyten S100P, gefolgt von CYP2B6 und CYP1A2 er-
mittelt, was nahelegt, dass sie die empfindlichsten Sensoren zur Erkennung dieser 
Effekte sind.   
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9 Supplementary Data 
A. Analytes Covered in this Thesis 
 
Table 30. Abbreviation of analytes covered in this work. Here all analytes that were initially used are defined 
with their abbreviation, their UniProtID, and the respective protein name after UniProt.90 
Abbreviation UniProtID 90 Name according to UniProt 90 
ACOX2 Q99424 Peroxisomal acyl-coenzyme A oxidase 2 
ADH1B P00325 Alcohol dehydrogenase 1B 
ALDH3A1 P30838 Aldehyde dehydrogenase, dimeric NADP-preferring 
ANXA10 Q9UJ72 Annexin A10 
ARG1 P05089 Arginase-1 
CCL20 P78556 C-C motif chemokine 20 
CD36 P16671 Platelet glycoprotein 4 
CES2 O00748 Cocaine esterase 
CGA P01215 Glycoprotein hormones alpha chain 
COX1 P00395 Cytochrome c oxidase subunit 1 
CYP1A1 P04798 Cytochrome P450 1A1 
CYP1A2 P05177 Cytochrome P450 1A2 
CYP2B6 P20813 Cytochrome P450 2B6 
CYP2C8 P10632 Cytochrome P450 2C8 
CYP2C9 P11712 Cytochrome P450 2C9 
CYP2C18 P33260 Cytochrome P450 2C18 
CYP2C19 P33261 Cytochrome P450 2C19 
CYP2D6 P10635 Cytochrome P450 2D6 
CYP2E1 P05181 Cytochrome P450 2E1 
CYP2F1 P24903 Cytochrome P450 2F1 
CYP3A4 P08684 Cytochrome P450 3A4 
CYP3A5 P20815 Cytochrome P450 3A5 
CYP3A7 P24462 Cytochrome P450 3A7 
CYP3A43 Q9HB55 Cytochrome P450 3A43 
CYP7A1 P22680 Cholesterol 7-alpha-monooxygenase 
FASN P49327 Fatty acid synthase 
G6PC P35575 Glucose-6-phosphatase 
GAPDH P04406 Glyceraldehyde-3-phosphate dehydrogenase 
GZMB P10144 Granzyme B 
HRG P04196 Histidine-rich glycoprotein 
HSD11B2 P80365 Corticosteroid 11-beta-dehydrogenase isozyme 2 
IL6 P05231 Interleukin-6 
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Abbreviation UniProtID 90 Name according to UniProt 90 
INSIG1 O15503 Insulin-induced gene 1 protein 
LMNA P02545 Prelamin-A/C 
LY6D Q14210 Lymphocyte antigen 6D 
MDR1 P08183 Multidrug resistance protein 1 
MLXIP Q9HAP2 MLX-interacting protein 
NCPR P16435 NADPH-cytochrome P450 reductase 
NQO1 P15559 NAD(P)H dehydrogenase [quinone] 1 
NR1I3 Q14994 Nuclear receptor subfamily 1 group I member 3 
PRKDC P78527 DNA-dependent protein kinase catalytic subunit 
S100P P25815 Protein S100-P 
SCARA3 Q6AZY7 Scavenger receptor class A member 3 
SCD O00767 Acyl-CoA desaturase 
SREBF1 P36956 Sterol regulatory element-binding protein 1 
SULT1B1 O43704 Sulfotransferase family cytosolic 1B member 1 
SYT1 P21579 Synaptotagmin-1 
TNFRSF12A Q9NP84 Tumor necrosis factor receptor superfamily member 12A 
UGT1A1 P22309 UDP-glucuronosyltransferase 1-1 
UGT1A3 P35503 UDP-glucuronosyltransferase 1-3 
UGT2B7 P16662 UDP-glucuronosyltransferase 2B7 
UGT2B15 P54855 UDP-glucuronosyltransferase 2B15 
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B. Results of Comprehensive Database Search 
 
Table 31. Results of the database search for potential target peptides. In this table, the proteins with their respective UniProt ID 90, the chosen peptide with its parameters like proteo-
typicity, length, natural variants, or modifications within the sequence and the hydrophobicity factor are shown. Besides, it was checked whether already an antibody existed and if these 
particular peptides have already been found in other mass spectrometric projects.  
Protein UniProt ID 90 Peptide 
Antibody 
available 
Proteotypic 
Length  
(amino acids) 
Natural Variant/ 
Modification 
Hydrophobicity 
factor 
Entry in  
ProteomicsDB 87 
ACOX2 Q99424 
LENEPAIQQVLK 
FAQVLPDGTYVK 
N 
N 
Y 
Y 
12 
12 
N/N 
N/N 
2.4 
2.6 
Y 
Y 
ADH1B P00325 
GAVYGGFK 
- 
N 
- 
Y 
- 
8 
- 
N/N 
- 
2.0 
- 
Y 
- 
ALDH3A1 P30838 
ISEAVK 
IQQLEALQR 
Y 
N 
Y 
Y 
6 
9 
N/N 
N/N 
1.9 
2.7 
Y 
Y 
ANXA10 Q9UJ72 
LYSAIHDFGFHNK 
NFASGHYK 
N 
N 
Y 
Y 
13 
8 
N/N 
N/N 
2.8 
1.2 
Y 
Y 
ARG1 P05089 
DVDPGEHYILK 
TIGIIGAPFSK 
N 
Y 
Y 
Y 
11 
11 
N/N 
Y/Y 
2.0 
3.0 
Y 
Y 
CCL20 P78556 
LSVCANPK 
- 
N 
- 
Y 
- 
8 
- 
N/N 
- 
1.4 
- 
Y 
- 
CD36 P16671 
LQVNLLVKPSEK 
- 
N 
- 
Y 
- 
12 
- 
N/N 
- 
2.7 
- 
Y 
- 
CES2 O00748 
IQELEEPEER 
TTHTGQVLGSLVHVK 
Y 
N 
Y 
Y 
10 
15 
N/N 
N/N 
1.6 
1.8 
Y 
Y 
CGA P01215 AYPTPLR N Y 7 N/N 2.0 Y 
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4
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Protein UniProt ID 90 Peptide 
Antibody 
available 
Proteotypic 
Length  
(amino acids) 
Natural Variant/ 
Modification 
Hydrophobicity 
factor 
Entry in  
ProteomicsDB 87 
- - - - - - - 
COX1 P00395 
DIGTLYLLFGAWAGVLG-
TALSLLIR 
- 
N 
 
- 
Y 
 
- 
25 
 
- 
N/N 
 
- 
4.5 
 
- 
Y 
 
- 
CYP7A1 P22680 
TLENAGQK 
LSSASLNIR 
N 
N 
Y 
Y 
8 
9 
N/N 
N/N 
0.7 
2.6 
Y 
Y 
FASN P49327 
TGTVSLEVR 
VVEVLAGHGHLYSR 
Y 
N 
Y 
Y 
9 
14 
N/N 
N/N 
1.9 
2.3 
Y 
Y 
G6PC P35575 
YFLITFFLFSFAIGFYLLLK 
GLGVDLLWTLEK 
N 
N 
Y 
Y 
20 
12 
Y/N 
Y/N 
6.7 
4.2 
N 
N 
GAPDH P04406 
AGAHLQGGAK 
QASEGPLK 
N 
N 
Y 
Y 
10 
8 
N/N 
N/N 
0.5 
0.8 
Y 
Y 
GZMB P10144 
VSSFVHWIK 
HSHTLQEVK 
N 
N 
Y 
Y 
9 
9 
N/N 
N/N 
3.9 
1.0 
Y 
Y 
HRG P04196 
EENDDFASFR 
HPNVFGFCR 
N 
Y 
Y 
Y 
10 
9 
N/N 
N/N 
1.8 
2.3 
Y 
Y 
HSD11B2 P80365 
VSIIQPGCFK 
- 
N 
- 
Y 
- 
10 
- 
N/N 
- 
2.7 
- 
Y 
- 
IL6 P05231 
FESSEEQAR 
- 
N 
- 
Y 
- 
9 
- 
N/N 
- 
0.8 
- 
Y 
- 
INSIG1 O15503 
LHDHFWSCSCAHSAR 
- 
N 
- 
Y 
- 
15 
- 
N/N 
- 
1.5 
- 
Y 
- 
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Protein UniProt ID 90 Peptide 
Antibody 
available 
Proteotypic 
Length  
(amino acids) 
Natural Variant/ 
Modification 
Hydrophobicity 
factor 
Entry in  
ProteomicsDB 87 
LMNA P02545 
LEAALGEAK 
DLEDSLAR 
N 
N 
Y 
Y 
9 
8 
N/N 
N/N 
2.1 
2.1 
Y 
Y 
LY6D Q14210 
HSVVCPASSR 
TTNTVEPLR 
N 
N 
Y 
Y 
10 
9 
N/N 
N/N 
0.5 
1.5 
Y 
Y 
MLXIP Q9HAP2 
LTSHAITLQK 
GYDFDTVNK 
N 
N 
Y 
Y 
10 
9 
N/N 
N/N 
2.4 
1.7 
Y 
Y 
NQO1 P15559 
FGLSVGHHLGK 
DPANFQYPAESVLAYK 
N 
N 
Y 
Y 
11 
16 
N/N 
N/N 
2.4 
1.9 
Y 
Y 
NR1I3 Q14994 
AQQTPVQLSK 
- 
N 
- 
Y 
- 
10 
- 
N/N 
- 
1.1 
- 
Y 
- 
PRKDC P78527 
VTELALTASDR 
LGLPGDEVDNK 
N 
N 
Y 
Y 
11 
11 
N/N 
N/N 
2.2 
1.7 
Y 
Y 
S100P P25815 
ELPGFLQSGK 
YSGSEGSTQTLTK 
N 
N 
Y 
Y 
10 
13 
N/N 
N/N 
2.5 
0.6 
Y 
Y 
SCARA3 Q6AZY7 
AVDTQHGEILR 
NLQGLDPK 
N 
N 
Y 
Y 
11 
8 
N/N 
N/N 
1.8 
1.8 
Y 
Y 
SCD O00767 
VLQNGGDK 
DDIYDPTYK 
N 
N 
Y 
Y 
8 
9 
N/N 
N/N 
1.0 
1.5 
Y 
Y 
SREBF1 P36956 
VFLHEATAR 
FLQHSNQK 
N 
N 
Y 
Y 
9 
8 
N/N 
N/N 
2.7 
1.6 
Y 
Y 
SULT1B1 O43704 
TSGIEQLEK 
NYFTVAQNEK 
N 
N 
Y 
Y 
9 
10 
N/N 
N/N 
1.5 
1.6 
Y 
Y 
  
1
4
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Protein UniProt ID 90 Peptide 
Antibody 
available 
Proteotypic 
Length  
(amino acids) 
Natural Variant/ 
Modification 
Hydrophobicity 
factor 
Entry in  
ProteomicsDB 87 
SYT1 P21579 
VFVGYNSTGAELR 
HDIIGEFK 
N 
N 
Y 
Y 
13 
8 
N/N 
N/N 
2.3 
2.8 
Y 
N 
TNFRSF12A Q9NP84 
GSSWSADLDK 
- 
N 
- 
Y 
- 
10 
- 
N/N 
- 
1.5 
- 
Y 
- 
UGT1A1 P22309 
TYPVPFQR 
- 
N 
- 
Y 
- 
8 
- 
Y/N 
- 
2.3 
- 
Y 
- 
UGT1A3 P35503 
YLSIPTVFFLR 
- 
N 
- 
Y 
- 
11 
- 
N/N 
- 
5.1 
- 
Y 
- 
UGT2B7 P16662 
ANVIASALAQIPQK 
IEIYPTSLTK 
N 
N 
Y 
Y 
14 
10 
N/N 
N/N 
2.1 
2.9 
Y 
Y 
UGT2B15 P54855 
SVINDPVYK 
- 
N 
- 
Y 
- 
9 
- 
N/N 
- 
2.0 
- 
Y 
- 
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C. Results of the Mass Spectrometric Detection  
Compatibility 
 
Table 32. Results of mass spectrometric detection compatibility. Analytes with determined precursor ions, 
charge state, quantifiers, and normalized collision energies (NCEs) are shown. 
Analyte Peptide sequence 
Precursor  
m/z 
Quantifier 
m/z 
NCE 
ACOX2 LENEPAIQQVLK 691.3879++ 896.5564+, y8 20 
ADH1B GAVYGGFK 399.7109++ 571.2875+, y5 25 
ALDH3A1 IQQLEALQR 549.8169++ 857.4839+, y7 20 
ANXA10 LYSAIHDFGFHNK 516.9246+++ 864.3999+, y7 25 
ARG1(PFSK) TIGIIGAPFSK 552.3266++ 889.5142+, y9 25 
ARG1(YILK) DVDPGEHYILK 643.3248++ 478.7636++, y8 25 
CCL20 LSVCANPK 444.7340++ 688.3447+, y6 20 
CD36 LQVNLLVKPSEK 456.6134+++ 460.2402+, y4 25 
CES2 IQELEEPEER 636.3093++ 530.2569+, y4 25 
CGA AYPTPLR 409.2320++ 583.3562+, y5 20 
COX1 
DIGTLYLLFGAWAGV
LGTALSLLIR 
878.5070+++ 943.5935+, y9 20 
CYP1A1 GFYIPK 362.7051++ 520.3130+, y4 15 
CYP1A2 DTTLNGFYIPK 634.8297++ 838.4458+, y7 20 
CYP2B6 AEAFSGR 369.1825++  537.2780+, y5 15 
CYP2C8 EALIDNGEEFSGR 718.8362++ 1010.4174+, y9 25 
CYP2C9 GIFPLAER 451.7584++ 585.3355+, y5 25 
CYP2C18 EALIDHGEEFSGR 730.3442++ 781.3475+, y7 30 
CYP2C19 GHFPLAER 463.7458++ 585.3355+, y5 25 
CYP2D6 GTTLITNLSSVLK 673.8981++ 861.5040+, y8 20 
CYP2E1 DEFSGR 355.6588++ 466.2409+, y4 15 
CYP2F1 EALVDQGEEFSGR 718.8362++ 1024.4330+, y9 25 
CYP3A4 LQEEIDAVLPNK 684.8721++ 1127.5943+, y10 20 
CYP3A5(FIPK) DVEINGVFIPK 615.8401++ 774.4509+, y7 20 
CYP3A5(LPNK) EIDAVLPNK 499.7795++ 471.2926+, y4 20 
CYP3A7 EIDTVLPNK 514.7848++ 358.2085+, y3 20 
CYP3A43 DIEINGVFIPK 622.8479++ 1016.5775+, y9 20 
CYP7A1 LSSASLNIR 480.7773++ 760.4312+, y7 20 
FASN TGTVSLEVR 481.2693++ 603.3461+, y5 25 
G6PC GLGVDLLWTLEK 672.3821++ 1017.5615+, y8 20 
GAPDH AGAHLQGGAK 455.2487++ 573.3355+, y6 25 
GZMB VSSFVHWIK 551.8058++ 916.5039+, y7 20 
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Analyte Peptide sequence 
Precursor  
m/z 
Quantifier 
m/z 
NCE 
HRG HPNVFGFCR 567.2691++ 996.4720+, y8 25 
HSD11B2 VSIIQPGCFK 574.8103++ 608.2861+, y5 25 
IL6 FESSEEQAR 541.7411++ 806.3639+, y7 25 
INSIG1 LHDHFWSCSCAHSAR 624.2669+++ 1035.4095+, y9 30 
LMNA LEAALGEAK 451.2531++ 659.3723+, y7 20 
LY6D TTNTVEPLR 515.7800++ 828.4574+, y7 20 
MDR1 EANIHAFIESLPNK 791.9148++ 358.2085+, y3 25 
MLXIP GYDFDTVNK 529.7431++ 838.3941+, y7 20 
NCPR ESSFVEK 413.2031++ 375.2238+, y3 25 
NQO1 FGLSVGHHLGK 384.5489+++ 417.7327++, y8 25 
NR1I3 AQQTPVQLSK 550.3089++ 900.5149+, y8 20 
PRKDC LGLPGDEVDNK 578.7959++ 437.2011++, y8 20 
S100P ELPGFLQSGK 538.2928++ 417.2294++, y8 20 
SCARA3 NLQGLDPK 442.7454++ 657.3566+, y6 20 
SCD DDIYDPTYK 565.2560++ 786.3668+, y6 20 
SREBF1 VFLHEATAR 522.2853++ 684.3424+, y6 25 
SULT1B1 TSGIEQLEK 502.7666++ 816.4462+, y7 20 
SYT1 HDIIGEFK 479.7533++ 480.2453+, y4 20 
TNFRSF12A GSSWSADLDK 533.2460++ 648.3199+, y6 25 
UGT1A1 TYPVPFQR 504.2691++ 547.2987+, y4 25 
UGT1A3 YLSIPTVFFLR 678.3897++ 879.5087+, y7 20 
UGT2B7 ANVIASALAQIPQK 475.2804+++ 684.4039+, y6 20 
UGT2B15 SVINDPVYK 517.7795++ 848.4512+, y7 20 
 
In Figure 45 on the next pages, the results for the optimized normalized collision 
energies (NCEs) are shown. 
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Figure 45. Summary of normalized collision energy optimization. The x-axis shows the four different normal-
ized collision energies (NCEs) examined, and the y-axis shows the respective peak areas. The ideal NCE is 
marked with a black frame.  
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D. Results of the Proteome Discoverer Screening after 
In-Gel Digest and Full-Scan (Full-MS) Measurement 
 
Table 33. Results of Proteome Discoverer screening for analytes of interest. Here the analyte is displayed with 
its sequence, UniProtID 90, and whether it was found after Proteome Discoverer processing. If not only the pro-
tein but also the peptide of interest was found, the retention time is also displayed.  
Analyte Peptide Sequence UniProtID 90 
Protein 
found 
Peptide 
found 
Retention 
time in min 
ACOX2 LENEPAIQQVLK Q99424 N N - 
ADH1B GAVYGGFK P00325 Y Y 53.10 
ALDH3A1 IQQLEALQR P30838 Y Y 69.69 
ANXA10 LYSAIHDFGFHNK Q9UJ72 N N - 
ARG1 TIGIIGAPFSK P05089 Y Y 106.02 
ARG1 DVDPGEHYILK P05089 Y Y 73.24 
CCL20 LSVCANPK P78556 N N - 
CD36 LQVNLLVKPSEK P16671 N N - 
CES2 IQELEEPEER O00748 Y N - 
CGA AYPTPLR P01215 N N - 
COX1 
DIGTLYLLFGAWAGVLG-
TALSLLIR 
P00395 Y N - 
CYP7A1 LSSASLNIR P22680 N N - 
FASN TGTVSLEVR P49327 Y Y 63.69 
G6PC GLGVDLLWTLEK P35575 N N - 
GAPDH AGAHLQGGAK P04406 Y N - 
GZMB VSSFVHWIK P10144 N N - 
HRG HPNVFGFCR P04196 N N - 
HSD11B2 VSIIQPGCFK P80365 N N - 
IL6 FESSEEQAR P05231 N N - 
INSIG1 LHDHFWSCSCAHSAR O15503 N N - 
LMNA LEAALGEAK P02545 Y Y 53.75 
LY6D TTNTVEPLR Q14210 N N - 
MLXIP GYDFDTVNK Q9HAP2 N N - 
NQO1 FGLSVGHHLGK P15559 N N - 
NR1I3 AQQTPVQLSK Q14994 N N - 
PRKDC LGLPGDEVDNK P78527 Y N - 
S100P ELPGFLQSGK P25815 N N - 
SCARA3 NLQGLDPK Q6AZY7 Y N - 
SCD DDIYDPTYK O00767 N N - 
SREBF1 VFLHEATAR P36956 N N - 
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Analyte Peptide Sequence UniProtID 90 
Protein 
found 
Peptide 
found 
Retention 
time in min 
SULT1B1 TSGIEQLEK O43704 N N - 
SYT1 HDIIGEFK P21579 N N - 
TNFRSF12A GSSWSADLDK Q9NP84 N N - 
UGT1A1 TYPVPFQR P22309 Y N - 
UGT1A3 YLSIPTVFFLR P35503 Y N - 
UGT2B7 ANVIASALAQIPQK P16662 Y Y 111.82 
UGT2B15 SVINDPVYK P54855 Y Y 66.73 
Y= Protein/peptide was found; N= Protein/peptide was not found 
 
E. Results of ENs Enrichment from a Complex Matrix 
 
Table 34. Target ENs enrichment from a complex matrix. A human blend sample in the ratio 1:1:1 (HEK, HCT, 
and HepG2) was used as a matrix, and by two antibodies that were generated for each respective TXP tag, ENs 
peptide enrichment was investigated. Measurements were done in triplicates, and coefficients of variation 
(C.V.s) were determined. 
Analyte TXP-tag 
Area  
(animal 1) 
C.V. 
in % 
Area  
(animal 2) 
C.V. 
in % 
ACOX2 QVLK 2.60E+07 10.4 1.05E+07 20.8 
ADH1B GGFK 4.73E+06 16.4 9.97E+06 18.6 
ALDH3A1 ALQR 3.82E+06 15.7 n.d. na 
ANXA10 FHNK 4.03E+07 21.7 4.42E+07 9.9 
ARG1 YILK 2.58E+08 13.4 1.79E+08 3.2 
ARG1 PFSK 5.97E+08 5.5 2.94E+08 3.1 
CCL20 ANPK 3.93E+07 21.6 4.50E+07 11.7 
CD36 PSEK 6.21E+04 28.0 2.37E+06 5.2 
CES2 PEER 3.60E+06 25.9 n.d. na 
CGA TPLR 4.36E+06 17.6 4.59E+06 20.3 
COX1 LLIR 3.07E+05 36.2 3.96E+05 13.8 
CYP7A1 LNIR 1.23E+08 8.4 1.13E+08 1.8 
FASN LEVR n.d. na 1.16E+07 18.8 
G6PC TLEK 1.91E+07 8.0 1.76E+06 33.2 
GAPDH GGAK 2.85E+05 49.0 9.59E+05 44.4 
GZMB HWIK 1.29E+07 11.3 9.50E+06 7.7 
HRG GFCR 1.40E+08 0.2 4.70E+07 5.7 
HSD11B2 GCFK 1.27E+08 16.2 1.37E+08 12.9 
IL6 EAQR 7.97E+05 54.3 4.44E+06 18.6 
INSIG1 HSAR 2.50E+05 12.0 1.20E+05 18.2 
LMNA GEAK 1.83E+07 4.7 1.74E+07 8.9 
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Analyte TXP-tag 
Area  
(animal 1) 
C.V. 
in % 
Area  
(animal 2) 
C.V. 
in % 
LY6D EPLR 2.85E+05 34.9 4.30E+05 6.7 
MLXIP TVNK 1.44E+06 10.1 3.81E+05 47.3 
NQO1 HLGK 1.46E+08 11.1 1.53E+08 14.2 
NR1I3 QLSK 1.98E+07 24.8 1.09E+07 28.5 
PRKDC VDNK 9.39E+07 20.5 6.52E+07 13.0 
S100P QSGK 1.30E+08 13.8 4.28E+08 7.4 
SCARA3 LDPK 3.99E+06 62.1 3.43E+06 50.0 
SCD PTYK 7.24E+04 13.6 n.d. na 
SREBF1 ATAR 2.11E+06 9.5 1.67E+04 39.2 
SULT1B1 QLEK 9.07E+07 7.7 2.15E+08 11.6 
SYT1 GEFK 1.22E+06 13.4 6.59E+04 21.3 
TNFRSF12A DLDK 5.06E+07 11.2 6.34E+07 20.0 
UGT1A1 PFQR 3.31E+05 10.5 3.35E+07 14.8 
UGT1A3 FFLR 3.87E+05 7.7 4.45E+08 14.4 
UGT2B7 IPQK 4.64E+07 7.2 1.36E+07 3.2 
UGT2B15 PVYK 9.60E+06 17.6 7.16E+06 7.8 
n.d.= not detected; na= not applicable 
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F. Linearity and Accuracy Plots  
 
In Figure 46, the linearity plots are shown for multiplex 1-6, as well as the 
CYP 17-plex.  
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Figure 46. Linearity results of multiplex assays in PBSC. The ratio of the non-labeled synthetic peptide and the 
internal isotopically labeled standard peptide (ENs/IS) area is plotted against the amount of substance of the 
ENs/IS ratio. Measurements were performed in parallel reaction monitoring (PRM) for multiplex assays 1-6 as 
well as for the CYP 17-plex. Dilutions were performed in triplicates. The dashed horizontal line in each graph 
indicates the limit of detection (LOD). 
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In Figure 47, the accuracy plots are shown for multiplex 1-6, as well as the 
CYP 17-plex. 
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Figure 47. Accuracy plots for analytes in PBSC. The accuracy in percentage is plotted against the theoretical 
amount of substance of the non-labeled synthetic peptide (ENs) in fmol. The dilution was done in triplicates. 
Accuracy criteria were met, when a data point was between 80 and 120%, and when the deviation between the 
replicate measurement was ≤ 20%. Measurements were performed in parallel reaction monitoring (PRM) for 
multiplex assays 1-6 as well as for the CYP 17-plex. 
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G. Results of Potential Mixture Effects (Log2 Graphs)  
  
  
  
  
Figure 48. Results of potential mixture effects on ADH1B and ALDH3A1. The upper part shows ADH1B; the 
lower part shows ALDH3A1. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. 
Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in  
Table 9 and Table 10. 
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Figure 49. Results of potential mixture effects on ARG1 (PFSK) and (YILK). The upper part shows TIGIIGAPFSK; 
the lower part shows DVDPGEHYILK. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in 
(D); n=3. Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used 
in Table 9 and Table 10. 
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Figure 50. Results of potential mixture effects on CYP1A1 and CYP1A2. The upper part shows CYP1A1; the lower 
part shows CYP1A2. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. For some 
treatments, only two (II) or even only one replicate (I) was measurable. The dashed horizontal line indicates 
0.5·LLOQ.; n.d.= not detected; <LLOQ= below the lower limit of quantification. Abbreviations for analytes and 
pesticides can be found in Table 30 and Table 25, concentrations used in Table 9 and Table 10. 
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Figure 51. Results of potential mixture effects on CYP2B6 and CYP2C8. The upper part shows CYP2B6; the lower 
part shows CYP2C8. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. For some 
treatments, only two (II) or even only one replicate (I) was measurable (<LLOQ= below the lower limit of quan-
tification). Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used 
in Table 9 and Table 10. 
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Figure 52. Results of potential mixture effects on CYP2C9 and CYP2C19. The upper part shows CYP2C9; the 
lower part shows CYP2C19. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. 
Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in  
Table 9 and Table 10. 
Supplementary Data 
172 
  
  
  
  
Figure 53. Results of potential mixture effects on CYP2E1 and CYP7A1. The upper part shows CYP2E1; the lower 
part shows CYP7A1. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. For some 
treatments, only two (II) or even only one replicate (I) was measurable. The dashed horizontal line indicates 
0.5·LLOQ. Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used 
in Table 9 and Table 10. 
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Figure 54. Results of potential mixture effects on FASN and HSD11B2. The upper part shows FASN; the lower 
part shows HSD11B2. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. Abbre-
viations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in Table 9 and 
Table 10. 
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Figure 55. Results of potential mixture effects on MDR1 and NCPR. The upper part shows MDR1; the lower part 
shows NCPR. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. Abbreviations 
for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in Table 9 and Table 10. 
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Figure 56. Results of potential mixture effects on NQO1 and PRKDC. The upper part shows NQO1; the lower part 
shows PRKDC. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. For some 
treatments, only two (II) or even only one replicate (I) was measurable. Abbreviations for analytes and pesti-
cides can be found in Table 30 and Table 25, concentrations used in Table 9 and Table 10. 
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Figure 57. Results of potential mixture effects on S100P and SULT1B1. The upper part shows S100P; the lower 
part shows SULT1B1. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. For 
some treatments, only two (II) or even only one replicate (I) was measurable (<LLOQ= below the lower limit of 
quantification). Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations 
used in Table 9 and Table 10. 
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Figure 58. Results of potential mixture effects on TNFRSF12A and UGT1A1. The upper part shows TNFRSF12A; 
the lower part shows UGT1A1. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); 
n=3. Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in 
Table 9 and Table 10. 
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Figure 59. Results of potential mixture effects on UGT1A3 and UGT2B7. The upper part shows UGT1A3; the 
lower part shows UGT2B7. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI in (C) and PPC/DIF in (D); n=3. 
Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, concentrations used in  
Table 9 and Table 10. 
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Figure 60. Results of potential mixture effects on UGT2B15. AOS/DIF is shown in (A); AOS/CC in (B); AOS/THI 
in (C) and PPC/DIF in (D); n=3. Abbreviations for analytes and pesticides can be found in Table 30 and Table 25, 
concentrations used in Table 9 and Table 10. 
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